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Methods and apparatus for performing fluorescence and 
Spatially resolved reflectance SpectroScopy on a Sample. A 
Sample is irradiated with a fluorescence excitation fiber and 
radiation is collected from the Sample with a fluorescence 
collection fiber and detected to form fluorescence spectra. 
The Sample is also illuminated with a reflectance illumina 
tion fiber and reflected light from the sample is collected at 
a plurality of collection positions and detected to form 
Spatially resolved reflectance spectra. The fibers may form a 
probe arranged in concentric Sections. The Spectra are ana 
lyzed by pre-processing and reducing the dimensionality of 
the Spectral data. 
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COMBINED FLUORESCIENCE AND 
REFLECTANCE SPECTROSCOPY 
This application claims priority to provisional patent 
application Ser. No. 60/084.290 filed May 4, 1998 entitled, 
“Combined Fluorescence and Reflectance Spectroscopy” by 
Rebecca Richards-Kortum, Urs Utzinger, Holger Fuchs, 
Ann M. Gillenwater, and Doug Heintzehnan. The entire text 
of the above-referenced disclosure is specifically incorpo 
rated by reference herein without disclaimer. 
The United States government has rights to the present 
invention pursuant to a grant from the National Institutes of 
Health. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the fields of 
optical imaging. More particularly, it concerns apparatus and 
methods for combining fluorescence and reflectance Spec 
troScopy for the imaging of Samples, including both in Situ 
and eX situ imagining of body tissues. 
2. Description of Related Art 
Cancer is one of the leading causes of death in the United 
States and in the world. In the United States alone, deaths 
from cancer are estimated to number 560,000 in 1997 
(American Cancer Society Online. Cancer Facts & Figures). 
Currently, diagnosis and treatment of cancer follow histo 
pathologic evaluation of directed biopsies. However, the 
tissue removal necessitated by these techniques not only 
may alter the progression of the disease (Robbins and 
Kumar, 1984) but is also very costly. Improving the capa 
bility for in Situ monitoring of disease progression could 
greatly enhance the ability to detect and treat cancer and 
precancer (Kelloff et al., 1992). 
A growing number of clinical Studies have demonstrated 
that fluorescence spectroscopy may be used to distinguish 
normal and abnormal human tissues in Vivo in the skin, head 
and neck, genito-urinary tract, gastro-intestinal tract, breast, 
and brain. It is well known that fluorescence intensity and 
lineshape are a function of both the excitation and emission 
wavelength in Samples containing multiple chromophores, 
Such as human tissue. A complete characterization of the 
fluorescence properties of an unknown Sample requires 
measurement of a fluorescence excitation emission matrix, 
in which the fluorescence intensity is recorded as a function 
of both excitation and emission wavelength. The field of 
analytical chemistry has exploited the fluorescence proper 
ties of different compounds to identify and quantify them in 
mixtures. 
Most clinical Studies reported to date have measured 
fluorescence emission spectra at only a Small number of 
excitation wavelengths (typically one to three) due to clini 
cal requirements imposed on the size, Speed and Sensitivity 
of instrumentation. The choice of excitation wavelength has 
been based on factors which vary from study to study, but 
include laser availability and predictions of chromophores 
thought to be present in normal and abnormal tissues and 
measurements of fluorescence excitation emission matrices 
(EEM) of normal and abnormal tissues in vitro. While in 
Vitro measurements of tissue EEMS are feasible using com 
mercially available Scanning fluorimeters, Several Studies 
have demonstrated that the optical properties of tissue 
change Significantly when tissue is examined in vitro due in 
part to interruption of the blood Supply, oxidation and Small 
Size of biopsies. Thus, in vitro Studies to Select excitation 











Several recent Studies have Suggested that differences in 
optical properties, assessed using diffuse reflectance 
Spectroscopy, may be used to discriminate normal and 
abnormal human tissues in Vivo in the urinary bladder and 
the skin. Furthermore, measuring both fluorescence and 
diffuse reflectance spectra may provide additional informa 
tion of diagnostic value. 
A System capable of measuring Spatially resolved reflec 
tance Spectra and fluorescence excitation emission matrices 
in Vivo would remove limitations of many previous Studies, 
potentially enabling prediction of excitation wavelengths 
that provide greatest discrimination of normal and abnormal 
tissues, as well as a better understanding of the relative 
diagnostic ability of changes in absorption, Scattering and 
fluorescence properties of tissue. Although fiber optic Sys 
tems to record fluorescence EEMS and reflectance spectra at 
a single Spatial location have been reported, Such Systems 
have measured data from only a single Spatial location, and 
have thus not been able to perform Spatially resolved spec 
troScopy. Additionally, previous Systems have not been 
well-adapted for in-vivo Studies of various tissues. 
SUMMARY OF THE INVENTION 
In one respect, the invention is an apparatus for perform 
ing fluorescence and Spatially resolved reflectance Spectros 
copy on a Sample, and it includes a light Source, a 
monochromator, a reflectance illumination fiber, a fluores 
cence excitation fiber, an imaging Spectrograph, a fluores 
cence collection fiber, a reflectance collection fiber, and a 
detector. The monochromator is in optical communication 
with the light source. The reflectance illumination fiber is in 
optical communication with the light Source. The fluores 
cence excitation fiber is in optical communication with the 
monochromator. The fluorescence collection fiber is in opti 
cal communication with the imaging Spectrograph. The 
reflectance collection fiber is in optical communication with 
the imaging spectrograph and is in Spaced relation with the 
reflectance illumination fiber. The detector is in optical 
communication with the imaging spectrograph. 
In other aspects, the light Source may include a Xe arc 
lamp. The monochromator may include a double monochro 
mator. The detector comprises a thermo-electrically cooled 
CCD camera. The fluorescence excitation fiber and the 
fluorescence collection fiber may be integral. One or more of 
the fibers may be positioned flush with the sample. The 
apparatus may also include a Spacer positioned between one 
or more of the fibers and the sample. The reflectance 
illumination fiber, the fluorescence excitation fiber, the fluo 
rescence collection fiber, and the reflectance collection fiber 
may define a fiber optic probe. The probe may be configured 
to be positioned within a trocar. The probe may include a 
center Section and an outer Section, and the fluorescence 
excitation fiber and the fluorescence collection fiber may be 
positioned in the center Section, and the reflectance illumi 
nation fiber and the reflectance collection fiber may be 
positioned in the outer Section. The apparatus may include a 
plurality of fluorescence excitation and collection fibers 
arranged in a circular bundle. The apparatus may include a 
plurality of reflectance collection fibers defining a plurality 
of collection positions. The plurality of collection positions 
may be spaced between about 0 and about 10 millimeters 
from the reflectance illumination fiber. The reflectance col 
lection fiber may define a collection position at about 180 
degrees relative to the reflectance illumination fiber. The 
reflectance collection fiber may define a collection position 
at about 90 degrees relative to the reflectance illumination 
fiber. The reflectance collection fiber may define a collection 
US 6,571,118 B1 
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position at about 45 degrees relative to the reflectance 
illumination fiber. The apparatus may include one or more 
fibers in optical communication with the light Source and 
configured to illuminate the Sample during operation of the 
apparatus. The apparatus may include a plurality of fluores 
cence excitation fibers arranged in one or more rows adja 
cent the monochromator. The apparatus may include a 
plurality of fluorescence excitation fibers and a plurality of 
reflectance collection fibers arranged in a single row adja 
cent the imaging spectrograph. The apparatus may include 
one or more unconnected fibers interspersed with the plu 
rality of fluorescence excitation fibers and the plurality of 
reflectance collection fibers. The apparatus may include a 
fiber connected from the light Source to the imaging Spec 
trograph to monitor Spectral output of the light Source. The 
apparatus may include a controller coupled to the detector. 
In another respect, the invention is an apparatus for 
measuring fluorescence and Spatially resolved reflectance 
Spectra of a Sample. The apparatus includes a light Source, 
a monochromator, a fiber optic probe, an imaging 
Spectrograph, and a detector. The monochromator is in 
optical communication with the light Source. The fiber optic 
probe is in optical communication with the light Source and 
with the monochromator. The probe includes a plurality of 
fluorescence excitation and collection fibers in Spaced rela 
tion and a plurality of reflectance collection fibers in Spaced 
relation with a reflectance illumination fiber. The imaging 
Spectrograph is in optical communication with the plurality 
of fluorescence collection fibers and with the plurality of 
reflectance collection fibers. The detector is in optical com 
munication with the imaging Spectrograph. 
In other aspects, the plurality of reflectance collection 
fibers and the reflectance illumination fiber may be posi 
tioned concentrically about the plurality of fluorescence 
excitation and collection fibers. At least one of the plurality 
of reflectance collection fibers may define a collection 
position at about 180 degrees relative to the reflectance 
illumination fiber. At least one of the plurality of reflectance 
collection fibers may define a collection position at about 90 
degrees relative to the reflectance illumination fiber. At least 
one of the plurality of reflectance collection fiberS may 
define a collection position at about 45 degrees relative to 
the reflectance illumination fiber. The plurality of collection 
positions may be spaced between about 0 and about 10 
millimeters from the reflectance illumination fiber. The 
probe may include between twenty-one and forty-six optical 
fibers. 
In another respect, the invention is a method for combined 
fluorescence and Spatially resolved reflectance spectroscopy 
of a Sample. The method includes directing radiation to the 
Sample with a fluorescence excitation fiber, collecting radia 
tion from the Sample with a fluorescence collection fiber, 
directing the radiation from the Sample to an imaging 
Spectrograph and a detector, illuminating the Sample with a 
reflectance illumination fiber, collecting reflected light from 
the Sample with a reflectance collection fiber in Spaced 
relation with the reflectance illumination fiber, and directing 
the reflected light from the Sample to an imaging Spec 
trograph and a detector. 
In other aspects, the Step of collecting reflected light may 
include collecting reflected light from a plurality of collec 
tion positions with a plurality of reflectance collection fibers. 
The Step of collecting reflected light may include collecting 
reflected light from the Sample with a reflectance collection 
fiber defining a collection position at about 180 degrees 
relative to the reflectance illumination fiber. The step of 











light from the sample with a reflectance collection fiber 
defining a collection position at about 90 degrees relative to 
the reflectance illumination fiber. The step of collecting 
reflected light may include collecting reflected light from the 
Sample with a reflectance collection fiber defining a collec 
tion position at about 45 degrees relative to the reflectance 
illumination fiber. The Sample may include ovarian, head 
and neck, or cervical tissue. The method may also include 
analyzing spectral data from the detector to characterize the 
Sample. The Step of analyzing may include pre-processing 
the data and reducing a dimension of the data using principal 
component analysis. The Step of analyzing may also include 
Selecting one or more diagnostic principal components of 
the data and forming one or more algorithms. The Step of 
analyzing may also include forming one or more composite 
algorithms. The Step of analyzing may also include evalu 
ating at least on of the algorithms using a croSS-Validation 
technique. 
In another respect, the invention is a method for combined 
fluorescence and Spatially resolved reflectance spectroscopy 
of a Sample. The method includes directing radiation to the 
Sample with a fluorescence excitation fiber, collecting radia 
tion from the Sample with a fluorescence collection fiber, 
directing the radiation from the Sample to an imaging 
Spectrograph and a detector, illuminating the Sample with a 
reflectance illumination fiber, collecting reflected light at a 
plurality of collection positions from the Sample with a 
plurality of reflectance collection fibers arranged in Spaced 
relation, directing the reflected light from the Sample to an 
imaging spectrograph and a detector to produce Spectral 
data, pre-processing the data, and reducing a dimension of 
the data using principal component analysis. 
The method may also include Selecting one or more 
diagnostic principal components of the data and forming one 
or more algorithms. The method may also include forming 
one or more composite algorithms. The method may also 
include evaluating at least one of the algorithms using a 
croSS-Validation technique. 
In another respect, the invention is a method for analyzing 
Spectroscopy data to define an optimized reduced data Set. 
The method includes pre-processing the SpectroScopy data, 
reducing a dimension of the SpectroScopy data using prin 
cipal component analysis, and Selecting one or more diag 
nostic principal components of the SpectroScopy data. 
In other aspects, the SpectroScopy data may include com 
bined fluorescence and Spatially resolved reflectance Spec 
troScopy data. The Step of pre-processing may include 
normalization of the Spectroscopy data. The Step of pre 
processing may include mean Scaling the Spectroscopy data. 
The Step of pre-processing may include calculating one or 
more derivatives on the Spectroscopy data. The method may 
also include eliminating redundant data from the Spectros 
copy data. The method may also include forming one or 
more algorithms and evaluating at least one of the algo 
rithms using a croSS Validation technique. The method may 
also include forming one or more composite algorithms. 
Applications for the methods and apparatus described 
herein are vast and include, but are not limited to, analysis 
and detection of disease including cancers and pre-cancers 
(Such as cervical, head and neck, colon, lung, esophageal, 
ovarian) and atherosclerosis. Applications also include 
industry, including, but not limited to, the Semiconductor 
industry. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
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aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 
embodiments presented herein. 
FIG. 1 Block diagram of a Fast EEM system according to 
one embodiment of the present disclosure. 
FIG. 2 Probe output at 332 nm according to one embodi 
ment of the present disclosure. 
FIG. 3 Inside of a light source according to one embodi 
ment of the present disclosure. 
FIG. 4 Outside connectors of the light Source according to 
one embodiment of the present disclosure. 
FIG. 5 Comparison between the monochromator and the 
Spectral lamp output. 
FIG. 6 A probe according to the present disclosure show 
ing fluorescence excitation fibers, fluorescence collection 
fibers, a quartz, rod, a reflectance excitation fiber, and reflec 
tance collection fibers. 
FIG. 7 Probe according to the present disclosure showing 
fluorescence fibers, a quartz rod, reflectance fibers, illumi 
nation fibers, a protection Shield, and a quartz, Shield. 
FIG. 8 Tip of a probe according to the present disclosure 
showing illumination of i) reflectance ii) fluorescence and 
iii) illumination fibers. 
FIGS. 9A-9C. Monochromator and spectrograph connec 
tor with fluorescence and reflectance collection fibers 
according to one embodiment of the present disclosure. 
FIG. 10 Probe including fiber connectors according to one 
embodiment of the present disclosure. Shown are visual 
illumination fiber 113, reflectance excitation fiber 115, fluo 
rescence excitation fiber 117, and reflectance collection 
position 119. 
FIG. 11 Correction factors for the spectrograph. 
FIG. 12 Schematic of Binning techniques: On chip bin 
ning (left), On chip and Software binning (right). 
FIG. 13 Main screen of a Fast-EEM user interface accord 
ing to one embodiment of the present disclosure. 
FIG. 14 System block diagram showing a variable exci 
tation light Source, a fiber optic delivery and collection 
probe, and a spectral multichannel analyzer according to one 
embodiment of the present disclosure. 
FIG. 15 (left) Schematic diagram of the distal ends of the 
probe: a outer shaft, b fluorescence excitation and emis 
Sion fibers, c) reflectance collection and illumination fibers, 
d mixing element, E reflectance excitation fiber, 1-3 
reflectance collection locations, (Right) Schematic diagram 
of the proximal ends of the probe. 
FIG. 16A Simulated EEM with peak shifting in 1 
excitation wavelength 2 and emission wavelength. 
FIG. 16B Simulated EEM with peak shifting in 1 
excitation wavelength 2 and emission wavelength. Calcu 
lated X and m for the Simulated EEM. X is sensitive to 
changes in the excitation position of the peak and m is 
Sensitive to the emission position. 
FIG. 17A EEM of Rhodamine standard Solution. 
FIG. 17B EEM of an FAD and microspheres-based tissue 
phantom measured using a FastEEM System. 
FIGS. 18A-18D (A) Emission spectra at 360 nm excita 
tion of the Rhodamine calibration standard measured with 
the FastEEM system and SPEX Fluorolog II fluorimeter. (B) 
Emission Spectra at 360 nm excitation of the Scattering 
tissue phanthom containing FAD and polystyrene micro 











Fluorolog II fluorimeter. (C) Emission spectra at 450 nm 
excitation of the Rhodamine calibration Standard measured 
with the FastEEM system and SPEX Fluorolog II fluorim 
eter. (D) Emission spectra at 450 nm excitation of the 
Scattering tissue phanthom containing FAD and polystyrene 
microspheres measured with the FastEEM system and SPEX 
Fluorolog II fluorimeter. 
FIGS. 19A and 19B In-vivo fluorescence measurements 
with the FastEEM system: (A) Fluorescence EEM of a 
normal site of the tongue. (B) Fluorescence EEM of a 
diseased site of the tongue, containing a moderately differ 
entiated Squamous cell carcinoma. 
FIG. 20 Fluorescence emission spectra of normal and 
moderately differentiated Squamous cell carcinoma of the 
tongue from FIG. 6. The spectra were normalized to the peak 
fluorescence at 350 nm excitation. (a) Fluorescence emis 
Sion spectra at 350 nm excitation. (b) Fluorescence emission 
spectra at 410 nm excitation. (c) Fluorescence emission 
Spectra at 460 nm excitation. 
FIGS. 21A and 21B Emission and excitation autocorre 
lation vectors of normal and moderately differentiated Squa 
mous cell carcinoma of the tongue from FIGS. 18. (A) 
Emission autocorrelation vectors. (B) Excitation autocorre 
lation vectors. 
FIGS. 22A-22C. Reflectance measurements of normal 
and moderately differentiated Squamous cell carcinoma of 
the tongue at three different Separations from the Source 
fiber. (A) Position 1, 1.1 mm separation. (B) Position 2, 2.1 
mm Separation. (C) Position 3, 3 mm separation. 
FIG. 23 A schematic of the portable fluorimeter used to 
measure cervical tissue fluorescence spectra at three exci 
tation wavelengths. 
FIG. 24A schematic of formal analytical process used to 
develop the Screening and diagnostic algorithms. The text in 
the dashed-line boxes represent mathematical StepS imple 
mented on the Spectral data and the text in the Solid line 
boxes represent outputs after each mathematical Step (NS 
normal squamous, NC normal columnar, LG-LG SIL 
and HG-HGSIL). 
FIG. 25 (a) Original and corresponding (b) normalized 
and (c) normalized, mean-Scaled spectra at 337 nm excita 
tion from a typical patient. 
FIG. 26 (a) Original and corresponding (b) normalized 
and (c) normalized, mean-Scaled spectra at 380 nm excita 
tion from the same patient. 
FIG. 27 (a) Original and corresponding (b) normalized 
and (c) normalized, mean-Scaled spectra at 460 nm excita 
tion from the same patient. 
FIG. 28 Aplot of the posterior probability of belonging to 
the SIL category of all SILS and normal Squamous epithelia 
from the calibration set. Evaluation of the misclassified SILS 
indicates that one samples with CIN III, two with CIN II, 
two with CINI and two with HPV are incorrectly classified. 
FIG. 29 Aplot of the posterior probability of belonging to 
the SIL category of all SILS and normal columnar epithelia 
from the calibration data set. Evaluation of the misclassified 
SILS indicates that three samples with CIN II, three with 
CIN I and one with HPV are incorrectly classified. 
FIG. 30 A plot of the posterior probability of belonging to 
the HG SIL category of all SILS from the calibration set. 
Evaluation of the misclassified HGSILS indicates that three 
samples with CIN III and three with CIN are incorrectly 
classified as LG SILS; five samples with CINI and two with 
HPV are misclassified as HG SIL. 
FIG.31 Component loadings (CL) of diagnostic principal 
components of constituent algorithm (1), obtained from 
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normalized spectra at (a) 337 (b) 380 and (c) 460 nm 
excitation, respectively. 
FIG. 32 Component loadings (CL) of diagnostic principal 
components of constituent algorithm (2), obtained from 
normalized, mean-scaled spectra at (a) 337 (b) 380 and (c) 
460 nm excitation, respectively. 
FIG.33 Component loadings (CL) of diagnostic principal 
components of constituent algorithm (3), obtained from 
normalized spectra at (a) 337 (b) 380 and (c) 460 nm 
excitation, respectively. 
FIG. 34 Plots of Frequency of occurrence vs. emission 
wavelength in top 25 performing combinations of three 
wavelengths: (a) ESL=65%, (b) ESL=75%, (c) ESL=85%, 
and (d) ESL=95% 
FIG. 35 Fluorescence emission spectra normalized by the 
peak intensity of the concatenated vector for all 62 Sites at 
350, 380 and 400 nm excitation. Red lines indicate histo 
logically cancerous, green lines indicate histologically 
dysplastic, and blue lines indicate visually and/or histologi 
cally normal Sites. 
FIG. 36 Plot of the only eigenvector of diagnostic impor 
tance at ESL=65% for wavelength combination (350 380 
400) (lower line at vector index=200) and the corresponding 
component loading (upper line at vector index=200). 
FIG. 37 Plot of emission vector for a wavelength com 
bination of three excitation wavelengths (350, 380,400 nm) 
normalized by the peak intensity of each emission spectra. 
FIGS. 38A-38C Reflectance spectra (A), first (B) and 
Second derivation (C) for position one. 
FIGS. 39A-39C Reflectance spectra (top), first (middle) 
and Second derivation (bottom) for position two. 
FIGS. 40A-40C Reflectance spectra (top), first (middle) 
and Second derivation (bottom) for position three. 
FIGS. 41A-41C Average reflectance spectra (top), first 
(middle) and Second derivation (bottom) for position one. 
Error bars show standard deviation. 
FIGS. 42A-42C Average reflectance spectra (top), first 
(middle) and second derivation (bottom) for position two. 
Error bars show standard deviation. 
FIGS. 43A-43C Average reflectance spectra (top), first 
(middle) and second derivation (bottom) for position three. 
Error bars show standard deviation. 
FIGS. 44A-44C p values comparing the mean intensity, 
mean first and Second derivatives of normal tissue verSuS 
abnormal tissues, at Source detector Separation 1 (top), 2 
(middle) and 3 (bottom). 
FIGS. 45A-45C p values comparing the mean intensity, 
mean first and Second derivatives of normal tissue verSuS 
dysplastic tissues, at Source detector separation 1 (top), 2 
(middle) and 3 (bottom). 
FIG. 46 Scatter plot of the second derivative at 430 nm for 
position 2 vs. the second derivative at 495 nm for position 
one. The Straight line represents an algorithm to Separate 
normal findings from dysplasias and cancers, and results in 
a sensitivity of 80% and a specificity of 85%. 
FIG. 47 Scatter plot of the second derivative at 450 nm for 
position 1 vs. the first derivative at 510 nm for position three. 
The Straight line represents an algorithm to Separate normal 
findings from dysplasias and cancers, and results in a 
sensitivity of 80% and a specificity of 82%. 
FIG. 48 Scatter plot of the second derivative at 410 nm for 
position 1 vs. the first derivative at 510 nm for position three. 
The Straight line represents an algorithm to Separate normal 
findings from dysplasias and cancers, and results in a 











DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
FIG. 1 shows one embodiment of an apparatus 10 accord 
ing to the present disclosure. The apparatus is adapted to 
measure both reflectance and fluorescence data, and may be 
referred to as a Fast-EEM system (where EEM stands for 
excitation emission matrix) system. Fast EEM system 10, in 
one embodiment, may include four main components, 
although those having skill in the art will recognize that 
more or fewer components may be utilized: The components 
are: (a) an excitation Source 20, which may include an arc 
lamp 22 and a monochromator 24 for monochromatic and 
broadband excitation, (b) a fiber optic probe 30, which may 
be configured to deliver excitation light to and collect 
remitted fluorescence from a Sample 60, (c) a detection 
apparatus 40, which may include a filter wheel, an imaging 
Spectrograph 42, and a CCD camera 44 and that spectrally 
resolves a collected signal, and (d) a control unit 50, which 
may be a personal computer used to run Fast EEM System 
10 and to acquire data. 
Excitation Source 20 
The light source 22 for Fast EEM system 10, which may 
provide both quasi-monochromatic excitation for fluores 
cence and broadband illumination for reflectance, may be, 
in one embodiment, a 150 W ozone free Xe arc lamp 
(Spectral Energy Corp., Westwood N.J.) with a spherical 
rear reflector. 
A condenser System including two piano convex quartz 
lenses may be used to couple light into a monochromator 24. 
With the benefit of the present disclosure, those having skill 
in the art will understand that any optical filter or device 
Suitable for creating bandpass filtered light may be used for 
monochromator 24. In one embodiment, monochromator 24 
may be a single monochromator. A manual shutter (not 
shown) may be located between condensing optics and 
monochromator 24 and may be closed to prevent fluores 
cence excitation light from reaching Sample 60 during 
reflectance measurements. The Scanning Speed of mono 
chromator 24 may be, in one embodiment, about 10 nm/sec. 
Light may be coupled from the output slit of monochromator 
24 into probe 30 via a fiber optic adapter (Spectral Energy, 
GMA257) (not shown) that includes a quartz plano-convex 
lens and a 5x quartz microScope objective. The light passing 
through the objective may be focused to an appropriate 
shape to fill one or more fibers of probe 30. In one 
embodiment, light passing through the objective may be 
focused onto a vertical line onto twenty-five fibers of probe 
30, the twenty-five fibers being arranged in two columns and 
placed at the focal plane of the objective (See FIG. 9A). 
A reflectance excitation fiber (See, e.g., FIG. 6) may be 
coupled to the lamp housing of light Source 22 via a 
micropositioner (not shown). Broadband light exiting the 
lamp housing through an exiting hole may be coupled to a 
reflectance illumination fiber using a quartz plano-convex 
lens (NA=0.24). A five position illumination filter wheel (not 
shown) placed between the lamp and the lens may include 
three long pass filters with 50% transmission at 295 nm, 515 
nm and 715 nm, respectively. One of the filter positions may 
be blocked and may act as a Shutter to prevent white light 
from reaching Sample 60 during fluorescence measurements. 
In another embodiment, the light source 22 for Fast EEM 
System 10, which may provide both quasi-monochromatic 
excitation for fluorescence and broad band illumination for 
reflectance, may be an ozone-free 450 W Xe arc lamp 
(FL-1007, Instruments SA, Edison, N.J.). 
Light used for monochromatic fluorescence excitation 
may be focused with a spherical mirror (not shown) onto the 
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input Slit of monochromator 24. In this embodiment, mono 
chromator 24 may be a double monochromator (DDD 180, 
Instruments SA, Edison, N.J.). A spherical rear reflector (not 
shown) may redirect light that is exiting the lamp in the 
opposite direction into the opposite direction onto the 
Spherical mirror. The slit may be covered with a Sapphire 
window, which may prevent hot air from flowing out of the 
lamp housing into the monochromator 24. A double mono 
chromator may be chosen for monochromator 24 because of 
its higher Stray light rejection compared to a single mono 
chromator. A double monochromator may be configured in 
additive mode, which means that the dispersions of the two 
holographic gratings are added. Stray light in Such a con 
figuration may be So Slight as to be negligible. The focal 
length of each of the two monochromators may be about 18 
cm and the high throughput may be f/3.9. The two holo 
graphic gratings may have about 1200 grooveS/mm and may 
be blazed at 500 nm. In this embodiment, the systems 
maximal resolution may be about 0.3 nm with an accuracy 
of about 0.5 nm. The scanning speed in this emboidiment 
may be about 150 nm/s, and the uSable wavelength range 
may be from about 300 to about 1000 nm. Wavelength 
Scanning may be achieved with a direct digital Stepper 
motor with a worm drive mechanism (not shown). Three 
computer-controlled slits (entrance, middle, and exit) may 
be opened between 0 and 7 mm in steps of 12.5 lum. In one 
embodiment, a slit-width of about 2 mm may be chosen for 
both the entrance and the exit slits. The middle slit twice 
may be opened as wide as the entrance and the exit slit to 
achieve an optimal performance. These Settings guaranteed 
a spectral resolution of about 6 nm FWHM. 
FIG. 2 shows a spectrum taken at 332 nm by coupling 
light through probe 30 through a fiber optic adapter into a 
scanning spectrofluorimeter (SPEX, Fluorolog II, Edison, 
N.J.). An emission scan from 300 nm to 600 nm was 
performed to collect the relative intensity of the probe 
output. 
In one embodiment, the coupling of light into a fluores 
cence excitation bundle (See, e.g., FIG. 6 and FIG. 7) was 
done using a fiber-optic interface kit (220F, Instruments SA, 
Edison, N.J.). Two plano-convex lenses (different focal 
lengths) may be matched to different NAS of the exit slit and 
of a fiber bundle of probe 30 to minimize coupling losses. A 
computer-controlled Shutter (LS6, Vincent ASSociates, 
Rochester, N.Y.) may be mounted in front of the probe 
connector to block fluorescence excitation light during 
reflectance measurements. 
Light Source 22 may be customized to provide white light 
output. White light may be needed (a) for reflectance 
measurements, (b) for visual observation of a measurement 
Site by a physician, and (c) to monitor the lamp output. 
FIG. 3 shows a top view drawing of the inside of the lamp 
housing according to one embodiment. Light bulb 25 and 
ray traces (dashed lines) for the monochromator light are 
shown. In one embodiment, the optimal Solution to provide 
white light output to the outside of the housing involved the 
use abundle of quartz fibers. One biconvex lens, mounted in 
a custom-made rack inside the lamp housing, coupled light 
into a bundle of three 600 um and one 50 um high 
temperature quartz fibers (Thermocoat, Fiberguide 
Industries, Stirling, N.J.). The light rays are indicated by the 
dotted line in FIG. 3. These fibers transported white light to 
four connectors on the outside of the housing (See FIG. 4). 
The first connector C1 may provide excitation light used for 
reflectance measurements. The five-position illumination 
filter wheel described previously may be placed between 











Second connector C2 may be equipped with one quartz lens 
(focal length=20 mm) that focuses light onto the illumina 
tion fiber bundle. A second shutter (LS6, Vincent Associates, 
Rochester, N.Y.) may be placed between the connector and 
the lens, which may be closed during data acquisition and 
may otherwise be held open to deliver light to the in 
illumination fibers of probe 30. The third 600 um fiber 
output C3 may be used for other purposes, or not at all. The 
50 um fiber output C4 may couple light into a fiber that is 
directly connected to imaging spectrograph 42 to record the 
lamp Spectrum for every measurement. In one embodiment, 
however, this option is not used. 
FIG. 5 illustrates the power output of two monochromatic 
illumination systems (one using a 150 W ozone free Xe arc 
lamp and the other using an ozone-free 450 WXe arc lamp). 
The output was measured through probe 30 using a cali 
brated power meter (818-UV, Newport, Irvine, Calif.) and 
represents the flux (W) that is provided to sample 60, which 
may be a tissue Sample. Above about 400 nm, an improve 
ment in power of a factor of four is noticeable. Note that the 
lamp performed poorly below 400 nm. The light output at 
about 330 nm is only about 20% of the peak performance at 
460 nm. The low UV output may be due to the fact that lamp 
is an ozone-free model. The light bulb is made out of UV 
blocking glass Since OZone is mainly produced in the 
Surrounding air within this spectral region. In order to have 
a useful S/N ratio prolonged exposure times in the Spectral 
region below 400 nm may become a necessity. 
Probe 30 
The combined spatial reflectance and fluorescence probe 
30 of the present disclosure may be built to meet the 
following criteria. First, the tissue volume probed by the 
reflectance and fluorescence measurements may Overlap. 
Second, because the collected fluorescence intensity may be 
typically three orders of magnitude lower than the reflec 
tance intensity, a detector with a high dynamic range may be 
required. Weakening the reflectance excitation light by using 
a Smaller excitation fiber or using a number of fluorescence 
excitation fibers may, however, alleviate this problem. Third, 
the total diameter of the probe may be Small enough So that 
it is possible to cover an area of only one tissue type, for 
example, dysplastic lesions around a tumor are likely to be 
only a few millimeters wide. Finally, a probe 30 Small in 
diameter may give the opportunity to use it for minimal 
invasive Surgeries through trocars. According to one 
embodiment, probe 30 may fit into a trocar. In one 
embodiment, it is designed to fit into a trocar (Reflex STR, 
5 mm, Richard-Allan Inc.) that is commonly used in the 
Gynecology Department at The University of Texas M. D. 
Anderson Cancer Center, Houston, Tex., (UT MDACC). 
One embodiment of a combined reflectance and fluores 
cence probe 30 includes a total of 21 quartz fibers (200 um 
core diameter, NA=0.22). With the benefit of the present 
disclosure, however, those of Skill in the art will recognize 
that more or fewer fibers may be used. Additionally, although 
the present disclosure refers to embodiments of a probe 
including “fibers”, it will be understood that any channel 
suitable for transmission of light may be substituted there 
with. In one embodiment, a ring of twelve fluorescence 
collection fibers 70 Surround a circle of seven fluorescence 
excitation fibers 72. In one embodiment (not shown), at least 
one fluorescence fiber may be an integral fluorescence 
excitation and collection fiber. At the distal end of fluores 
cence excitation and collection fibers may be a quartz rod 
(about 1.5 mm diameter, about 7 mm thick) 74 located to 
ensure an overlap at the Sample Surface between fluores 
cence excitation and collection fibers. One reflectance exci 
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tation fiber 76 and one reflectance collection fiber 78 (both 
about 90 um core diameter) may be placed outside of the 
quartz, rod and flush to the Sample, which may be tissue, on 
opposite sides. The reflectance fibers may be about 1.7 mm 
apart from each other, and light may be Scattered through the 
Same tissue Volume that is examined for fluorescence. 
In one embodiment, a probe 30 may have a total length of 
about 28 cm to about 35 cm, which allows the probe to pass 
a trocar shaft. With the benefit of the present disclosure, 
however, those having skill in the art will recognize that the 
probe 30, and other components described herein, may be 
made of different size (and materials) according to need or 
desire. 
Turning to FIG. 7 and FIG. 8, it may be seen that the 
diagnostic portion of probe 30 may include forty-six optical 
fibers (about 200 um, NA=0.22) in two concentric sections. 
With the benefit of the present disclosure, however, those of 
skill in the art will recognize that more or fewer fibers may 
be used. The center bundle 80 (See FIG. 7) may contain 
twenty-five fluorescence excitation fibers and twelve fluo 
rescence collection fibers. At the distal end of the probe 30, 
these fibers may be arranged randomly in central bundle 80 
and may be placed in mechanical contact with a short piece 
(about 1.5 cm long) of thick quartz fiber 82. Light sent 
through this rod may be distributed over an examined area. 
The rod's length may be determined by the radius of the rod 
and the NA of the fibers and may be calculated by taking 
twice the radius and dividing it by the fiber NA. 
Nine fibers for illumination and collection of diffuse 
reflectance may be arranged in a ring around the fluores 
cence fibers (See element 84, FIG. 7). Three collection fibers 
86 may be located at about 180°, two fibers 88 and 90 may 
be located at about 90, and two fibers 92 and 98 may be 
located at about 45 from the illumination fiber 94. A single 
collection fiber 96 may be placed directly beside the reflec 
tance excitation fiber in to measure Single backScattered 
light. Fibers 92 and 98 may have a distance to the excitation 
Source of about 1.4 mm, fibers 88 and 90 of about 2.4 mm, 
and fibers 86 of about 3.3 mm. The distal ends of the 
reflectance fibers may be flush with the tip of the central 
fiber and placed in contact with the Sample Surface. 
For measurements that take longer than about 30 S, an 
optical feedback mechanism for the probe operator may 
need to be provided to avoid a displacement of the instru 
ment. Therefore, a third ring of seven fibers 100, with an 
offset of about 2 cm (for a 28 cm probe) and about 5 cm (for 
a 35 cm probe) from the tip may be added for illumination 
purposes. Probe 30 may have a screw-on protection shield 
102 at the tip of the probe. Specularly reflected light between 
a quartz shield 104 and the probe 30, however, may lead to 
an uncorrectable biasing of the probe performance, and 
therefore protection shield 102 may optionally not be used. 
A 30-minute soaking of probe 30 in a disinfecting solution 
like CidexTM (Johnson and Johnson Inc.) allows the probe to 
be used in the Sterile environment of an operating room. 
The arrangement of fibers at the monochromator 24 and 
the Spectrograph 42 connectors, according to one 
embodiment, are shown in FIG. 9 The fluorescence excita 
tion fibers 108 may be arranged in two rows for optimally 
filling by a rectangular output beam of the monochromator 
24. The fibers on the spectrograph 42 end may be lined up 
in a single row, as shown. Fibers 110 are fluorescence 
collection fibers, and fibers 112 (represented by darkened 
circles) are the reflectance collection fibers. Because Satu 
ration in one fiber location may bloom to adjacent pixels on 
the detector, additional spacing, realized by unconnected 











lem. In this embodiment, the Spectrograph connector con 
tains fiber 114 that may be connected directly to a white light 
output of light Source 22, which may be a Xe lamp, to 
monitor the spectral output of the light Source over time. 
FIG. 10 illustrates an entire probe 30, according to one 
embodiment, including connectors and connecting fibers. 
Note that reflectance collection fiber 94 (See FIG. 8), the 
position right next to the excitation fiber, may be interrupted 
by disconnecting SMA connector #2. This feature was 
created in this embodiment in case the directly backScattered 
light signal was too strong and needed attenuation. 
Spectrograph 42 and Filter Wheel 
Imaging spectrograph 42, in one embodiment, may be a 
commercial imaging spectrograph (Chromex 250 IS, 
Albuquerque, N.MeX.). A grating of about 100 grooves/mm, 
blazed at about 450 nm may be used. With the benefit of the 
present disclosure, however, those of skill in the art will 
understand that any optical filter or device Suitable for 
analyzing spectral content of light from one or mutliple 
Sources simultaneously may be used for imaging Spec 
trograph 42. 
Light collected by fluorescence and reflectance fibers and 
the excitation light guided directly from the Source may be 
coupled through an 8-position, computer controlled collec 
tion filter wheel (Optomechanics Research, Inc., Vail, Ariz.), 
into imaging Spectrograph 42. The filter wheel blocks the 
fluorescence excitation light from entering the Spectrograph 
42. The spectrograph may contain a holographic grating 
blazed at about 380 nm with about 100 grooves/mm. The 
fibers may be projected onto an entrance slit (about 250 um) 
to yield a spectral resolution of about 7 nm. 
The non-uniform spectral response of the System may be 
corrected as shown in FIG. 11. These correction factors may 
be determined from measurements of calibration Sources, in 
the visible, a N.I.S.T traceable tungsten ribbon filament 
lamp, and in the UV, a deuterium lamp may be used (550C 
and 45D, Optronic Laboratories Inc., Orlando, Fla.). 
Variations in the intensity of fluorescence excitation light 
Source at different excitation wavelengths may be corrected 
using measurements of the intensity at each excitation 
wavelength at the probe tip using a calibrated photodiode 
(818-UV, Newport). 
CCD Camera 44 
A thermo-electrically cooled CCD camera 44 
(Spectrasource HPC-1, Westlake Village, Calif.) may be 
operated at about -30° C. and may be located at the back 
focal plane of the imaging spectrograph 42. Chip dimen 
sions may be about 13.8x9.2 mm with 1536x1024 pixels 
(Kodak KAF-1600 grade 2), to yield a nominal spectral 
range of about 410 nm for a single grating position. Each 
fiber may take up about 40 pixels. The dark current of the 
CCD chip, in this embodiment, was specified and confirmed 
as 0.25 electrons/pixel/sec when operated at -30° C. Quan 
tum efficiency of the lumogen-coated chip may range from 
a peak of about 40% at about 550 nm to a low of about 15% 
at about 250 nm. 
Binning Pixels 
The HPC-1 CCD camera 44 allows a user to perform 
on-chip binning of pixels. Binning means that neighboring 
pixels may be added together to represent only one data 
point. This feature is attractive for at least two reasons: (1) 
it allows a reduction in the time required to read data from 
the chip, and (2) it increases the Signal-to-noise ratio by 
reducing the effective read out and shot noise. 
Although a useful feature, excessive binning may dimin 
ish the resolution of the system. Furthermore, because the 
full well capacity of the pixels and shift register is limited, 
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it is possible to exceed this capacity by either grouping too 
many pixels together or by encountering an unexpectedly 
Strong Signal (blooming). When blooming occurs, a charge 
in excess of the full well capacity of a capacitive element 
may spill into adjacent pixels. This can essentially fill the 
pixels with charge and render them unavailable for Signal 
detection or perhaps give a false indication of Signal where 
none exists. 
In one embodiment, binning was only electronically 
implemented in the Spatial direction on the chip. The 12 
fluorescence excitation fibers filled 480 pixels and were all 
binned together. For the reflectance excitation, a combined 
binning in hardware and Software was used in one embodi 
ment. This technique had two advantages: (1) it increased 
the dynamic range compared to a full binning in hardware, 
and (2) it increased the data transfer rates as compared to 
non-binned data. FIG. 12 shows the two different binning 
techniques. 
In one embodiment, the camera 44 and the readout 
electronics did not operate in a reliable manner. Long-term 
testing showed that counts on every pixel can vary from 
exposure to exposure when the Shutter remains closed. ADC 
offset variation on the chip, resulting in an average count of 
700/pixel/s to 1500/pixel/s was monitored during a 12 hour 
period. The origin of this behavior was expected to be either 
a cooling problem of the CCD camera 42 or an unstable DC 
offset Supplied to the A/D converter. In an attempt to cure at 
least Some of the problems, a higher number of pixels were 
digitized that were actually physically present. The count of 
these fake pixels reflected the DC offset of the signal and 
was found to be independent of the detector temperature. 
Testing showed that the count of these fake pixels varied the 
same way as the real pixels did. In this embodiment, 
monitoring of the background was required at every Single 
measurement, Since a low fluorescence Signal may lie in this 
range. The background could be Subtracted from the 
acquired data. In the embodiment, another problem was 
discovered with the readout of the chip. The first electroni 
cally binned line that was read out was always corrupted and 
had to be discharged. This meant that the double amount of 
pixels were binned into two columns from which the first 
corrupted one was dumped. 
Software and Control 
In one embodiment, National Instruments Labview Ver 
Sion 3.0 (Austin, Tex.) a graphical programming develop 
ment environment based on the G (Graphic) programming 
language may be used to control Fast EEM system 10. The 
platform for the control software may be any suitable control 
device or computer 50. In one embodiment, a laptop 486/75 
MHz personal computer with docking Station (Austin Inc., 
Austin, Tex.) was used as computer 50. Communication 
with the excitation monochromator may be provided via an 
RS-232 control module that is interfaced to the COM port of 
the docking Station of computer 50. A camera control card 
may be mounted in the docking Station. The imaging Spec 
trograph 42 may be operated using a National Instruments 
GPIB IEEE-488 board that is also located inside the docking 
station of computer 50. 
In another embodiment, a desktop computer was chosen 
(Optiplex 233GXa, Dell Computer Corporation, Round 
Rock, Tex.) equipped with a Windows95TM operating sys 
tem as computer 50. All mentioned cards in this embodiment 
may be connected to the ISA-bus of computer 50. A double 
monochromator 24 and spectrograph 42 controls may be 
connected by a GPIB IEEE-488 interface (ATGPIB/TNT, 
National Instruments, Austin,Tex.). The two shutters and the 











(PC-DIO-24, National Instruments, Austin,Tex.). The CCD 
camera 44 may have its own ISA-bus interface card. The 
readout rate of the chip in this embodiment was greater than 
about 65,000 pixels/s. This gave a readout time of about 24 
s for the whole chip if no binning was used. In this 
embodiment, no on board RAM was available to buffer 
acquired data. 
In one embodiment, Lab view V.5.0 (National 
Instruments, Austin, Tex.) was chosen as the Software to 
control the entire Fast EEM system 10. In this embodiment, 
the goal of Software development was to create an easy to 
use interface that made the System controllable by an 
operator with basic computer knowledge after only a few 
days of training. 
Such Software may be designed using a Small number of 
basic Sub-Vis (Vi: virtual instrument. National Instruments 
expression for Software units). Operator interaction may be 
minimized to avoid human errors. Automation of file Saving 
and auto-naming of Saved files may be implemented to 
prevent loss of data by mislabeling or accidentally overwrit 
ing certain files. Such automation may also speed up the 
interaction time of an operator with the Software between 
measurementS. 
In one embodiment, Stored fluorescence data was loaded 
immediately after Storage and could be visually inspected in 
the center of the Screen. Such a routine may be added as a 
quality-enSuring feature, and it may also help to prevent data 
loSS caused by Saving errorS or misalignment of the System 
if the operator was experienced in interpreting the acquired 
data. 
Software Structure 
FIG. 13 shows a main user interface according to one 
embodiment from which the Fast EEM system 10 may be 
controlled. With the benefit of the present disclosure, those 
having skill in the art will understand that there are numer 
ous ways in which system 10 may be controlled and that the 
interface shown in FIG. 13 is but only one of those ways. 
Other user interfaces may be implemented as is known in the 
art. In FIG. 13, the center displays show four spectra of the 
last fluorescence measurement (top graph) and the acquired 
reflectance data (bottom). The excitation wavelengths of the 
displayed spectra may be changed online. Around this 
Screen, different buttons may be present, which allow access 
to the certain main features. 
In the configuration component of the Software interface 
illustrated in FIG. 13, all the configurations were accessible 
and controllable. In the 'Saving parameter Sub program, a 
patient number and the directory path may be defined. The 
integration time for the individual exposures and the Settings 
of the CCD camera 44 may be stored in the corresponding 
Subroutine. The Spectrograph Settings may be changed in the 
Chromex-Vi. The buttons for the mercury calibration, the 
lamp monitoring, and the power output of the probe may 
also be associated with the configuration Settings of the 
Software. 
In regard to acquiring date, individual Switches for Start 
ing the background and the Standards measurements may be 
placed on the left Side of the Spectra display. The 
fluorescence, reflectance and combined reflectance and fluo 
rescence measurements may be initiated in the Main Mea 
Surements box. Naming of files with the acquired data may 
be dependent on which kind of measurement is chosen. In 
one embodiment, no manual naming of files by the operator 
was necessary. 
Many additional features may be added to the software 
and user interface. For example, an image of the whole CCD 
chip with all possible Settings and binnings may be achieved. 
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The monochromator 24 may be moved to any desired 
wavelength. The center wavelength of the Spectrograph 42 
may be set manually, too. The camera's 44 exposure time 
may be adjusted, and it may possible to choose if the Shutter 
of the Spectrograph 42 should open or if it should remain 
closed to image the dark current. Another Sub Vi may be 
designed to change all the Settings of the monochiomator 24, 
Such as wavelength, and Slit width. Emission and reflectance 
Spectra may be loaded and Visually compared on the Screen. 
It may be possible to turn on and off the probe's illumination 
light from the main Screen. It shall be understood that none 
of these extra features need influence the Settings for the 
main measurements. Default values may always be restored 
when measurements are Started. When exiting the Software, 
a protocol file may be created that contains all the important 
Settings, the date, file names and the name of the operator. 
In one embodiment, about 112 individual Vi's were created 
to design a reliable, easy-to-use and fault-proof System, 
although it will be understood that more or fewer routines 
may be implemented according to the needs or desires of the 
user. In other embodiments, for instance, a simpler or more 
complicated user interface may be easily implemented as is 
known in the art. 
Temporal Performance 
Table 2.1 compares the temporal performance of the two 
embodiments of Fast EEM systems described above-one 
utilizing a 150 W ozone free Xe arc lamp, single 
monochromator, and twenty-one fiber probe (Embodiment 
A); and the other system using a 450 W ozone free Xe arc 
lamp, a double monochromator, and a forty-six fiber probe 
(Embodiment B). Overall, the time to obtain a complete 
EEM in Embodiment B between 330 nm and 500 nm. 
excitation in Steps of 10 nm was cut down to less than 45 S, 
a temporal improvement of 105 seconds over Embodiment 
A. To obtain the same amount of counts on the CCD chip, 
the exposure times may be cut down from 1500 ms to 200 
ms, depending on the excitation wavelength. An exposure 
time of 375 ms may be expected since the amount of light 
delivered to the tissue may increase by a factor of 4. The 
alignment on the emission side was improved in Embodi 
ment B, So that the throughput was almost twice as much as 
before. The monochromator's Scanning Speed may be 
decreased from 34 S for an entire Scan and resetting to the 
Starting wavelength to less than 3 S. A faster computer and 
the use of a 32-bit operating system in Embodiment B cut 
down the computation time by almost 50%. However, it still 
required about 2 S per exposure to transfer the data from the 
camera to the computer. This value adds up to 42 s, 75% of 
the whole data acquisition time. This handicap may be 
further improved by replacing the readout electronics of the 
CCD chip. The control of the illumination shutter, a new 
feature of the System, did not add any extra time to the 
measurements. The shutter opened and closed in less than 5 
S. 
In embodiment B, reflectance measurements may be sped 
up by using a 200 um fiber for the excitation light instead of 
a 80 um fiber, since more light is provided to the sample 60, 
which may be a tissue. A more intense white light output of 
the System may serve the same purpose. By using a different 
imaging spectrograph 42 with a grating with lower spectral 
dispersion, a wider Spectrum may be covered on the CCD 
chip. To cover the desired Spectral range for reflectance 
measurements, only two (instead of three) Sub-range expo 
Sures may be necessary. Overall data acquisition time over 
2 wavelength ranges and four positions may be achieved in 
31s in Embodiment B, which is about three times faster than 
that in Embodiment A, in which only 3 spatial positions had 











Comparison of Temporal Performance: 
Embodiment A Embodiment B 
Fluorescence 
Scanning time: 2 x 170 nmf 2 x 70 nmf 
2 x 500 nm - 300 mm 10 nmfs = 34s 150 mm.fs = 2.7s 
Exposure time 18 x 1.5 s = 27 s 20 exposures: X = 6.0 s 
(see 3.1.2) 
Moving filter wheel 8 x 1 s = 8 s 8 x 1 s = 8s 
Camera shutter, data 18 x 4.5 s = 81s 21 x 2 s = 42s 
transport 
illumination shutter <1s 
X = 150s X = 53.7s 
Reflectance 
Exposure time 9 exposures: 27 s 8 exposures: 6 s 
Camera shutter, data 63S 25 s 
transport 
X = 90s X = 31s 
In Summary, a combined reflectance and fluorescence 
measurement with the Embodiment B may be obtained in 85 
S, about three times faster than with the Embodiment A. This 
temporal improvement may benefit the patient and may also 
minimize the chance that the physician moves the probe 
during measurements. 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
EXAMPLE 1. 
Fluorescence Excitation Emission Matrices of 
Human Tissue: A System for In Vivo Measurement 
and Method of Data Analysis 
This example describes a Fast EEM system capable of 
measuring Spatially resolved reflectance spectra from 
380-950 nm and fluorescence excitation emission matrices 
from 330-500 nm excitation and 380-700 nm emission in 
Vivo. System performance was compared to a Standard 
scanning spectrofluorimeter. This FastEEM system was used 
to interrogate human normal and neoplastic oral cavity 
mucosa in Vivo. Measurements were made through a fiber 
optic probe and required about 4 minutes total measurement 
time. This example also presents a method based on auto 
correlation vectors to identify excitation and emission wave 
lengths where the Spectra of normal and pathologic tissues 
differ most. The FastEEM system provides a tool with which 
to Study the relative diagnostic ability of changes in 
absorption, Scattering and fluorescence properties of 
Samples, including tissue Samples. 
Materials and Methods: 
FIG. 14 illustrates a block diagram of a Fast EEM system 
10 in accordance with the present disclosure. This system 
includes at least three main components: (1) an arc lamp 22, 
Stepper motor driven monochromator 24 and filter wheel, 
which provides monochromatic and broad band excitation, 
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(2) a fiber optic probe 30 which directs excitation light to the 
Sample 60, which may be a tissue Sample, and collects 
remitted fluorescence from, in this embodiment, one loca 
tion and diffusely reflected light from, in this embodiment, 
three locations, and (3) a filter wheel, imaging spectrograph 
42 and CCD camera 44 which detects the spectrally resolved 
reflectance and fluorescence Signals. Excitation monochro 
mator position, filter wheel position, Spectrograph grating 
position, CCD operation and data acquisition are controlled 
using a laptop personal computer 50 mated to a docking 
Station. The Specifications of each Sub-System are described 
below. 
The probe 30, illustrated in FIG. 15, included a total of 
forty-six optical fibers (200 um diameter, NA=0.2) arranged 
in two concentric bundles. The center bundle contained 
twenty-five fluorescence excitation fibers and twelve fluo 
rescence collection fibers. The proximal ends of the fluo 
rescence excitation fibers were arranged in two vertical lines 
at the exit slit of the excitation monochromator 24 to 
maximize the coupling of the light into the Sample. The 
proximal ends of the fluorescence collection fibers were 
arranged in a single vertical line at the entrance Slit of the 
imaging spectrograph 42. At the distal end of the probe 30, 
the fibers that eXcite and collect fluorescence were arranged 
randomly in a central bundle and placed in contact with a 
Short piece of a thick quartz fiber (2 mm diameter, 15 mm 
long, NA=0.2). The distal tip of this fiber was placed in 
contact with the Sample Surface 60, and ensured that the area 
from which fluorescence was collected was the same as that 
directly illuminated. 
The nine fibers for illumination and collection of diffuse 
reflectance were arranged in a concentric ring around the 
thick quartz fluorescence measurement fiber. The distal ends 
of these fibers were flush with the tip of the central fiber and 
were placed in contact with the sample surface 60. White 
light from a port on the Side of the lamp housing was coupled 
to the proximal end of a single illumination fiber (80 um, NA 
0.2). Photons that scatter through the tissue and exit the 
surface were collected at four different positions with seven 
collection fibers; three located 180 from the illumination 
fiber (3 mm distance), two located 90° from the illumination 
fiber (2.1 mm) and two located 45° from the illumination 
fiber as shown (1.1 mm) (See FIG. 15). The proximal ends 
of the reflectance collection fibers were situated at the top of 
the Vertical line of fluorescence collection fibers, Separated 
by dummy fibers as shown in FIG. 15. 
The light source 22 for the instrument, which provided 
both quasi-monochromatic excitation for fluorescence and 
broadband illumination for reflectance, was a 150 W ozone 
free Xe arc lamp (Spectral Energy Corp., Westwood N.J.) 
with a spherical rear reflector. A condenser System consist 
ing of two plano-convex quartz lenses was used to couple 
light into monochromator 24. The primary condenser was 
1.5 inches in diameter with an aperture ratio of f/1.5. The 
Secondary condenser was also 1.5 inches in diameter, but 
was masked to provide numerical aperture matching to the 
monochromator 24. A manual Shutter was located between 
the condensing optics and monochromator 24 and was 
closed to prevent fluorescence excitation light from reaching 
the Sample 60 during reflectance measurements. The mono 
chromator 24 had an aperture ratio of f/3.6 (Spectral Energy, 
GM 252) and was used with an ion-etched holographic 
grating (ISA, Edison, N.J., 240 nm blaze, 1180 grooves/mm, 
dispersion=3.3 nm/mm). An RS-232 controlled stepper 
motor drove the monochromator 24 with a maximum step 
ping rate of about 400 step/sec (about 10 nm/sec). A band 











the monochromator to about 2.0 mm. Light was coupled 
from the monochromator 24 into the probe 30 via a fiber 
optic adapter (Spectral Energy, GMA 257) consisting of a 
quartz plano-convex lens and a 5xquartz microScope objec 
tive. The light passing through the objective was focused 
onto a vertical line of 25 fibers in two columns, placed at the 
focal plane of the objective (See FIG. 15). The reflectance 
excitation fiber was attached to the lamp housing via a 
micropositioner. Broadband light exiting the lamp housing 
through an existing hole was coupled to the reflectance 
illumination fiber using a quartz plano-convex lens (NA= 
0.24). A five position illumination filter wheel placed 
between the lamp and the lens contained three long pass 
filters with 50% transmission at 295 nm, 515 nm and 715 
nm. One of the filter positions was blocked and acted as a 
Shutter to prevent white light from reaching the Sample 
during fluorescence measurements. 
Light collected by fluorescence and reflectance fibers was 
coupled through an 8 position, computer controlled collec 
tion filter wheel, into a Chromex 250 IS (Albuquerque, 
N.Mex.) imaging spectrograph 42 containing a holographic 
grating blazed at 380 nm with 150 grooves/mm and a 
reciprocal linear dispersion (RLD) of 20 nm/mm. The fibers 
were projected onto an entrance slit (250 um) which yielded 
a spectral resolution of about 5 nm. A thermo-electrically 
cooled CCD camera 44 operated at about -30° C. 
(Spectrasource HPC-1, Westlake Village, Calif.) was located 
at the back focal plane of the imaging spectrograph 42. Chip 
dimensions were 13.8x9.2 mm with 1536x1024 pixels 
(Kodak KAF-1600 grade 2), yielding a nominal spectral 
range of about 276 nm for a single grating position. Dark 
current was Specified as 0.25 electrons/pixel/sec when oper 
ated at -30° C. The quantum efficiency of the lumogen 
coated chip ranged from a peak of 40% at 550 nm to a low 
of 15% at 250 nm. 
The detector and imaging Spectrograph were wavelength 
calibrated by measuring the room light spectra that showed 
three Mercury peaks at 404.7, 436 and 546 mm. The relation 
between pixels and wavelength was then linearly fitted 
through these points. 
Fluorescence and reflectance measurements were 
obtained Sequentially. Prior to fluorescence measurements, 
the white light port was closed and pixels illuminated by the 
fluorescence fibers were selected to be read from the CCD 
44. Dark current and A/D conversion offset was measured 
with the Same Setting as the Subsequent measurement but 
with a closed camera shutter. These were Subtracted from all 
fluorescence and reflectance measurements. The first exci 
tation wavelength was Selected by Scanning the excitation 
monochromator, the emission filter wheel was rotated to 
Select the appropriate long pass filter and the spectrograph 
grating was adjusted to record Signal over the desired 
emission wavelength range. The monochromator 24 and 
camera Shutters were then opened for the desired exposure 
time to record the fluorescence emission spectrum (1.5 
Seconds). The excitation wavelength was then incremented, 
and the proceSS repeated until all desired excitation wave 
lengths have been measured. The excitation wavelengths 
were incremented from 330 to 500 nm in 10 nm steps. Table 
1 contains a list of the excitation wavelengths and corre 
sponding long pass filters and emission wavelength ranges 
used in this Example. 
Following collection of fluorescence Spectra, diffuse 
reflectance Spectra were then measured. For these 
measurements, the monochromator Shutter was closed, the 
emission filter wheel was set to the lowest filter position and 
the pixels illuminated by the corresponding reflectance 
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collection fibers were selected to be read from the CCD 44. 
Dark current and A/D conversion offsets were measured and 
stored for subtraction of the following measurements. The 
reflectance spectrum was collected over three illumination 
wavelength ranges. Prior to measurement of each range, the 
appropriate long-pass filter was Selected in the illumination 
filter wheel, and the Spectrograph grating was adjusted to 
record Signal over the desired wavelength range. The lamp 
and camera shutters were then opened for the desired 
exposure time to record the reflectance spectrum (0.4–4.8 
Seconds). The illumination wavelength range was then 
incremented, and the process repeated until all desired 
wavelength ranges have been measured. Exposure times 
were determined empirically to achieve a Signal to noise 
ratio greater than 20. Table 1 contains a list of the illumi 
nation wavelength ranges and corresponding long pass fil 
ters used for diffuse reflectance measurements. The high 
dynamic range of the reflectance measurements, Spanning 
over three orders of magnitude, required that each spatial 
position be read out individually from the CCD 44. This 
prevented Saturation and blooming artifacts. 
There are no accepted Safety Standards for illumination of 
mucosal Surfaces other than skin and cornea. However, the 
exposure of Solar radiation that is equivalent to the exposure 
received when a measurement is made with this System has 
been calculated. The method compares the spectral irradi 
ance IW/cm nm) of the excitation source with solar irra 
diance data obtained from NSF Polar Programs UV Spec 
troradiometer Network 1994–1995 Operations Report; NSF 
UV Radiation Monitoring Network 1994 to 1995 Volume 
5.0 Data Set. Available at WWW.BIOSPHERICAL.COM.). 
The comparison includes a point-wise division of the irra 
diance from the FastEEM System to the Solar irradiance at 
the same wavelength. This ratio gives a relative Solar 
exposure factor. The Solar data is for a Sunny day in San 
Diego, Calif. Irradiation during fluorescence excitation is 
less than 7 times Solar exposure at all wavelengths. Given 
that fluorescence excitation times were 1.5 Seconds, this 
corresponds to exposure to Solar radiation for less than 11 
Seconds in any given wavelength band. During diffuse 
reflectance measurements, the lamp exposure is maximum at 
300 nm, where the relative exposure is a factor of 25 that of 
the Sun. Since the total exposure time for this wavelength 
band is 14 Seconds, the exposure corresponds to 350 Seconds 
or less than 6 minutes. All other wavelengths have relative 
exposure factors of 10 or less resulting in a shorter equiva 
lent total Solar exposure. 
Prior to every patient measurement the probe output was 
measured with a calibrated power meter (Newport, Irvine, 
Calif., 818-UV) at 400 nm excitation wavelength. An aver 
age output of 86 W+/-12 W was achieved at this wave 
length with a bandwidth of 6.6 mm. Background fluores 
cence Spectra were measured with the probe dipped in a 
non-fluorescent bottle containing distilled water. This back 
ground EEM was Subtracted from all Subsequently acquired 
EEMS to correct for room lights and probe autofluorescence. 
The non-uniform spectral response of the System was cor 
rected using correction factors determined from measure 
ments of calibration Sources; in the visible a N.I.S.T trace 
able tungsten ribbon filament lamp and in the UV a 
deuterium lamp were used (550C and 45D, Optronic Labo 
ratories Inc., Orlando, Fla.). Variations in the intensity of 
fluorescence excitation light Source at different excitation 
wavelengths were corrected using measurements of the 
intensity at each excitation wavelength at the probe tip using 
a calibrated photodiode (818-UV, Newport). Background 











contributions were measured with all parameters Set as for 
tissue measurements except the white light shutter was 
closed. These measurements were Subtracted from all Sub 
Sequent reflectance spectra. 
Fluorescence and reflectance Standards were measured 
before each patient measurement. The fluorescence intensity 
was reported relative to the fluorescence intensity of a 
solution of 2 mg/L Rhodamine 610 (Exciton, Dayton, Ohio) 
in ethylene glycol at 460 nm excitation and 580 nm emis 
Sion. Reflectance data are reported relative a 2.68% by 
volume solution of 1.072 micron diameter polystyrene 
microspheres (Polyscience Inc., Warrington, Pa.). The 
microSphere Standard was used for its well-characterized 
optical properties. The total integrated reflectance of this 
Standard was measured on a double beam spectrophotometer 
(U-3300 Hitachi, Tokyo, Japan) with an integrating sphere 
attachment (Labsphere Inc., North Sutton, N.H.). This was 
used to correct the reflectance Standard measurements made 
with the FastEEM system. Tissue spectra at each collection 
fiber position were divided pointwise by the corrected 
Standard reflectance spectrum at the corresponding fiber 
position. 
The EEMs were assembled offline from each series of 
fluorescence emission Scans. Data processing and plotting 
were performed with Matlab, (The MathWorks Inc., Natick, 
Mass.). Reflectance spectra were assembled from three 
wavelength areas giving a range from 380 to 950 nm. The 
wavelength range was further reduced (380-800 nm) to 
comply with the range of calibration measurements of the 
reflectance standards on the U-3300. Reflectance data were 
reported between 380 and 595 nm, a range where the 
possible influence of room lights in the measurement was 
minimized. 
System Validation 
System performance was assessed using two fluorescence 
standards. The first standard was a 2 mg/L Rhodamine 610 
(Exciton Inc., Dayton, Ohio)ethylene glycol Solution that is 
non-Scattering, but has peak fluorescence intensity approxi 
mately twice the average intensity of human cervix. The 
Second Standard mimics the optical properties of tissue and 
consists of 20 uM Flavin Adenine Dinucleotide (FAD, 
Kodak, Rochester, N.Y.), 0.625 vol % polystyrene micro 
spheres (PolyScience Inc., diameter=1.072 um). 
Both standards were measured with the FastEEM system 
10 and a scanning spectrofluorimeter (SPEX, Fluorolog II, 
Edison, N.J.). The EEMs measured with the SPEX were 
considered as Standards Since the performance of the System 
is well documented (dynamic range=10, spectral resolution 
5 nm, corrected for non-uniform spectral response). The 
excitation light was incident perpendicular to the Sampling 
cuvette and the emitted light was collected at approximately 
a 20 degree angle with respect to excitation light. A front 
focus arrangement with a 10 mm cuvette was used in the 
SPEX. 60 minutes were required to collect a full EEM from 
each sample with the SPEX. 
Clinical Studies 
In Vivo data were obtained from a group of patients with 
a known or Suspected premalignant or malignant lesions of 
the oral cavity. The studies were reviewed and approved by 
the Internal Review Board of the University of Texas at 
Austin and the Surveillance Committee at the UT MD 
Anderson Cancer Center (Houston). Informed consent was 
obtained from each perSon in the Study. Before using the 
probe, it was disinfected with Metricide (Metrex Research 
Corp.) in accordance with the standard clinical protocol. 
Background fluorescence EEM and reflectance Spectra were 
measured by dipping the fiber optic probe in a non 
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fluorescent bottle filled with deionized water. These EEMs 
and Spectra correspond to the System autofluorescence, and 
were subtracted from all subsequently acquired EEMs for 
that patient. Next an EEM was measured from a Rhodamine 
calibration Standard and a reflectance spectrum was mea 
Sured from a polystyrene Solution calibration Standard. The 
probe was then guided to the tissue site to be examined and 
its tip positioned flush with the tissue. A fluorescence EEM 
and reflectance spectra were obtained from Sites within a 
lesion and a clinically normal site. Post-SpectroScopy, a 2-4 
mm biopsy of the tissue was taken from normal and abnor 
mal Sites where the probe measured Spectra. These speci 
mens were evaluated by an experienced pathologist, Bonnie 
Kemp, M.D., using light microScopy and classified using 
Standard diagnostic criteria. 
Data Analysis 
One of the goals of the Fast EEM instrument 10 is to 
provide information for the identification of excitation 
wavelengths suitable for the differentiation of tissue of 
differing pathological characteristics, as well as identifica 
tion of the chromophores responsible for the differences. 
While all such information is present in the EEMs collected, 
it can be difficult to extract due to the dimensionality of the 
data Set. A method was devised to Separately characterize the 
excitation and emission characteristics of the data Set. 
Given that the EEM has dimensions corresponding to (), 
2), the following autocorrelation vectors are defined: 
W 
Xay(A) =X EEMA, An). EEM (A.A.) 
i=l 
W 
ma(A) =XEEM (A.A.). EEM (A.A.) 
i=l 
where x(0) is the excitation autocorrelation vector and 
m(0) is the emission autocorrelation vector. Essentially, 
the emission autocorrelation vector is the diagonal of the 
product of the EEM with its transpose, and the excitation 
autocorrelation vector is the diagonal of the product of the 
transpose of the EEM with the EEM. Note that in signal 
processing terms, the autocorrelation Vectors, X, and m, 
are a measure of the average Signal of the EEM at each 
excitation or emission wavelength, respectively. In this way 
they provide qualitative information about and EEM. 
An example with simulated data is presented in FIGS. 
16A and 16B to illustrate how autocorrelation vectors reflect 
changes in fluorescence peak positions in EEMS. Two kinds 
of changes are simulated in the modeled data: a shift in the 
excitation wavelength at which a fluorescence peak appears, 
and a shift in the emission wavelength at which a fluores 
cence peak appears. The original peak in the EEM was 
modeled as a Single gaussian at 380 nm excitation, 550 nm 
emission with a FWHM of 35 nm in emission and excitation 
wavelengths. The original peak was then shifted by 30 nm 
in excitation as shown by arrow 1 in FIG.16A. The shift in 
emission wavelength is shown by arrow 2 in FIG.16A, and 
corresponds to a 30 nm shift in the emission peak of the 
original data. Three Sets of autocorrelation vectors were 
computed: one for the EEM with the original peak, one for 
the EEM with the excitation wavelength-shifted peak, and 
one for the EEM with the emission wavelength-shifted peak. 
The autocorrelation vectors are shown in FIG. 16B. Com 
paring the vectors for the original EEM (row 1 in FIG. 16B) 
with the vectors from the EEM with the excitation 
wavelength-shifted EEM (row 2 in FIG.16B), it is seen that 











change in excitation wavelength but not in emission wave 
length. Similarly, comparing the autocorrelation vectors for 
the original EEM with the vectors from the EEM with the 
emission wavelength shift in the peak (row 3 in FIG. 16B) 
shows that the emission autocorrelation vector is Sensitive to 
the changes in emission wavelength but not excitation 
wavelength. 
It is Sometimes desirable to normalize the autocorrelation 
vectors to facilitate comparisons between different Sets of 
measurements. Normalized autocorrelation vectors have 
been calculated by dividing these vectors by their RMS 
value, in effect forcing the area of the vector to one unit of 
Signal energy. The normalized emission autocorrelation vec 
tor is well Suited for the identification of differential features 
in EEMS, Such as the shifting or broadening of fluorescence 
peaks. 
Results and Discussion: 
FIGS. 17A and 17B show fluorescence EEMs of the 
non-Scattering Rhodamine Standard and the Scattering FAD 
phantom obtained with a FastEEM system 10. Intensities are 
reported relative the Rhodamine intensity measured at 460 
nm excitation and 580 nm emission wavelength. FIGS. 18A 
and 18B show fluorescence emission spectra of the 
Rhodamine standard obtained at 370 and 450 nm excitation 
with the SPEX and the FastEEM system 10 as well as the 
fluorescence background. FIGS. 18B and 18D show the 
Same spectra for Scattering FAD phantom obtained at the 
Same excitation wavelengths. The Spectra are normalized at 
their maximum. Note the presence of Rayleigh Scattering 
peaks from the excitation Source in the data taken with the 
SPEX. In general, from non-scattering samples (FIGS. 18A, 
18C) the FastEEM system 10 collects less light above 600 
nm than the SPEX. This may be due to the different 
collection efficiencies of the FastEEM probe and the front 
face collection geometry of the SPEX. Under scattering 
conditions and with lower fluorescence Signal, the influence 
of background fluorescence becomes more critical. At 370 
nm excitation wavelength the FastEEM system 10 measures 
more fluorescence below 500 nm. A comparison with the 
measured fluorescence background however shows that the 
additional Signal has the same shape as the background. It 
has been hypothesized that the background may have been 
underestimated by measuring it in a non-Scattering non 
fluorescent media. 
In-vivo fluorescence EEMs of the oral cavity were mea 
Sured from 71 sites and in-vivo reflectance spectra were 
measured from 49 sites. These were obtained from patients 
in two studies. The first study included patients with abnor 
mal oral lesions identified in a previous medical examination 
(17 patients). The Second study, contributing nine patients, 
was of normal Volunteers. All Sites interrogated Spectro 
Scopically in patients with lesions were biopsied and Sub 
mitted for histopathological analysis. Spectra and biopsies 
were also obtained from a contralateral Site with no lesion in 
these patients with abnormal lesions. These biopsies were 
also evaluated histopathologically. No biopsies were taken 
from the normal volunteers. In this Example, we show 
representative EEMs from tissue found to be histopathologi 
cally normal and malignant to illustrate spectral features 
detectable with the FastEEM system. 
Two EEM contour plots from a normal and an abnormal 
area of the tongue are presented in FIGS. 19A and 19B, 
respectively. In the normal Sample, fluorescence is observed 
throughout the whole collection range, with a peak located 
at 330/380 (excitation/emission) and a ridge extending from 
340/450 to 450/500. Table II lists excitation-emission 
maxima pairs of endogenous tissue chromophores. Com 
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parison of the observed peaks with Table II shows these 
peaks are consistent with the emission of Structural proteins 
Such as collagen and elastin, pyridine nucleotides (NADH) 
and flavoproteins (FAD). The normal site shows overall 
increased fluorescence with respect to the abnormal site 
shown in FIG. 19B. The abnormal site, assessed by a 
pathologist as being moderately differentiated Squamous cell 
carcinoma, also shows broad fluorescence throughout. Peaks 
are observed at 330/380, 350/460, 460/520 and 500/630. A 
valley is seen at 420 nm excitation between 560 and 580 
emission. This valley is seen to extend along the 420 nm 
excitation line as well as the 580 nm emission line. Table III 
Suggests that these features are produced by hemoglobin 
reabsorption. Hemoglobin reabsorption may also in part 
account for the shift in the peaks of the abnormal EEM 
relative to the normal EEM. A summary of the excitation and 
emission maxima for the peaks observed in the normal and 
abnormal sites measured is presented in Table IV. 
Fluorescence emission spectra at three Selected excitation 
wavelengths are shown in FIG. 20, illustrating changes in 
relative intensities of fluorescence emission. For comparison 
purposes each set (normal/abnormal) was normalized to the 
maximum at 350 nm excitation. FIG. 200a) shows the 
emission spectra at 350 nm excitation. Fluorescence from 
the normal site is seen as a broad peak with a maximum at 
455 nm. The peak from the abnormal site is seen to be 
narrower and red-shifted. Examination of this spectrum at 
410, 540 and 580 nm Suggests that the change in lineshape 
is due to oxygenated hemoglobin. The general line shapes of 
the fluorescence observed at 410 nm excitation (FIG.20(b)) 
are seen to be similar for both sites in the 450-575 nm. 
excitation range, with a broad peak at 500 nm. The abnormal 
Site shows a significantly lower fluorescence intensity, as 
well as an extra, narrow fluorescence peak at 640 nm, 
attributed to porphyrin fluorescence. FIG.20(c) shows the 
emission spectra at 460 nm excitation. The normal site 
shows a broad peak at 520 nm and clear modulation from 
hemoglobin reabsorption at 540 and 580 nm. Fluorescence 
from the abnormal site shows an even more marked hemo 
globin reabsorption; also the overall fluorescence intensity is 
reduced. 
FIGS. 21A and 21B show the emission and excitation 
autocorrelation vectors for the same measurements. Note 
that the plots have a logarithmic y-axis. The emission 
autocorrelation vectors have a large broad peak at 460 nm 
corresponding to the main fluorescence peak observed in the 
EEMs. The vectors show the effect of hemoglobin absorp 
tion around 410, 540 and 580 nm in the abnormal site and 
the presence of additional fluorescence in the UV in the 
normal sample (FIG. 21A). This autocorrelation vector also 
highlights the peak at 610 nm in the abnormal Sample. The 
excitation autocorrelation vectors show different line shapes. 
The curve corresponding to the normal site decreases 
steadily from 330 nm to 500 nm excitation. The curve from 
the abnormal Site shows a peak at 350 nm and a minimum 
at 410 nm. The latter illustrates the greater influence of 
hemoglobin reabsorption in the abnormal Sample also shown 
in FIG. 20. 
The corresponding reflectance data is shown in FIGS. 
22A-22C. Position 1 corresponds to the collection fibers 
closest to the source fiber and position 3 to those furthest 
from the Source fiber as shown in FIG. 15. The difference in 
position allow for spatially resolved reflectance measure 
ments. Differences induced by the fluorescence reabsorption 
of oxygenated hemoglobin in the normal Site and abnormal 
site are shown. The modulation of the spectrum by the 540 











in the abnormal Sample; this is consistent with the increased 
reabsorption Seen in the fluorescence Spectrum of the abnor 
mal sample. The reflectance in the blue range (450–500 nm) 
of the abnormal site is consistently higher than that of the 
normal site. Below 450 nm the reflectance seems not to 
differ between the normal and abnormal Samples. 
Conclusions 
The total data acquisition time for the data presented here 
was 2.5 minutes for a fluorescence EEM, and 1.5 minutes for 
the Spatially resolved reflectance measurements. However, 
only 29 Seconds of this time represented fluorescence col 
lection. Actual reflectance collection time was 26 Seconds. 
The most time consuming process was changing the exci 
tation wavelength using the Stepper motor controlled exci 
tation spectrograph and changing the corresponding long 
pass filter using the remotely controlled filter wheel. Worm 
drive based monochromators are available (DDD180, ISA) 
which require less than 10 Seconds to Scan our entire 
wavelength range in 10 nm Steps, and could Substantially 
reduce the total measurement time. Using a higher power 
lamp may further reduce acquisition time of both fluores 
cence and reflectance. 
This Example has demonstrated the acquisition of EEMs 
in combination with Spatially resolved reflectance measure 
ments of tissue phantoms and in the oral cavity in Vivo with 
good Signal to noise ratio. The System features easy and 
arbitrary selection of excitation wavelengths in the UV and 
Visible range. The System is also portable, and capable of 
functioning in a hospital operating room. Probes used in the 
Fast EEM System incorporate channels to measure Spatially 
resolved reflectance and fluorescence, and are built Small 
enough (less than about 5 mm) to be used during endoscopic 
Surgical procedures. Autocorrelation vectors x and mare 
a Suitable method to reduce the data Set while preserving 
information about the wavelength bands carrying informa 
tion. Based on the representative data shown here, fluores 
cence emission and excitation as well as reflectance data 
appear promising for the identification of tumors of the oral 
cavity. The Fast EEM system is an ideal tool to identify a 
Subset of the most promising optical features to identify 
pathological findings in large clinical Studies. 
TABLE I 
Fluorescence long-pass and diffuse reflectance filters 
used. Fluorescence long-pass filters are shown with the correspond 
ing fluorescence excitation wavelength. Diffuse reflectance filters are 
shown with the corresponding measurement range. 
Fluorescence excitation wavelengths 
Fluorescence long-pass filter (nm) 
(1) GG 375 330, 340 
(2) GG 395 350, 360 
(3) GG 420 370, 380,390 
(4) GG 445 400, 410, 420 
(5) GG 475 430, 440 
(6) OG 495 450, 460 
(7) OG 515 470, 480 
(8) OG 530 490, 500 
Possible reflectance measurement 
Reflectance filter range 
(1) WG 295 + GG 375 350-628 
(2) OG 515 + GG 375 500-778 
(3) RG 715 + GG 375 700-978 
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TABLE II 
Summary of excitation femission maxima of endogenous 
tissue chromophores. 





Collagen I 340/4101 
Collagen I 500/52011 
Elastin 330/405 
TABLE III 
Summary of absorption maxima of Oxy- and deoxy 
hemoglobin. 
Absorbers Absorption wavelength (nm) 
Oxygenated hemoglobin 41522 
Oxygenated hemoglobin 542,41 
Oxygenated hemoglobin 57744 
Deoxygenated hemoglobin 43O44 
Deoxygenated hemoglobin 5.5544 
TABLE IV 
Summary of excitation/emission maxima for peaks in 
the fluorescence EEMs of normal and abnormal oral cavity samples. 
The intensity is reported relative to the rhodamine Standard at 460/S80 nm. 
Fluorescence intensity 
(Relative to rhodamine standard 
at 460/580 nm) 
Peak location 
Excitation femission nm. 










Cervical Pre-Cancer Detection Using A 
Multivariate Statistical Algorithm Based On Laser 
Induced Fluorescence Spectra. At Multiple 
Excitation Wavelengths 
A portable fluorimeter was developed and utilized to 
acquire fluorescence spectra from 381 cervical Sites in 95 
patients at 337,380 and 460 nm excitation immediately prior 
to colposcopy. A multivariate Statistical algorithm was used 
to extract clinically useful information from tissue Spectra 
acquired in Vivo. Two full-parameter algorithms were devel 
oped using tissue fluorescence emission spectra at all three 
excitation wavelengths (161 excitation-emission wave 
length pairs) for cervical pre-cancer (Squamous intraepithe 
lial lesion (SIL)) detection: a Screening algorithm which 
discriminates between SILS and non SILS with a sensitivity 
of 82%+1.4 and specificity of 68%+0.0, and a diagnostic 
algorithm which differentiates high grade SILS from non 
high grade SILS with a sensitivity and specificity of 79%+2 











was also employed to reduce the number of fluorescence 
excitation-emission wavelength pairs needed to re-develop 
algorithms that demonstrate a minimum decrease in classi 
fication accuracy. Two reduced-parameter algorithms which 
employ fluorescence intensities at only 15 excitation 
emission wavelength pairs were developed: the Screening 
algorithm differentiates SILS from non SILS with a sensi 
tivity of 84%+1.5 and specificity of 65%+2 and the diag 
nostic algorithm discriminates high grade SILS from non 
high grade SILS with a Sensitivity and Specificity of 
78%+0.7 and 74%+2, respectively. Both the full-parameter 
and reduced-parameter Screening algorithms discriminate 
between SILS and non SILS with a similar specificity (+5%) 
and a substantially improved sensitivity relative to Pap 
Smear Screening. A comparison of the full-parameter and 
reduced-parameter diagnostic algorithms to colposcopy in 
expert hands indicated that all three have a very similar 
Sensitivity and Specificity for differentiating high grade SILS 
from non high grade SILS. 
This paper presents the development and application of a 
detection technique for human cervical pre-cancer based on 
laser induced fluorescence Spectroscopy. A portable fluorim 
eter consisting of two nitrogen pumped-dye lasers, a fiber 
optic probe and a polychromator coupled to an optical 
multi-channel analyzer was utilized to acquire fluorescence 
spectra from 381 cervical sites in 95 patients at three 
excitation wavelengths: 337, 380 and 460 nm. A general 
multivariate Statistical algorithm was then used to analyze 
and extract clinically useful information from tissue Spectra 
acquired in Vivo. First, a Screening algorithm was developed 
to discriminate between SILS and non SILS (normal Squa 
mous and columnar epithelia and inflammation); Second, a 
diagnostic algorithm was developed to differentiate HGSILS 
from non HG SILS (LG SILs, normal epithelia and 
inflammation). The retrospective and prospective accuracy 
of both the Screening and diagnostic algorithms were com 
pared to the accuracy of Pap Smear Screening and to col 
poScopy in expert hands. 
The general multivariate Statistical algorithm was initially 
developed and tested using cervical tissue spectra acquired 
at 337 nm excitation from 476 cervical sites in 92 patients. 
This algorithm could be used to differentiate SILS and 
normal Squamous tissues with an average Sensitivity and 
specificity of 91%+2 and 78%+3, respectively. A limitation 
however is that Spectra of normal columnar tissues and 
inflammation were indistinguishable from those of SILS at 
this single excitation wavelength. Furthermore, a multivari 
ate Statistical algorithm based Solely on spectra at 337 mm 
excitation could not discriminate between HGSILS and LG 
SILS effectively. 
However, multivariate Statistical analysis of cervical tis 
Sue fluorescence spectra acquired in Vivo at 380 nm and 460 
nm excitation from a subset of the 92 patients indicated that 
Spectra at these excitation wavelengths can overcome the 
limitations of spectra at 337 nm excitation. Spectra at 380 
nm excitation from 165 Sites in a first group of 40 patients 
could be used to differentiate SILS from normal columnar 
epithelia and inflammation with a Sensitivity and Specificity 
of 77%+1 and 72%+9, respectively; spectra at 460 nm 
excitation from 149 Sites in a Second group of 24 patients 
could be used to differentiate HG SILS from LG SILS with 
a sensitivity and specificity of 80%+4 and 76%+5, respec 
tively. 
The results from previous clinical Studies Suggested that 
an algorithm based on normalized, mean-Scaled Spectra at 
337 nm excitation may be used to differentiate between SILS 
and normal Squamous tissues, while an algorithm based on 
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Similarly pre-processed spectra at 380 nm excitation may be 
used to differentiate SILS from normal columnar tissues and 
Samples with inflammation. Finally, a third algorithm based 
on normalized tissue Spectra at 460 nm excitation may be 
used to discriminate between LGSILS and HGSILS. These 
results suggest that (1) a composite Screening algorithm 
based on a combination of the first two constituent algo 
rithms may be used to differentiate between SILS and non 
SILS (normal epithelia and inflammation) and (2) a com 
posite diagnostic algorithm which combines all three con 
stituent algorithms may be used to differentiate HG SILS 
from non HG SILS (LG SILs, normal tissues and 
inflammation). 
The primary goal of the clinical Study described in this 
Example was to evaluate the accuracy of constituent and 
composite algorithms which address certain limitations of 
previous clinical Studies. Fluorescence spectra acquired in 
vivo at all three excitation wavelengths from 381 cervical 
sites in 95 patients were analyzed to determine if the 
accuracy of each of the three constituent algorithms previ 
ously developed may be improved using tissue Spectra at a 
combination of two or three excitation wavelengths rather 
than at a single excitation wavelength. A Second goal of the 
analysis was to integrate the three independently developed 
constituent algorithms that discriminate between pairs of 
tissue types into composite Screening and diagnostic algo 
rithms that may achieve discrimination between many of the 
clinically relevant tissue types. The effective accuracy of a 
composite Screening algorithm for the identification of SILS 
and a composite diagnostic algorithm for the identification 
of HG SILS was evaluated. 
The final goal of the analysis was to determine if fluo 
rescence intensities at a reduced number of excitation 
emission wavelength pairs may be used to re-develop con 
Stituent and composite algorithms that may achieve 
classification with a minimum decrease in predictive ability. 
A significant reduction in the number of required fluores 
cence excitation-emission wavelength pairs may enable the 
development of a cost-effective clinical fluorimeter. The 
accuracy of the constituent and composite algorithms based 
on the reduced emission variables was compared to the 
accuracy of those that utilize entire fluorescence emission 
Spectra. 
Instrumentation 
Aschematic of the portable fluorimeter which was used to 
acquire cervical tissue fluorescence Spectra at three excita 
tion wavelengths is shown in FIG. 23(a). The fiber-optic 
probe (Valdor Fiber Optics, VSC/FER/4SMA-1/7-BUN) 
included a central fiber Surrounded by a circular array of Six 
fibers; all Seven fibers having the same characteristics (0.22 
NA, 200um core diameter, 245 um diameter with cladding). 
Three fibers along the diameter of the distal end of the probe 
(FIG. 23(b)) were used for excitation light delivery. The 
purpose of the remaining four fibers was to collect the 
emitted fluorescence from the area directly illuminated by 
the probe. A quartz, Shield (3 mm in diameter and 2 mm 
thick) at the tip of the distal end of the probe that is in direct 
tissue contact (FIG.23(c)) provided a fixed distance between 
the optical fibers and the tissue Surface So fluorescence 
intensity can be measured in calibrated units. 
An area, 1 mm in diameter was illuminated by each 
excitation fiber. The overlap of the illumination area viewed 
by the three excitation fibers and the four collection fibers 
was approximately 80% at the outer Surface of the quartz 
shield. Note that the central excitation fiber has four adjacent 
collection fibers whereas the two excitation fibers in the 











fibers (FIG. 23(b)). However, due to the large overlap of the 
optical fibers at the outer face of the quartz, Shield, this 
difference in the excitation-emission configuration relates 
only to a small difference in the collection efficiency of the 
fluorescence generated due to excitation delivered by the 
central and peripheral excitation fibers. The difference in 
collection efficiency is accounted for by normalizing tissue 
fluorescence Spectra to the peak fluorescence intensity of a 
Rhodamine 610 calibration Standard measured using the 
Same probe configuration. 
Two nitrogen pumped-dye lasers (laser characteristics: 5 
ns pulse duration, 30 Hz repetition rate) (Laser Photonics, 
LN300C) were used to provide illumination at three differ 
ent excitation wavelengths: one laser Served to deliver 
excitation light at 337 nm (fundamental) and had a dye 
module which was used to generate light at 380 nm using the 
fluorescent dye, BBQ (1E-03 M in 7 parts toluene and 3 
parts ethanol). The dye module of the Second laser was used 
to provide illumination at 460 nm, using the fluorescent dye, 
Coumarin 460 (1E-02 M in ethanol). Laser illumination at 
each excitation wavelength, 337, 380 and 460 nm was 
coupled into each of the three excitation fibers of the probe. 
Note that two 10 nm bandpass filters, one centered at 380 nm 
and the other centered at 460 nm were placed between the 
excitation fiber and the dye module used to generate illu 
mination at 380 and 460 nm, respectively to prevent leakage 
from the fundamental at 337 nm. In this Example, the 
average fluence per pulse at 337,380 and 460 nm excitation 
were 15.2, 11.5 and 18 u/mm, respectively. The pulse 
energy at 337 nm excitation was intentionally reduced So 
that the measured fluorescence Signal did not exceed the 
dynamic range of the detector. 
The proximal ends of the four collection fibers were 
arranged in a circular array and imaged at the 500 um wide 
entrance Slit of a f/3.8 spectrograph equipped with a 300 
ln/mm grating (Jarrell Ash, Monospec 18) coupled to a 
1,024 intensified diode array controlled by a multi-channel 
analyzer (Princeton Instruments, OMA). The collection 
optics between the proximal end of the four emission 
collection fibers and the polychromator included two quartz 
plano convex lenses. Between these lenses was a filter wheel 
assembly containing long pass filters with 50% transmission 
at 360 (GG360), 400 (GG400) and 475 (GG475) nm which 
are used to block scattered excitation light at 337, 380 and 
460 nm excitation, respectively from the detector. The 
purpose of the filter wheel was to position the appropriate 
long pass filter in the optical path during fluorescence 
measurements at each excitation wavelength. The nitrogen 
pumped-dye lasers were used to externally trigger a pulser 
(Princeton Instruments, PG200) which served to synchro 
nize the 200 ns collection gate of the detector to the leading 
edge of the laser pulse. The gating of the detector eliminated 
the effects of the colposcope's white light illumination 
during fluorescence measurements. Data acquisition was 
computer controlled. 
Clinical measurements 
A randomly Selected group of non-pregnant patients 
referred to the colposcopy clinic of the University of Texas 
MD Anderson Cancer Center on the basis of abnormal 
cervical cytology was asked to participate in the in vivo 
fluorescence SpectroScopy Study. Informed consent was 
obtained from each patient who participated and the Study 
was reviewed and approved by the Institutional Review 
Boards of the University of Texas, Austin and the University 
of Texas, MD Anderson Cancer Center. Each patient under 
went a complete history and a physical examination includ 
ing a pelvic exam, a Pap Smear and colposcopy of the cervix, 
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vagina and Vulva. After colposcopic examination of the 
cervix, but before tissue biopsy, fluorescence spectra were 
acquired on average from two colposcopically abnormal 
Sites, two colposcopically normal Squamous sites and 1 
normal columnar site (if colposcopically visible) from each 
patient. Tissue biopsies were obtained only from abnormal 
Sites after they had been identified by colposcopy and then 
analyzed by the probe. Tissue biopsies were not obtained 
from normal Squamous or columnar Sites analyzed by the 
probe to comply with routine patient care procedure. All 
tissue biopsies were fixed in formalin and Submitted for 
histologic examination. Hemotoxylin and eosin Stained Sec 
tions of each biopsy Specimen were evaluated by a panel of 
four board certified pathologists and a consensus diagnosis 
was established using the Bethesda classification System. 
This classification System which has previously been used to 
grade cytologic Specimens has now been extended to clas 
sification of histology Samples. Samples were classified as 
normal Squamous, normal columnar, inflammation, LG SIL 
or HGSIL. Samples with multiple diagnoses were classified 
into the most Severe histo-pathologic category. 
Prior to each patient Study, the probe was disinfected and 
a background spectrum was acquired at all three excitation 
wavelengths consecutively with the probe dipped in a non 
fluorescent bottle containing distilled water. The background 
Spectrum indicated no fluorescence due to optical compo 
nents of the fluorimeter or the disinfectant and was Sub 
tracted from all Subsequently acquired spectra at corre 
sponding excitation wavelengths for that patient. Next, with 
the probe placed on the face of a quartz cuvette containing 
a solution of Rhodamine 610 dissolved in ethylene glycol (2 
mg/L), 50 fluorescence spectra were measured at each 
excitation wavelength. After calibration, fluorescence Spec 
tra were acquired from the cervix: 10 spectra for 10 con 
secutive pulses were acquired at 337 nm excitation; next, 50 
spectra for 50 consecutive laser pulses were measured at 380 
nm excitation and then at 460 nm excitation. The data 
acquisition time was 0.33 s at 337 nm excitation and 1.67s 
at each 380 and 460 nm excitation per cervical site. The time 
required to Switch between the two nitrogen pumped-dye 
lasers and the three long pass filters was approximately 5 S. 
Hence, the total time required to record fluorescence emis 
Sion spectra at all three excitation wavelengths from one 
cervical Site was approximately 10 S. Spectra were collected 
in the visible region of the electromagnetic Spectrum with a 
resolution of 10 nm (full width at half maximum) and a 
Signal to noise ratio of 100:1 at the fluorescence maximum 
at each excitation wavelength. 
All Spectra were corrected for the non-uniform spectral 
response of the detection System using correction factors 
obtained by recording the spectrum of an N.I.S.T traceable 
calibrated tungsten ribbon filament lamp. Spectra from each 
cervical Site at each excitation wavelength were averaged to 
obtain a single Spectrum per site. The fluorescence Spectra 
obtained at each excitation wavelength from the Rhodamine 
610 calibration Standard were also averaged to obtain a 
Single spectrum per excitation wavelength. The average 
tissue Spectra were then normalized to the average peak 
fluorescence intensity of the Rhodamine 610 calibration 
Standard at the corresponding excitation wavelength for that 
patient; absolute fluorescence intensities are reported in 
these calibrated units. In this clinical Study, fluorescence 
Spectra were acquired at all three excitation wavelengths 
from each cervical site from a total of 381 sites in 95 patients 
during colposcopy. 
Development of Screening and Diagnostic Algorithms 
FIG. 24 illustrates a schematic of the formal analytical 











for the differential detection of SILS, in vivo. In FIG. 24, the 
text in the dashed-line boxes represent the mathematical 
StepS implemented on the Spectral data, and the text in the 
Solid-line boxes represent the output after each mathematical 
process. There are four primary Steps involved in the mul 
tivariate statistical analysis of tissue spectral data (FIG. 24). 
The first Step is to pre-proceSS spectral data to reduce 
inter-patient and intra-patient variation within a tissue type; 
the pre-processed spectra are then dimensionally reduced 
into an informative Set of principal components that describe 
most of the variance of the original Spectral data Set using 
Principal Component Analysis (PCA). Next, the principal 
components that contain diagnostically relevant information 
are Selected using an unpaired, one-sided Student's t-test, 
and finally a classification algorithm based on logistic dis 
crimination is developed using these diagnostically relevant 
principal components. 
In Summary, three constituent algorithms were developed 
using multivariate Statistical analysis (FIG. 24): constituent 
algorithm (1) discriminates between SILS and normal Squa 
mous tissues, constituent algorithm (2) discriminates 
between SILS and normal columnar tissues and finally, 
algorithm (3) differentiates HG SILS from LG SILS. The 
three constituent algorithms were then combined to develop 
two composite algorithms (FIG. 24): constituent algorithms 
(1) and (2) were combined to develop a composite Screening 
algorithm which discriminates between SILS and non SILS. 
All three constituent algorithms were then combined to 
develop a composite diagnostic algorithm which differenti 
ates HG SILS from non HG SILS. 
Multivariate Statistical Analysis of Cervical Tissue Spectra 
AS a first Step, three methods of pre-processing were 
applied to the Spectral data at each excitation Wavelength: 
(1) normalization (2) mean-Scaling and (3) a combination of 
normalization and mean-Scaling. Similarly pre-processed 
Spectra at each excitation wavelength were combined to 
create spectral inputs at the following combinations of 
excitation wavelengths: (337, 460) nm, (337,380) nm, (380, 
460) mm and (337,380, 460) nm. Pre-processing of spectral 
data resulted in four types of spectral inputs (original and 
three types of pre-processed spectral inputs) at three single 
excitation wavelengths and at four possible combinations of 
multiple excitation wavelengths. Hence, there were a total of 
12 Spectral inputs at Single excitation wavelengths and 16 
Spectral inputs at multiple excitation wavelengths which 
were evaluated using the multivariate Statistical algorithm. 
Prior to PCA, the input data matrix, D (rxc) was created 
So each row of the matrix corresponded to the pre-processed 
fluorescence Spectrum of a Sample and each column corre 
sponded to the pre-processed fluorescence intensity at each 
emission wavelength. Spectral inputs at multiple excitation 
wavelengths were created by arranging Spectra at each 
excitation wavelength in Series in the original Spectral data 
matrix. PCA was used to dimensionally reduce the pre 
processed spectral data matrix into a Smaller orthogonal Set 
of linear combinations of the emission variables that account 
for most of the variance of the Spectral data Set. 
Average values of principal component Scores were cal 
culated for each principal component of each tissue type. An 
unpaired, one-sided Student's t-test was employed to deter 
mine the diagnostic content of each principal component. 
The hypothesis that the means of the principal component 
Scores of two tissue types are different was tested for (1) 
normal Squamous epithelia and SILS, (2) normal columnar 
epithelia and SILS and (3) inflammation and SILS. The t-test 
was extended a step further to determine if there were any 
Statistically significant differences between the means of the 
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principal component scores of HG SILS and LG SILS. 
Principal components for which the hypothesis stated above 
was statistically significant (P<0.05) were retained for fur 
ther analysis. 
Next, a Statistical classification algorithm was developed 
using the diagnostically useful principal components to 
calculate the posterior probability that an unknown Sample 
belongs to each tissue type under consideration. The poste 
rior probability of an unknown Sample belonging to each 
tissue type was calculated using logistic discrimination. The 
posterior probability is related to the prior and conditional 
joint probabilities and to the costs of misclassification of the 
tissue types under consideration. The prior probability of 
each tissue type was determined by calculating the observed 
proportion of cases in each group. The cost of misclassifi 
cation of a particular tissue type was varied from 0 to 1 in 
0.1 increments, and the optimal cost was identified when the 
total number of misclassified Samples based on the classi 
fication algorithm was a minimum. If there was more than 
one cost at which the total number of misclassified Samples 
was a minimum, the cost that maximized Sensitivity was 
selected. The conditional joint probabilities were developed 
by modeling the probability distribution of each principal 
component of each tissue type using the normal probability 
density function, which is characterized by u (mean) and O 
(standard deviation). The best fit of the normal probability 
density function to the probability distribution of each 
principal component (score) of each tissue type was 
obtained in the least Squares Sense, using it and O as free 
parameters of the fit. The normal probability density func 
tion was then used to calculate the conditional joint prob 
ability that an unknown Sample, given that it is from tissue 
type i, will exhibit a set of principal component Scores, X. 
The multivariate Statistical algorithm was developed and 
optimized using a calibration Set and then tested on a 
prediction Set of approximately equal prior probability 
(Table 1). The purpose of testing the algorithm on the 
prediction set was to determine (1) an unbiased estimate of 
the algorithms classification accuracy and (2) if the number 
of Sample Spectra within each category in the calibration Set 
is Sufficient to describe the Spectral data in the prediction Set. 
The calibration and prediction sets were developed by 
randomly assigning the Spectral data into the two Sets with 
the condition that both contain roughly equal number of 
Samples from each histo-pathologic category. The random 
assignment ensured that not all spectra from a Single patient 
were contained in the Same data Set. 
Development of Constituent Algorithms 
The multivariate Statistical algorithm was developed and 
optimized using all 28 types of pre-processed spectral inputs 
from the calibration set. The algorithm was used to identify 
Spectral inputs which provide the greatest discrimination 
between the following pairs of tissue types: (1) SILS and 
normal Squamous epithelia, (2) SILS and normal columnar 
epithelia, (3) SILS and inflammation, and (4) HG SILS and 
LG SILS. The optimal spectral input for differentiating 
between two particular tissue types was identified when the 
total number of Samples misclassified from the calibration 
Set using the multivariate Statistical algorithm was a mini 
mum. The algorithm based on the Spectral input that mini 
mized misclassification between the two tissue types under 
consideration was implemented on the prediction data Set. 
Three multivariate Statistical constituent algorithms were 
developed using tissue spectra at three excitation wave 
lengths. Constituent algorithm (1) was developed to differ 
entiate between SILS and normal Squamous epithelia, con 











SILS and normal columnar epithelia and constituent algo 
rithm (3) could be used to discriminate between LG SILS 
and HGSILs. A constituent algorithm which can discrimi 
nate between SILS and tissues with inflammation could not 
be developed using spectral data from the current clinical 
Study. 
Development of Composite Algorithms 
Each of the independently developed constituent algo 
rithms was intended to discriminate only between pairs of 
tissue types. A combination of these constituent algorithms 
was required to provide discrimination between Several of 
the clinically relevant tissue types. Therefore, two composite 
algorithms were developed: a composite Screening algo 
rithm was developed to differentiate between SILS and non 
SILS (normal Squamous and columnar epithelia and 
inflammation) using constituent algorithms (1) and (2) and 
a composite diagnostic algorithm was developed to differ 
entiate HG SILS from non HG SILS (LG SILs, normal 
epithelia and inflammation) using all three constituent algo 
rithms. 
The composite Screening algorithm was developed in the 
following manner. First, constituent algorithms (1) and (2) 
were developed independently using the calibration data Set. 
The classification outputs from both constituent algorithms 
were used to determine if a Sample being evaluated is SIL or 
non SIL: first, using constituent algorithm (1), Samples were 
classified as non SIL if they had a probability that is less than 
0.5; otherwise, they were classified as SIL. Next, only 
Samples that were classified as SIL based on the algorithm 
(1) were tested using algorithm (2). Again, Samples were 
classified as non SIL if their posterior probability was less 
than 0.5; otherwise they were classified as SIL. The spectral 
data from the prediction set was evaluated using the com 
posite Screening algorithm in an identical manner. 
The composite diagnostic algorithm was implemented in 
the following manner. The three constituent algorithms were 
developed independently using the calibration Set. Algo 
rithms (1) and (2) were implemented on each Sample from 
the calibration data Set, as described previously. Only 
Samples that were classified as SIL based on algorithms (1) 
and (2) were tested using algorithm (3). If samples evaluated 
using algorithm (3) had a posterior probability greater than 
0.5, they were classified as HG SIL; otherwise they were 
classified as non HG SIL. The spectral data from the 
prediction Set was evaluated using the composite diagnostic 
algorithm in an identical manner. 
Results 
Constituent Algorithms (1), (2) and (3) 
Table 2 Summarizes the components of the optimal Set of 
three constituent algorithms. Constituent algorithm (1) can 
be used to differentiate between SILS and normal Squamous 
epithelia; algorithm (2) differentiates between SILS and 
normal columnar epithelia and algorithm (3) discriminates 
between LG SILS and HG SILS. 
Pre-processing 
FIG. 25(a) illustrates average fluorescence spectra per site 
acquired from cervical Sites at 337 nm excitation from a 
typical patient. All fluorescence intensities are reported in 
the same Set of calibrated units. Corresponding normalized 
and normalized, meanscaled spectra are illustrated in FIG. 
25(b) and 25(c), respectively. Evaluation of the original 
spectra at 337 nm excitation (FIG. 25(a)) indicates that the 
fluorescence intensity of SILS is less than that of the corre 
sponding normal Squamous tissue and greater than that of 
the corresponding normal columnar tissue over the entire 
emission Spectrum. Examination of normalized Spectra from 
this patient (FIG. 25(b)) indicates that following 
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normalization, the fluorescence intensity of the normal Squa 
mous tissue is greater than that of corresponding SILS over 
the wavelength range 360 to 450 nm only; between 460 and 
600 nm, the fluorescence intensity of SILS is greater than 
that of the corresponding normal Squamous tissue which in 
part reflects the longer peak emission wavelength of SILS. A 
comparison of the spectral line shape of SILS to that of the 
normal columnar tissue illustrates the opposite phenomenon. 
The normalized fluorescence intensity of SILS is greater than 
that of the corresponding normal columnar tissue over the 
wavelength range 360 to 450 nm; however, between 460 and 
600 nm, the fluorescence intensity of the normal columnar 
tissue is greater than that of the SILS, this spectral difference 
reflects the longer peak emission wavelength of the normal 
columnar tissue relative to that of SILS. Further evaluation 
of normalized spectra in FIG. 25(b) indicates that there are 
spectral line shape differences between LG SILS and HG 
SILS over the wavelength range 360 to 420 nm. 
The corresponding normalized, mean-Scaled spectra of 
this patient, shown in FIG. 25(c) displays differences in the 
normalized fluorescence spectrum (FIG. 25(b)) from a par 
ticular site with respect to the average normalized spectrum 
(the average of all normalized spectra obtained from this 
patient). As the average normalized spectrum has been 
Subtracted from each normalized spectrum obtained from 
this patient, the mean now lies at Y=0 over the entire 
emission wavelength range. Evaluation of FIG. 25(c) indi 
cates that between 360 and 450 nm, the normalized, mean 
Scaled fluorescence intensity of the normal Squamous tissue 
is greater than the mean, and that of the normal columnar 
tissue is less than the mean. Above 460 nm, the opposite 
phenomenon is observed; the fluorescence intensity of the 
normal Squamous tissue is less than the mean, while that of 
the normal columnar tissue is greater than the mean. The 
fluorescence intensity of SILS lies close to the mean and is 
bounded by the intensities of the two normal tissue types. In 
addition, between 360 and 420 nm, the normalized, mean 
scaled fluorescence intensity of the LG SIL is slightly 
greater than the mean, while that of the HGSIL is less than 
the mean. 
FIG. 26(a) illustrates average fluorescence spectra per site 
acquired from cervical Sites at 380 nm excitation, from the 
same patient. FIGS. 26(b-c) show the corresponding 
normalized, and normalized, mean-Scaled spectra, respec 
tively. In FIG. 26(a), the fluorescence intensity of SILS is 
less than that of the corresponding normal Squamous tissue, 
with the LG SIL exhibiting the weakest fluorescence inten 
sity over the entire emission spectrum. Note that the fluo 
rescence intensity of the normal columnar Sample is indis 
tinguishable from that of the HGSIL. Normalized spectra at 
380 nm excitation, (26(b)), indicate that over the wavelength 
range 400 to 450 nm, the fluorescence intensity of the 
normal Squamous tissue is slightly greater than that of SILS 
and that of the normal columnar tissue is less than that of 
SILS. The opposite phenomenon is observed above 580 nm. 
A careful examination of the spectra of the LGSIL and HG 
SIL indicates that between 460 and 580 nm, the normalized 
fluorescence intensity of the LGSIL is higher than that of the 
HGSIL. The normalized, mean-scaled spectra (FIG. 26(c)) 
enhances the previously observed normalized spectral line 
shape differences by displaying them relative to the average 
normalized spectrum of this patient. FIG. 26(c) indicates 
that between 400 to 450 nm, the fluorescence intensity of the 
normal Squamous tissue is greater than the mean and that of 
the normal columnar tissue is less than the mean. The 
opposite phenomenon is observed above 460 nm. The fluo 












of the two normal tissue types over the entire emission 
spectrum. The LG SIL and HGSIL also show spectral line 
shape differences, above 460 nm, the normalized, mean 
scaled fluorescence intensity of the LG SIL lies above the 
mean and that of the HGSIL lies below the mean. 
FIGS. 27(a-c) illustrate original, normalized and 
normalized, mean-Scaled Spectra, respectively at 460 nm 
excitation from the same patient. Evaluation of FIG. 27(a) 
indicates that the fluorescence intensity of SILS is less than 
that of the corresponding normal Squamous tissue and 
greater than that of the corresponding normal columnar 
Sample over the entire emission spectrum. Evaluation of 
normalized spectra at this excitation wavelength (FIG. 
27(b)) demonstrates that below 510 nm, the fluorescence 
intensity of SILS is less than that of the normal Squamous 
tissue and greater than that of the corresponding normal 
columnar tissue. Above, 580 nm, the normalized fluores 
cence intensity of SILS is less than that of the normal 
columnar tissue and greater then that of normal Squamous 
tissue. Note that there are spectral line shape differences 
between the LGSIL and HGSIL between 580 and 660 nm, 
the normalized fluorescence intensity of the LG SIL is 
greater than that of the HG SIL. The normalized, mean 
scaled spectra shown in FIG. 27(c) reflects the differences 
observed in the normalized spectra relative to the average 
normalized spectrum of this patient. Below 510 nm, the 
fluorescence intensity of the normal Squamous tissue is 
greater than the mean, while that of the normal columnar 
tissue is less than the mean. Above 580 nm, the opposite 
phenomenon is observed. The fluorescence intensity of the 
SILS lies between those of the two normal tissue types. 
Above 580 nm, the fluorescence intensity of the LG SIL is 
greater than the mean and that of the HGSIL is less than the 
ca. 
Principal Component Analysis and Logistic Discrimination 
Constituent Algorithm (1) which Differentiates SILS from 
Normal Squamous Tissues 
A constituent algorithm based on normalized spectra 
arranged in Series at all three excitation wavelengths pro 
Vided the greatest discrimination between SILS and normal 
Squamous tissues. The algorithm demonstrated an incremen 
tal improvement in Sensitivity without Sacrificing Specificity 
relative to the previously developed constituent algorithm 
(1) that employed normalized, mean-Scaled spectra at 337 
nm excitation only. Multivariate Statistical analysis of nor 
malized tissue spectra at all three excitation wavelengths, 
indicated three principal components show Statistically Sig 
nificant differences between SILS and normal Squamous 
tissues (Table 2). These three principal components account 
collectively for 65% of the total variance of the spectral data 
Set. Logistic discrimination was used to develop a classifi 
cation algorithm to discriminate between SILS and normal 
Squamous epithelia based on these three informative prin 
cipal components. Prior probabilities were determined by 
calculating the percentage of each tissue type from the data 
set: 62% normal squamous tissues and 38% SILS. The cost 
of misclassification of SIL was optimized at 0.7. Posterior 
probabilities of belonging to each tissue type were calcu 
lated for all Samples from the data Set, using the known prior 
probabilities, cost of misclassification of SILS and the con 
ditional joint probabilities calculated from the normal prob 
ability density function. FIG. 28 illustrates the retrospective 
accuracy of the algorithm applied to the calibration data Set. 
The posterior probability of being classified into the SIL 
category is plotted for all SILS and normal Squamous 
epithelia. FIG. 28 indicates that 92% of HG SILS and 83% 
of LG SILS are correctly classified with a posterior prob 
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ability greater than 0.5. Approximately 70% of colposcopi 
cally normal Squamous epithelia are correctly classified with 
a posterior probability less than 0.5. 
The confusion matrix in Table 3 compares the retrospec 
tive accuracy of the algorithm on the calibration data Set to 
its prospective accuracy on the prediction Set. In the confu 
Sion matrix, the first row corresponds to the histo-pathologic 
classification and the first column corresponds to the Spec 
troscopic classification of the Samples. A prospective evalu 
ation of the algorithms accuracy indicates that there is a 
Small increase in the proportion of correctly classified LG 
SILS and no change in the proportion of correctly classified 
HGSILS or normal squamous tissues. Note that the majority 
of normal columnar tissues and Samples with inflammation 
from both calibration and prediction Sets are misclassified as 
SIL using this algorithm. Evaluation of the misclassified 
SILS from the calibration set indicates that one sample (out 
of 19) with CIN III, two samples (out of 16) with CIN II, two 
samples (out of 16) with CIN I and two samples (out of 7) 
with HPV are incorrectly classified. From the prediction set, 
two samples (out of 19) with GIN III, one samples (out of 
16) with GIN II, two samples (out of 16) with CINI and one 
sample (out of 8) with HPV are incorrectly classified as non 
SIL. 
Constituent Algorithm (2) which Differentiates SILS from 
Normal Columnar Tissues 
The greatest discrimination between SILS and normal 
columnar epithelia was achieved using a constituent algo 
rithm based on normalized, mean-Scaled spectra at all three 
excitation wavelengths. This algorithm demonstrated a Sub 
Stantially improved Sensitivity for a similar specificity rela 
tive to the previously developed constituent algorithm (2) 
which used normalized, mean-Scaled spectra at 380 nm 
excitation, only. Multivariate Statistical analysis of a com 
bination of normalized, mean-Scaled tissue spectra at all 
three excitation wavelengths resulted in four principal com 
ponents that demonstrate Statistically significant differences 
between SILS and normal columnar epithelia (Table 2). 
These four principal components collectively account for 
80% of the total variance of the spectral data set. Logistic 
discrimination was employed to develop a classification 
algorithm to discriminate between SILS and normal colum 
nar epithelia. The prior probabilities were determined to be: 
28% normal columnar tissues and 72% SILS. The optimized 
cost of misclassification of SIL was equal to 0.58. Posterior 
probabilities of belonging to each tissue type were calcu 
lated for all samples from the data set. FIG. 29 illustrates the 
retrospective accuracy of the algorithm applied to the cali 
bration data set. The posterior probability of being classified 
into the SIL category is plotted for all SILS and normal 
columnar Samples examined. FIG. 29 graphically indicates 
that 91% of HGSILS and 83% of LGSILs have a posterior 
probability that is greater than 0.5. Seventy-six percent of 
colposcopically normal columnar epithelia are correctly 
classified with a posterior probability less than 0.5. 
The confusion matrix in Table 4 compares the retrospec 
tive accuracy of the constituent algorithm on the calibration 
data Set to its prospective accuracy on the prediction Set. The 
prospective accuracy of the algorithm (Table 4) indicates 
that there is a Small increase in the proportion of correctly 
classified LGSILS and a Small decrease in the proportion of 
correctly classified HGSILs; there is approximately a 10% 
decrease in the proportion of correctly classified normal 
columnar tissues. Note that the majority of normal Squa 
mous tissues and Samples with inflammation from both the 
calibration and prediction Sets are misclassified as SIL using 











calibration set indicates that three samples (out of 16) with 
CIN II, three samples (out of 16) with CINI and one sample 
(out of 7) with HPV are incorrectly classified. From the 
prediction set, two samples (out of 19) with CIN III, three 
samples (out of 16) with CIN II, and three samples (out of 
16) with CINI are incorrectly classified. 
Constituent Algorithm (3) which Differentiates HGSILS 
and LG SILS 
A combination of normalized spectra at all three excita 
tion wavelengths significantly enhanced the accuracy of the 
previously developed constituent algorithm (3) which dif 
ferentiated HGSILS from LGSILS using normalized spectra 
at 460 nm excitation. Multivariate statistical analysis of 
normalized spectra at all three excitation wavelengths 
resulted in four Statistically Significant principal 
components, that account collectively for 67% of the total 
variance of the spectral data Set (Table 2). Again, a prob 
ability based classification algorithm was developed to dif 
ferentiate HG SILS from LG SILS. The prior probability 
was: 40% LG SILS and 60% HGSILs. The optimal cost of 
misclassification of HG SIL was equal to 0.51. Posterior 
probabilities of belonging to each tissue type were calcu 
lated. FIG. 30 illustrates the retrospective accuracy of the 
algorithm applied to the calibration data Set. The posterior 
probability of being classified into the HGSIL category is 
plotted for all SILS evaluated. FIG. 30 indicates that 83% of 
HG SILS have a posterior probability greater than 0.5, and 
70% of LGSILs have a posterior probability less than 0.5. 
The confusion matrix in Table 5 compares the retrospec 
tive accuracy of the constituent algorithm on the calibration 
Set to its prospective accuracy on the prediction Set. Its 
prospective accuracy indicates that there is a 5% decrease in 
the proportion of correctly classified LGSILS and no change 
in the proportion of correctly classified HG SILS. From the 
calibration Set, Six HG SILS are misclassified; three Samples 
(out 19) with CIN III and three samples (out of 16) with CIN 
II are misclassified as LG SIL. The misclassified LG SILS 
comprise of five samples (out of 16) with CIN I and two 
samples (out of 7) with HPV. From the prediction set, five 
HGSILS are misclassified; two samples (out of 19) with CIN 
III and three (out of 16) with CIN II. There were ten 
misclassified LG SILS from the prediction set: seven with 
CIN I (out of 16) and three (out of 8) with HPV. 
“Full-parameter Composite Screening and Diagnostic 
Algorithms 
A composite Screening algorithm was developed to dif 
ferentiate SILS and non SILS (normal Squamous and colum 
nar epithelia and inflammation) and a composite diagnostic 
algorithm was developed to differentiate HGSILS from non 
HGSILS (LGSILs, normal epithelia and inflammation). The 
effective accuracy of both composite algorithms were com 
pared to those of the constituent algorithms from which they 
were developed and to the accuracy of current detection 
modalities. 
A Composite Screening Algorithm which Discriminates 
Between SILS and Non SILS 
A composite Screening algorithm to differentiate SILS 
from non SILS was developed using a combination of the 
two constituent algorithms: algorithm (1) which differenti 
ates SILS from normal Squamous tissues and algorithm (2) 
which differentiates SILS from normal columnar epithelia. 
The optimal cost of miclassification of SIL was equal to 0.66 
for constituent algorithm (1) and 0.64 for constituent algo 
rithm (2). Only the costs of misclassification of SIL of the 
two constituent algorithms was altered for the development 
of the composite Screening algorithm. These costs were 
Selected to minimize the total number of misclassified 
Samples. 
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The accuracy of the composite Screening algorithm on the 
calibration and prediction data Sets is illustrated in the 
confusion matrix in Table 6. Examination of the confusion 
matrix indicates that the algorithm correctly classifies 
approximately 90% of HG SILS and 75% of LGSIL from 
the calibration data set. Furthermore, approximately, 80% of 
normal Squamous tissues and 70% of normal columnar 
epithelia from the calibration Set are correctly classified. 
Evaluation of the prediction Set indicates that there is a Small 
change in the proportion of correctly classified HGSILS and 
LG SILS. There is a negligible change in the correct clas 
sification of normal Squamous and columnar tissues. Note 
that while 80% of samples with inflammation from the 
calibration set are incorrectly classified as SIL, only 43% of 
these Samples from the prediction Set are incorrectly clas 
sified. 
A comparison of the accuracy of the composite Screening 
algorithm (Table 6) to that of each of the constituent 
algorithms (1) (Table 3) and (2) (Table 4) on the same 
Spectral data Set indicates that in general, there is less than 
a 10% decrease in the proportion of correctly classified SILS 
using the composite Screening algorithm relative to using 
either of the constituent algorithms independently. Note 
however that the proportion of correctly classified normal 
(Squamous and columnar) epithelia is Substantially higher 
using the composite algorithm relative to using either of the 
constituent algorithms independently. These results confirm 
that utilization of a combination of the two constituent 
algorithms, significantly reduces the false-positive rate rela 
tive to that using each algorithm independently. Evaluation 
of the spectroscopically misclassified SILS from the calibra 
tion set (Table 6) indicates that only one sample (out of 19) 
with CIN III, three samples (out of 16) with CIN II, two 
samples (out of 16) with CIN I and four samples (out of 7) 
with HPV are incorrectly classified. From the prediction data 
set (Table 6), two samples (out of 19) with CIN III, four 
samples (out of 16) with CIN II, three samples (out of 16) 
with CIN I and one sample (out of 8) with HPV are 
incorrectly classified. 
A Composite Diagnostic Algorithm which Differentiates HG 
SILS from Non HG SILS 
A composite diagnostic algorithm which differentially 
detects HG SILS was developed using a combination of all 
three constituent algorithms: algorithm (1) which differen 
tiates SILS from normal Squamous tissues, algorithm (2) 
which differentiates SILS from normal columnar epithelia 
and algorithm (3) which differentiates HG SILS from LG 
SILS. The optimal costs of miclassification of SIL was equal 
to 0.87 for algorithm (1) and 0.65 for algorithm (2); the 
optimal cost of misclassification of HG SIL was equal to 
0.49 for algorithm (3). Only the costs of misclassification of 
SIL of constituent algorithms (1) and (2) and the cost of 
misclassification of HG SIL of constituent algorithm (3) 
were altered during development of the composite diagnos 
tic algorithm. These costs were Selected to minimize the 
total number of misclassified Samples. 
The results of the composite diagnostic algorithm on the 
calibration and prediction Sets are shown in the confusion 
matrix in Table 7. The algorithm correctly classifies 80% of 
HG SILs, 74% of LGSILS and more than 80% of normal 
epithelia. Evaluation of the prediction Set using this com 
posite algorithm indicates that there is only a 3% decrease in 
the proportion of correctly classified HG SILS and a 7% 
decrease in the proportion of correctly classified LG SILS. 
There is less than a 10% decrease in the proportion of 
correctly classified normal epithelia. A comparison between 











than 70% of samples with inflammation from the calibration 
data set are incorrectly classified as HG SIL, only 14% of 
Samples with inflammation from the prediction Set are 
incorrectly identified. Due to the relatively small number of 
Samples examined in this histo-pathologic category, the 
results presented here do not conclusively establish if the 
algorithm is capable of correctly identifying inflammation. 
A comparison of the accuracy of the composite diagnostic 
algorithm to that of constituent algorithm (3) which differ 
entiates HGSILS from LG SILS (Table 5) indicates there is 
less than a 5% decrease in the proportion of correctly 
classified HG SILS and a 5% increase in the proportion of 
correctly classified LG SILS using the composite diagnostic 
algorithm relative to using the constituent algorithm (3). 
Evaluation of the HGSILS from the calibration set (Table 7) 
that were incorrectly classified indicates that three Samples 
(out of 19) with CIN III and four samples (out of 16) with 
CIN II are incorrectly classified. From the prediction set, 
four samples (out of 19) with CIN III and five samples (out 
of 16) with CIN II are incorrectly classified. 
"Reduced-parameter Composite Screening and Diagnostic 
Algorithms 
Component Loadings: A component loading represents 
the correlation between each principal component and the 
original pre-processed fluorescence emission spectra at a 
particular excitation wavelength. FIGS. 31(a-c) illustrate 
component loadings of the diagnostically relevant principal 
components of constituent algorithm (1) obtained from 
normalized spectra at 337, 380 and 460 nm excitation, 
respectively. FIGS. 32(a-c) display component loadings that 
correspond to the diagnostically relevant principal compo 
nents of constituent algorithm (2) obtained from normalized, 
mean-Scaled spectra at 337, 380 and 460 nm excitation, 
respectively. Finally, FIGS. 33(a-c) display the component 
loadings corresponding to the diagnostically relevant prin 
cipal components of constituent algorithm (3), obtained 
from normalized spectra at 337,380 and 460 nm excitation, 
respectively. In each graph shown, the abscissa corresponds 
to the emission wavelength range at a particular excitation 
wavelength and the ordinate corresponds to the correlation 
coefficient of the component loading. Correlation coeffi 
cients of the component loading above 0.5 and below -0.5 
are considered to be significant. 
FIGS. 31(a), 32(a) and 33(a) display component loadings 
of principal components of constituent algorithms (1), (2) 
and (3), respectively, obtained from pre-processed spectra at 
337 nm excitation. A closer examination indicates that 
component loading 1 is nearly identical for all three algo 
rithms. Evaluation of this loading indicates that it is posi 
tively correlated with corresponding emission spectra over 
the wavelength range 360-440 nm and negatively correlated 
with corresponding emission spectra over the wavelength 
range 460–660 nm. All remaining principal components of 
all three algorithms display a correlation between -0.5 and 
0.5, except component loading 4 of algorithm (2) (FIG. 
32(a)) which displays a positive correlation of 0.75 with the 
corresponding emission Spectra at 460 nm. 
FIGS. 31(b), 32(b) and 33(b) display component loadings 
that correspond to the diagnostically relevant principal com 
ponents of constituent algorithms (1), (2) and (3), respec 
tively obtained from pre-processed spectra at 380 nm exci 
tation. Component loading 1 of all three algorithms is 
positively correlated with corresponding emission spectra 
over the wavelength range, 400-450 nm. Between 500-600 
nm, component loading 1 of algorithm (2) (FIG. 32(b)) is 
correlated negatively with corresponding emission spectra. 
Examination of component loading 3 of algorithm (1) (FIG. 
US 6,571,118 B1 
39 
31(b)) and algorithm (3) (FIG.33(b)) indicates that they are 
also negatively correlated with corresponding emission 
spectra from 500-600 nm. Only component loading 2 of 
algorithm (2) (FIG. 32(b)) is positively correlated with 
corresponding emission spectra from 500-600 nm. Also 
note that component loading 3 of algorithm (1) (FIG.31(b)) 
and component loadings 3 and 6 of algorithm (3) (FIG. 
33(b)) display a correlation with corresponding emission 
Spectra at approximately 640 nm. 
FIGS. 31(c), 32(c) and 33(c) display component loadings 
that correspond to the diagnostic principal components of 
constituent algorithms (1), (2) and (3), respectively obtained 
from pre-processed spectra at 460 nm excitation. Note that 
only component loading 1 displays a negative correlation 
(<-0.5) with corresponding emission spectra for all three 
algorithms. This component loading is correlated with cor 
responding emission spectra over the wavelength range 
580–660 nm. The remaining principal components of all 
three algorithms display a correlation between -0.5 and 0.5. 
The component loadings at all three excitation wave 
lengths of all three constituent algorithms were evaluated to 
Select fluorescence intensities at a minimum number of 
excitation-emission wavelength pairs required for the pre 
viously developed constituent and composite algorithms to 
perform with a minimal decrease in classification accuracy. 
Portions of the component loadings of the three constituent 
algorithms most highly correlated (correlation>0.5 or <-0.5) 
with corresponding emission Spectra at each excitation 
wavelength were Selected and the reduced data matrix was 
then used to regenerate and evaluate the constituent and 
composite algorithms. It was iteratively determined that 
fluorescence intensities at a minimum of 15 excitation 
emission Wavelength pairs are required to re-develop con 
Stituent and composite algorithms that demonstrate a mini 
mum decrease in classification accuracy. At 337 mm 
excitation, fluorescence intensities at two emission wave 
lengths between 360-450 nm and intensities at two emission 
wavelengths between 460–660 nm were selected. At 380 nm 
excitation, intensities at two emission wavelengths between 
400-450 nm and intensities at four emission wavelengths 
between 500-640 nm were selected. Finally, at 460 nm 
excitation, fluorescence intensities at five emission wave 
lengths over the range 580–660 nm was selected. Table 8 
lists these excitation-emission wavelength pairs for each of 
the three constituent algorithms, (1), (2) and (3). These 
excitation-emission wavelength pairs are also indicated on 
the component loading plots in FIGS. 31-33. The bandwidth 
at each emission wavelength is 10 nm. 
Reduced-parameter Composite Algorithms 
Using the fluorescence intensities only at the Selected 
excitation-emission wavelength pairs, the three constituent 
algorithms were re-developed using the same formal ana 
lytical process as was done previously using the entire 
fluorescence emission Spectra at all three excitation wave 
lengths (FIG. 24). The three constituent algorithms were 
then independently optimized using the calibration Set and 
tested prospectively on the prediction data Set. They were 
combined as described previously into composite Screening 
and diagnostic algorithms. The effective accuracy of these 
reduced-parameter composite algorithms were compared to 
that of the full-parameter composite algorithms developed 
previously using fluorescence emission spectra at all three 
excitation wavelengths. 
Table 9 displays the accuracy of the reduced-parameter 
composite Screening algorithm (based on fluorescence inten 
Sities at 15 excitation-emission wavelength pairs) which 











calibration and prediction Sets. A comparison between the 
calibration and prediction data Sets indicates that there is leSS 
than a 10% decrease in the proportion of correctly classified 
SILS and normal Squamous tissues from the prediction Set. 
Note however that there is a 20% increase in the proportion 
of correctly classified normal columnar epithelia and a 40% 
increase in the proportion of correctly classified Samples 
with inflammation from the prediction set. 
The accuracy of the reduced-parameter composite Screen 
ing algorithm (Table 9) was compared to that of the full 
parameter composite Screening algorithm (Table 6) applied 
to the same Spectral data Set. A comparison indicates that in 
general there is less than a 10% decrease in the accuracy of 
the reduced-parameter composite algorithm relative to that 
of the full-parameter composite Screening algorithm, except 
for a 20% decrease in the proportion of correctly classified 
normal columnar epithelia from the calibration Set tested 
using the reduced-parameter composite Screening algorithm 
(Table 9). 
Table 10 displays the accuracy of the reduced-parameter 
composite diagnostic algorithm that differentially identifies 
HG SILS from the calibration and prediction sets. A com 
parison of Sample classification between the calibration and 
prediction data Sets indicates that there is negligible change 
in the proportion of correctly classified HG SILS, LG SILS 
and normal Squamous epithelia. Note that there is approxi 
mately a 20% increase in the proportion of correctly clas 
sified normal columnar epithelia and Samples with inflam 
mation from the prediction Set. 
A comparison of the composite diagnostic algorithm 
based on the reduced emission variables (Table 10) to that 
using fluorescence emission spectra at all three excitation 
wavelengths (Table 7) applied to the same spectral data set 
indicates that in general, the accuracy of the reduced 
parameter composite diagnostic algorithm is within 10% of 
that reported for the full-parameter composite diagnostic 
algorithm; however, a comparison between Tables 7 and 10 
indicates that there is approximately a 15% decrease and a 
20% increase in the proportion of correctly classified normal 
columnar epithelia from the calibration and prediction Sets 
(Table 10), respectively which were tested using the 
reduced-parameter composite diagnostic algorithm. The 
opposite trend is observed for Samples with inflammation 
tested using the reduced-parameter composite diagnostic 
algorithm (Table 10). 
Table 11 compares the sensitivity and specificity of the 
full-parameter and reduced-parameter composite algorithms 
to that of Pap Smear Screening and colposcopy in expert 
hands. Table 11 indicates that the composite Screening 
algorithms have a similar Specificity and a significantly 
improved Sensitivity relative to Pap Smear Screening. A 
comparison of the Sensitivity of the composite Screening 
algorithms to that of colposcopy in expert hands for differ 
entiating SILS from non SILS indicates that these algorithms 
demonstrate a 10% decrease in sensitivity, but a 20% 
improvement in Specificity. The composite diagnostic algo 
rithms and colposcopy in expert hands discriminate HG 
SILS from non HGSILS with a very similar sensitivity and 
Specificity. Also note that the variability (Standard deviation) 
of both Pap Smear Screening and colposcopy in expert hands 
is Substantially higher than that of the full-parameter and 
reduced-parameter Screening and diagnostic algorithms. A 
comparison between the full-parameter and reduced 
parameter composite algorithms indicates that the algo 
rithms based on the reduced emission variables demonstrate 
a minimal decrease in classification accuracy relative to 
those that employ fluorescence emission spectra at all three 
excitation wavelengths. 
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Discussion and Conclusions 
Cervical tissue fluorescence spectra recorded at 337,380 
and 460 nm excitation can be used to develop composite 
Screening and diagnostic algorithms for the differential 
detection of SILS in Vivo. The composite Screening algo 
rithm discriminates between SILS and non SILS with a 
Similar Specificity and a Substantially improved Sensitivity 
relative to Standard Pap Smear Screening. When compared to 
colposcopy in expert hands, the composite Screening algo 
rithm displays a 10% decrease in sensitivity but almost a 
20% improvement in Specificity. A comparison between the 
composite diagnostic algorithm and colposcopy in the hands 
of expert practitioners indicates that both have a very similar 
Sensitivity and Specificity for discriminating between HG 
SILS and non HG SILS. Note that as spectroscopic interro 
gation of diseased and non-diseased cervical tissue Sites in 
the current clinical Study was directed by colposcopic 
impression, the Sensitivity of the Spectroscopic algorithms 
could not exceed the Sensitivity of colposcopy. In other 
words, if there were histologically diseased cervical tissue 
Sites that were overlooked by colposcopy, these false 
negatives were not be evaluated Spectroscopically. AS a 
result, the potential of fluorescence spectroscopy to correctly 
classify these false-negatives could not be determined. 
The full-parameter composite algorithms were 
re-developed using fluorescence intensities at 15 excitation 
emission wavelength pairs, to generate reduced-parameter 
composite algorithms. The fluorescence intensities at these 
reduced number of excitation-emission wavelength pairs 
were Selected using a parameter called the component 
loading calculated from the principal components. Evalua 
tion of the reduced-parameter composite algorithms indi 
cates that they display a minimal decrease in Sensitivity and 
Specificity relative to the full-parameter composite algo 
rithms. The reduction in the number of excitation-emission 
wavelength pairs from 161 to 15 implies reduction in the 
complexity and cost of the portable fluorimeter which would 
be used to measure cervical tissue fluorescence. For 
example, if fluorescence intensities at only 15 excitation 
emission wavelength pairs need to be measured, the poly 
chromator and intensified diode array can be replaced by a 
mechanical filter assembly and a Single channel detector. 
This represents a Substantial decrease in cost and complexity 
of this instrumentation at the expense of less than a 1% 
decrease in Sensitivity. 
Several Significant improvements and refinements have 
been made in previously developed constituent algorithms 
using tissue spectra at all three excitation wavelengths. 
Previously, the constituent algorithm (1) which differentiates 
SILS from normal Squamous epithelia was developed using 
normalized, mean-Scaled spectra at a single excitation wave 
length: 337 nm. Spectra at this excitation wavelength had to 
be mean-Scaled in order to calibrate for the significant 
inter-patient variation in Spectral line shape. This algorithm 
demonstrates the greatest classification accuracy when the 
patient being evaluated has equal numbers of diseased and 
non-diseased tissue sites. This restriction clearly reduces the 
clinical effectiveness of this algorithm. The new algorithm 
which is based on normalized emission Spectra at all three 
excitation wavelengths, minimizes this inter-patient varia 
tion and hence obviates the need for mean-Scaling, while 












Inclusion of Spectra at additional excitation wavelengths 
represents a significant improvement in the clinical effec 
tiveness of this algorithm as it can be applied to a much 
wider population of patients. 
The accuracy of previously developed constituent algo 
rithm (2) which discriminates between SILS and normal 
columnar epithelia was significantly improved by using 
normalized, mean-Scaled Spectra at all three excitation 
wavelengths rather than at a Single excitation wavelength. 
Despite the Significant improvement in these results, this 
algorithm is also based on tissue spectra that require mean 
Scaling at each excitation wavelength. A multivariate Statis 
tical algorithm based on normalized spectra only, at all three 
excitation wavelengths differentiates SILS from normal 
columnar epithelia with a Significantly poorer Sensitivity 
than the algorithm that uses normalized, mean-Scaled Spec 
tra at all three excitation wavelengths. Therefore, mean 
Scaling is essential for the optimal operation of this algo 
rithm. 
Finally, an improvement that is significant is the devel 
opment of the third constituent algorithm which discrimi 
nates between LGSILS and HG SILS using tissue spectra at 
all three excitation wavelengths. The utilization of spectra at 
all three excitation wavelengths results in a Substantial 
improvement in Sensitivity relative to using the constituent 
algorithm (3) which is based on a single excitation wave 
length. Furthermore, spectra required for this algorithm do 
not have to be mean-Scaled for inter-patient variation in 
Spectral line shape. 
Each of the three constituent algorithms developed using 
Spectral data from the current clinical Study discriminate 
between a specific pair of tissue types. Using each constitu 
ent algorithm, a posterior probability assignment of an 
unknown Sample to a particular tissue category is calculated 
using a set of diagnostically relevant principal components 
that demonstrate Statistically significant differences between 
the two tissue types under consideration. The posterior 
probability output of the constituent algorithms are then 
combined to develop composite Screening and diagnostic 
algorithms that discriminate between many of the clinically 
relevant tissues types. Hence, development of the two com 
posite algorithms is based on the prior development of the 
three constituent algorithms. 
To test the feasibility of an alternate approach, the two 
composite algorithms were developed directly from diag 
nostically relevant principal components of their corre 
sponding constituent algorithms, thereby by-passing the 
constituent algorithm development phase. The composite 
Screening algorithm which discriminates between SILS and 
non SILS was developed using logistic discrimination based 
on the diagnostically relevant principal components of con 
Stituent algorithms (1) and (2); the posterior probability of 
an unknown Sample being classified as either SIL or non SIL 
was calculated. The composite diagnostic algorithm which 
discriminates between HG SILS and non HG SILS was 
developed using logistic discrimination based on the diag 
nostically relevant principal components of constituent algo 
rithms (1), (2) and (3); the posterior probability of an 
unknown sample being classified as either HGSIL or non 
HG SIL was calculated. The composite algorithms devel 
oped directly from the diagnostically relevant principal 
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components of their corresponding constituent algorithms 
demonstrated a poorer classification accuracy relative to 
composite algorithms that were developed using a combi 
nation of corresponding constituent algorithms. Therefore, 
composite Screening and diagnostic algorithms were devel 
oped using a combination of independently developed con 
Stituent algorithms. 
Pre-processing to remove inter-patient and intra-patient 
variation prior to the development of the multivariate Sta 
tistical algorithm may remove the Spectral variations that 
may be Significant from a biological Standpoint. However, in 
the development of multivariate Statistical Screening and 
diagnostic algorithms that can Successfully identify disease 
in any given patient, the intra-patient and inter-patient 
Spectral variations must be removed if they do obscure the 
important inter-category differences that the algorithm needs 
to extract. If a Sophisticated physical model can be devel 
oped to describe the biological basis of the Spectral data as 
well as the inter-patient and intra-patient spectral variations 
accurately, then this information can be used to develop 
better methods of pre-processing or direct the need for 
additional measurements to calibrate for these variations. 
This is an important issue to address and is currently the 
Subject of Study in our laboratory. 
In spite of the Successful development of algorithms that 
can differentiate (1) SILS from normal tissues and (2) HG 
SILS from non HG SILS and normal epithelia, these algo 
rithms do not consistently classify Samples with inflamma 
tion as non SIL, this results in a decrease in their Specificity. 
Although the number of Samples examined in this histo 
pathologic category is limited, analysis from previous and 
current clinical studies indicates that it relatively difficult to 
correctly classify these samples. A plausible explanation for 
this is that (1) the current excitation wavelengths used may 
not be optimum for identification of fluorophores that are 
unique to inflammation and/or (2) the penetration depth of 
the light may not be Sufficiently long to spectroscopically 
interrogate the underlying Stromal layers where inflamma 
tion developS. 
The Specificity of fluorescence spectroScopy for the detec 
tion of cervical neoplasia may be improved by using fluo 
rescent photoSensitizers to enhance the contrast between 
neoplastic and non-neoplastic tissues in Vivo. The use of 
photoSensitizerS Such as photofrin, hematoporphyrin deriva 
tive or 5-ALA may potentially enhance the Spectroscopic 
differences between neoplastic and non-neoplastic (normal 
and inflammatory) cervical tissues and hence contribute to 







Another limitation is that the portable fluorimeter 
described in this Example to measure in Vivo tissue fluo 
rescence Spectra utilizes a single-pixel probe that interro 
gates a 1 mm diameter area on the cervix. Although the 
Single-pixel probe that we have used provides the capability 
to determine whether a Small region of cervical tissue 
contains pre-cancerous changes, mapping the entire cervix 
with this System is extremely time consuming, making 
wide-scale application of this technology impractical. To 
address this limitation, a multi-pixel probe that can be used 
to acquire fluorescence Spectra from multiple Sites on the 
cervix, Simultaneously may be used. This may provide to a 
user not only information regarding the presence of pre 
cancer but can also indicate. its location and extent. 
In Summary, in Vivo fluorescence spectroScopy has the 
capability to significantly improve the Sensitivity of Pap 
Smear Screening and the Specificity of colposcopy in expert 
hands. Hence, this technique may play an important clinical 
role as a Screening/re-Screening tool (to Screen women who 
have already had an initial positive Pap Smear, but who have 
not undergone colposcopy and directed biopsy) and as an 
adjunct to colposcopy in expert hands. Advantages realized 
by using this technique include, but are not limited to: (1) 
Screening and diagnostic information may be obtained in 
near real-time and (2) this technique may be easily auto 
mated hence reducing the need for Subjective interpretation. 
Furthermore, while the Pap Smear examines only exfoliated 
cervical epithelial cells, fluorescence SpectroScopy may 
interrogate the full thickness of the epithelium. 
TABLE 1. 
Histopathologic classification of samples from the calibration and 
prediction sets. Note, biopsies for histologic evaluation were not obtained 
from colposcopically normal squamous and columnar tissue sites to 
comply with routine patient care procedure 
Histo 
pathology Calibration set Prediction set 
Normal 94 94 
squamous 
Normal 13 14 
columnar 
Inflam- 15 14 
mation 
LG SL, 23 (7 HPV, 16 CIN I) 24 (8 HPV, 16 CIN I) 
HG SIL 35 (16 CIN II, 19 CIN III) 35 (16 CIN II, 19 CIN III) 
TABLE 2 
Components of an optimal set of three constituent algorithms. Algorithm 1 discriminates between SIL and 
normal squamous tissues, algorithm 2 discriminates between SIL and normal columnar tissues and 




Excitation Preprocessing V Logistic discrimination 
Constituent algorithms wavelengths method PC* (76)f (u, O): PPs 
1. 337, 380, 460 Normalization PC1 51 NS: (3.59, 0.843): SIL: (2.514, 0.671) NS: 62% 
SIL vs normal PC3 11 NS: (2.631, 0.292); SIL: (2.535, 0.427) SIL: 38% 




Components of an optimal set of three constituent algorithms. Algorithm 1 discriminates between SIL and 
normal squamous tissues, algorithm 2 discriminates between SIL and normal columnar tissues and 




Excitation Preprocessing V Logistic discrimination 
Constituent algorithms wavelengths method PC (76)f (u, O): PPs 
squamous (NS) PC7 3 NS: (2.850, 0.145); SIL: (2.775, 0.209) 
2 337, 380, 460 Normalization PC1 59 NC: (2.479, 0.444); SIL: (2.737, 0.482) NC: 28% 
SIL vs normal mean-scaling PC2 12 NC: (2.894, 0.330); SIL: (2.990, 0.367) SIL: 72% 
columnar (NC) PC4 6 NC: (3.006, 0.186); SIL: (3.051, 0.167) 
PC5 3 NC: (3.004, 0.101); SIL: (2.994, 0.199) 
3 337, 380, 460 Normalization PC1 51 LG: (2.755, 0.663); HG (2.353, 0.759) LG: 40% 
HG SIL (HG) vs PC3 11 LG: (2.549, 0.394); HG (2.453, 0.497) HG: 60% 
LG SIL (LG) PC6 3 LG: (2.042, 0.180); HG (2.100, 0.180) 
PC8 2 LG: (2.486, 0.223); HG (2.550, 0.130) 
*Principal component. 
Variance accounted for by principal component. 
iMean (u) and standard deviation (o) of principal component scores of tissue types under consideration. 
SPrior probabilities of tissue types under consideration. 
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TABLE 3 TABLE 5 
Accuracy of constituent algorithm 1, which differentiates 3O Accuracy of constituent algorithm 3, which differentiates 
SIL and normal squamous tissues from the calibration and prediction HG SIL and LG SIL from the calibration and prediction sets. The 
sets. The first column corresponds to the spectroscopic classification first column corresponds to the spectroscopic classification and the 
and the first row corresponds to the histopathologic classification first row corresponds to the histopathologic classification 
Normal 35 
LG SL, HG SIL 
Squa- Normal Inflam 
OS columnar mation LG SL, HG SL, 
Classification in calibration set 
Classification in calibration set 
40 LG SL, 69% 17% 
Non-SIL, 68% 8% 7% 17% 9% HG SIL 31% 83% 
SIL 32% 92% 93% 83% 91% Classification in prediction set 
Classification in prediction set 
45 LG SL, 63% 19% 
Non-SIL, 68% 29% 21% 12% 9% HG SIL 37% 81% 
SIL 32% 71% 79% 88% 91% 
50 TABLE 6 
TABLE 4 
Accuracy of the full-parameter composite screening al 
Accuracy of constituent algorithm 2, which differentiates gorithm that differentiates SIL and non-SIL from the calibration and 
SIL and normal columnar tissues from the calibration and prediction prediction sets. The first column corresponds to the spectroscopic 
sets. The first column corresponds to the spectroscopic classification classification and the first row corresponds to the histopathologic 
and the first row corresponds to the histopathologic classification 55 classification 
Normal Normal 
Squa- Normal Inflam- Squa- Normal Inflam 
OS columnar mation LG SL, HG SL, OS columnar mation LG SL, HG SL, 
Classification in calibration set 60 Classification in calibration set 
Non-SIL, 7% 77% 27% 17% 9% Non-SIL, 79% 69% 20% 26% 11% 
SIL 93% 23% 73% 83% 91% SIL 21% 31% 80% 74% 89% 
Classification in prediction set Classification in prediction set 
Non-SIL, 5% 64% 27% 13% 14% Non-SIL, 75% 69% 57% 25% 14% 
SIL 95% 36% 73% 87% 86% 65 SIL 25% 31% 43% 75% 86% 
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TABLE 7 
Accuracy of the full-parameter composite diagnostic al 
gorithm that discriminates between HG SIL and non-HG SIL from 
the calibration and prediction sets. The first column corresponds to 
the spectroscopic classification and the first row corresponds to the 
histopathologic classification 
Normal 
Squa- Normal Inflam 
mous columnar mation LG SL, HG SL 
Classification in calibration set 
Non-HG SIL 84% 77% 27% 74% 20% 
HG SIL 16% 23% 73% 26% 80% 
Classification in prediction set 
Non-HGSIL 85% 69% 86% 67% 23% 
HG SIL 15% 31% 14% 33% 77% 
TABLE 8 
Fluorescence intensities at 15 excitation-emission wave 
length pairs needed to redevelop the three constituent algorithms 1, 
2 and 3 with a minimal decrease in classification accuracy 
Algorithm 1 Algorithm 2 Algorithm 3 
(Wexcs wem) (Wexcs wem) (Wexcs wem) 
337, 410 mm 337, 410 mm 337, 410 mm 
337, 430 mm 337, 430 mm 337, 430 mm 
337, 510 mm 337, 510 mm 337, 510 mm 
337, 580 mm 337, 580 mm 337, 580 mm 
380, 410 mm 380, 410 mm 380, 410 mm 
380, 430 mm 380, 430 mm 380, 430 mm 
380,510 mm 380,510 mm 380,510 mm 
380, 580 mm 380, 580 mm 380, 580 mm 
380, 640 mm 380, 600 mm 380, 640 mm 
460, 580 mm 460, 580 mm 460, 580 mm 
460, 600 mm 460, 600 mm 460, 600 mm 
460, 620 mm 460, 620 mm 460, 620 mm 
460, 640 mm 460, 660 mm 460, 640 mm 
TABLE 9 
Accuracy of the reduced-parameter composite screening 
algorithm that differentiates SIL and non-SIL from the calibration 
and prediction sets. The first column corresponds to the spectro 
scopic classification and the first row corresponds to the histopath 
ologic classification 
Normal 
Squa- Normal Inflam 
OS columnar mation LG SL, HG SL 
Classification in calibration set 
Non-SIL, 73% 46% 13% 17% 15% 
SIL 27% 54% 87% 83% 85% 
Classification in prediction set 
Non-SIL, 72% 64% 50% 25% 11% 












Accuracy of the reduced-parameter composite diagnos 
tic algorithm that differentiates HG SIL and non-HG SIL from the 
calibration and prediction sets. The first column corresponds to the 
spectroscopic classification and the first row corresponds to the his 
topathologic classification 
Normal 
Squa- Normal Inflam 
mous columnar mation LG SL, HG SIL 
Classification in calibration set 
Non-HGSIL 79% 62% 40% 65% 23% 
HG SIL 21% 38% 60% 35% 77% 
Classification in prediction set 
Non-HGSIL 82% 86% 64% 63% 20% 
HG SIL 18% 14% 36% 37% 80% 
TABLE 11 
Comparison of accuracy of composite screening and diagnostic algorithms 
to that of Pap Smear Screening and Colposcopy in expert hands 
SIL ws Non-SIL, HG SIL ws Non-HG SL, 
Classification Sensitivity Specificity Sensitivity Specificity 
Pap smear screening 62 + 23% 68.21% NA* N/A 
Colposcopy in ex- 94 - 6% 48 - 23% 79 - 23%. 7613%, 
pert hands 
Full-parameter com- 82 + 1.4% 68 + 0.0% 79 + 2% 78 6% 
posite algorithm 
Reduced-parameter 84 + 1.5% 65 + 2% 78 O.7% 74 - 2% 
composite algorithm 
*N/A = not applicable. 
EXAMPLE 3 
Head and Neck Analysis-Fluorescence 
Analysis of fluorescence data collected in a clinical head 
and neck Study has been analyzed in accordance with the 
present disclosure. The Example that follows describes 
analysis of these data. 
Materials and Methods 
Fluorescence excitation emission matrices were measured 
in vivo from sixty two sites in 9 normal volunteers and 11 
patients with a known or Suspected premalignant or malig 
nant oral cavity lesion. Excitation wavelength ranged from 
330 to 500 nm and emission wavelength ranged from 340 to 
600 nm. Fluorescence data were analyzed to determine 
which excitation and emission wavelengths contained the 
most diagnostically useful information and to estimate the 
performance of diagnostic algorithms based on this infor 
mation. Algorithms were developed based on combinations 
of emission spectra at various excitation wavelengths in 
order to determine which excitation wavelengths contained 
the most diagnostic information. Then, at those excitation 
wavelengths, algorithms were developed based on reduced 
numbers of emission wavelengths to determine whether 
complete emission spectra were required or whether accu 
rate diagnosis could be made using multi-spectral measure 
ments at a few excitation/emission wavelength combina 
tions. The algorithm development process, consisted of the 
following steps: (1) data pre-processing to reduce inter 
patient variations, (2) data reduction to reduce the dimen 
Sionality of the data Set, (3) feature Selection and classifi 
cation to develop algorithms which maximize diagnostic 
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performance and minimized the likelihood of over-training 
in a training Set, (4) unbiased evaluation of these algorithms 
using the technique of croSS-Validation. 
Results 
The optimal excitation wavelengths for the in Vivo detec 
tion of oral cancers with fluorescence SpectroScopy were 
found to be 350, 380 and 400 nm. An unbiased estimate of 
an algorithm based on the entire emission spectra at these 
excitation wavelengths yields a sensitivity of 100% and 
specificity of 88%. Increasing the number of excitation 
wavelengths did not improve algorithm performance. Better 
algorithm performance was obtained when data were nor 
malized to the peak emission intensity of the concatenated 
vector than when each emission Spectrum was normalized to 
its own peak emission wavelength. The number of emission 
wavelengths could be significantly reduced without com 
promising algorithm performance. When only a Single emis 
Sion wavelength of 472 nm, common to all three excitation 
wavelengths, was used algorithm performance on croSS 
validation was 90% sensitivity and 88% specificity. The 
unbiased performance estimate for the diagnostic algorithms 
based on fluorescence spectroscopy have a higher Sensitivity 
than current visual Screening techniques done by experts. 
Study Subjects 
9 normal volunteers and 11 patients with a known or 
Suspected premalignant or malignant oral cavity lesion were 
recruited to participate in the Study at the Head and Neck 
Surgery Clinical at The University of Texas M.D. Anderson 
Cancer Center. Written informed consent was obtained from 
each perSon in the Study. 
Instrument 
A FastEEM system in accordance with the present dis 
closure was used for this Study. Briefly, the System measured 
fluorescence emission spectra at 18 excitation Wavelengths, 
ranging from 330 nm to 500 nm in 10 nm increments. The 
System incorporated a fiberoptic probe, a Xenon arc lamp 
coupled to a monochromator to provide excitation light and 
a polychromator and thermo-electrically cooled CCD cam 
era to record fluorescence intensity as a function of emission 
wavelength. 
Calibration 
A background EEM, to be subtracted from the acquired 
patient data, was obtained with the probe immersed in a 
non-fluorescent bottle filled with distilled water at the begin 
ning of each measurement day. Then a fluorescence EEM 
was measured with the probe placed on the Surface of a 
quartz cuvette containing a Solution of Rhodamine 610 
(Exciton, Dayton, Ohio) dissolved in ethylene glycol (2 
mg/mL). 
To correct for the non-uniform Spectral response of the 
detection System, the spectra of two calibrated Sources were 
measured; in the visible an NIST traceable calibrated tung 
sten ribbon filament lamp was used and in the UV a 
deuterium lamp was used (550C and 45D, Optronic Labo 
ratories Inc, Orlando, Fla.). Correction factors were derived 
from these spectra. Background subtracted EEMs from 
patients were then corrected for the non-uniform spectral 
response of the detection System. Variations in the intensity 
of the fluorescence excitation light Source at different exci 
tation wavelengths were corrected using measurements of 
the intensity at each excitation wavelength at the probe tip 
made using a calibrated photodiode (818-UV, Newport 
Research Corp.). Finally, corrected fluorescence intensities 
from each Site were divided by the fluorescence emission 
intensity of the Rhodamine standard at 460 nm excitation, 
580 nm emission. Thus, data illustrated in this paper are not 
the absolute fluorescence intensities of tissue but rather the 












Before the probe was used it was disinfected with Metri 
cide (Metrex Research Corp.) in accordance with Standard 
protocol. The probe was then guided into the oral cavity and 
its tip positioned flush with the mucosa. Then fluorescence 
EEMs were measured. 
Fluorescence EEMs were measured from 9 volunteers 
with no history of oral cavity neoplasia at 35 clinically 
normal sites in the oral cavity (Table 1). No biopsies were 
obtained from Volunteers. Following visual Screening in 11 
patients with a known or Suspected premalignant or malig 
nant oral cavity lesion, fluorescence EEMS were measured 
from 27 sites (Table 1). The physician placed the fiber optic 
probe on a lesion or Suspected lesion and the fluorescence of 
that site was measured. In addition to the three to five 
Visually abnormal Sites, fluorescence EEMS were measured 
from one to three contralateral normal Sites. Post 
Spectroscopy, abnormal Sites were tattooed with India Ink 
where the probe measured the Spectra. A clinical diagnosis 
of each lesion as normal, abnormal (not dysplastic), abnor 
mal (dysplastic) or cancerous was recorded by an experi 
enced head and neck Surgeon (AMG) or dental oncologist 
(RJ). During follow up Surgery, a 2–4 mm biopsy of the 
tissue was taken from the tattooed area. These specimens 
were evaluated by an experienced pathologist (BK) using 
light microscopy and classified as normal, mucosal reactive 
atypia (MRA), dysplasia or cancer using standard diagnostic 
criterion. Biopsies with multiple diagnoses were classified 
according to the most Severe pathological diagnosis. The 
pathologist and clinicians were blinded to the results of the 
Spectroscopic analyses. 
Data Review 
A total of 88 sites were measured from 26 Subjects. All 
Spectra were reviewed by a Single investigator blinded to the 
pathologic results (DLH). Spectra were discarded if files 
were not saved properly due to Software error (8 Sites), 
instrument error (2 Sites), operator error (4 Sites), probe 
movement (3 sites), and the presence of room light artifacts 
at wavelengths below 600 nm (3 sites) in at least one of the 
emission Spectra. From the remaining Sites, Spectra from Six 
Sites were excluded because the tattoo could not be located 
and consequently reliable histologic diagnosis was not avail 
able for these sites. Therefore, fluorescence EEMs from 62 
sites from 20 subjects were available for further analysis 
(Table 1). 
Data Analysis 
Fluorescence data were analyzed to determine which 
excitation and emission wavelengths contained the most 
diagnostically useful information and to estimate the per 
formance of diagnostic algorithms based on this informa 
tion. Algorithms based on multi-variate discriminant analy 
sis were considered. Algorithms based on combinations of 
emission spectra at various excitation wavelengths were 
developed in order to determine which excitation wave 
lengths contained the most diagnostic information. Then, at 
those excitation wavelengths, spectra based on reduced 
numbers of emission wavelengths were developed to deter 
mine whether complete emission Spectra were required or 
whether accurate diagnosis could be made using multi 
Spectral measurements at a few excitation/emission wave 
length combinations. 
In each case, the algorithm development process, 
described in detail below, included the following major 
Steps: (1) data pre-processing to reduce inter-patient 
variations, (2) data reduction to reduce the dimensionality of 
the data Set, (3) feature Selection and classification to 
develop algorithms which maximized diagnostic perfor 
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mance and minimized the likelihood of over-training in a 
training Set, (4) unbiased evaluation of these algorithms 
using the technique of croSS-Validation. 
Diagnostic Categories 
Multi-variate discriminant algorithms were Sought to 
Separate two tissue categories: normal and abnormal. The 
abnormal class contained sites with dysplasia, carcinoma in 
Situ and Squamous cell carcinoma, the normal class con 
tained Sites which were clinically and/or histologically nor 
mal as well as benign changes Such as inflammation. 
Data Pre-Processing 
Fluorescence data from a single measurement Site is 
represented as a matrix containing calibrated fluorescence 
intensity as a function of excitation and emission wave 
length. Columns of this matrix correspond to emission 
Spectra at a particular excitation wavelength; rows of this 
matrix correspond to excitation Spectra at a particular emis 
Sion wavelength. Each excitation spectrum contains 18 
intensity measurements, each emission spectrum contains 
between 50 and 130 intensity measurements depending on 
the excitation wavelength. Most multi-variate data analysis 
techniques require vector input rather than matrix input, So 
the column vectors containing the emission spectra at exci 
tation wavelengths Selected for evaluation were concat 
enated into a Single vector in order to explore which exci 
tation wavelengths contained the most diagnostic 
information. 
Our previous work illustrated that Spectra of oral cavity 
obtained in Vivo show large patient to patient variations in 
intensity that can be greater than the inter-category differ 
ences. Therefore, we explored pre-processing methods to 
reduce the inter-patient variations, while preserving inter 
category differences. While many different methods of pre 
processing are possible, two methods were Selected for 
evaluation here: (1) normalization of all emission spectra of 
a given excitation wavelength combination to the maximum 
intensity contained within that combination, and (2) normal 
ization of each emission spectra to its maximum intensity. 
Reduction of Excitation Wavelength Number 
In this Study, fluorescence emission Spectra were mea 
Sured at 18 different excitation wavelengths. One goal of 
data analysis was to determine which combination of exci 
tation wavelengths contains the most diagnostic informa 
tion. We considered combinations of up to four emission 
Spectra. Limiting the number of wavelengths to four allows 
for construction of a reasonably cost-effective clinical Spec 
troScopy System. Two Strategies were considered to identify 
the optimal wavelength combination. The first was to iden 
tify the Single wavelength which gives the best diagnostic 
performance, then the wavelength of those remaining that 
most improves diagnostic performance, and So forth until 
performance no longer improves or four wavelengths have 
been Selected. The Second method was to evaluate all 
possible combinations of up to four wavelengths chosen 
from the 18 possible excitation wavelengths. This equates to 
18 combinations of one, 153 combinations of two, 816 
combinations of three, and 3,060 combinations of four 
excitation wavelengths, for a total of 4,047 combinations. 
While the first method requires less computational time, it is 
only appropriate for normalization methods that remove 
relative intensity information. Otherwise, the best Single 
wavelength may not be part of the best wavelength pair that 
exploits differences in relative intensity. The second method 
can be used with either normalization Scheme and in 
addition, provides a tool to rank the top wavelength 
combinations, rather than identifying the Single best wave 












For each of the 4,047 combinations of one to four 
excitation wavelengths, Spectra from the entire data Set were 
used as a training Set to develop multi-variate algorithms to 
Separate normal and abnormal tissues based on their fluo 
rescence emission spectra at all possible wavelength com 
binations. Algorithm development included of three Steps: 
(1) pre-processing, (2) data reduction and (3) development 
of a classification algorithm which maximized diagnostic 
performance. Data were pre-processed using the two nor 
malization Schemes described above. For each 
normalization, principal component analysis was performed 
using the entire dataset and eigenvectors accounting for 65, 
75, 85, and 95% of the total variance were retained. Prin 
cipal component Scores associated with these eigenvectors 
were calculated for each Sample. Discriminant functions 
were then formed to classify each Sample as normal or 
abnormal. The classification was based on the Mahalanobis 
distance, which is a multivariate measure of the Separation 
of a point from a dataSet in n-dimensional Space. Each 
Sample was held out one at a time and the Mahalanobis 
distances between to the held out Sample and the remaining 
normal and abnormal Samples were calculated; the Sample 
was classified according to the category corresponding to the 
Smallest distance. The Sensitivity and Specificity of the 
algorithm were then evaluated relative to diagnoses based on 
histopathology (in patients Suspected to have oral cavity 
malignancy) or clinical impression (in normal volunteers). 
Overall diagnostic performance was evaluated as the Sum of 
the Sensitivity and the Specificity, thus minimizing the num 
ber of misclassifications (when prevalence of disease and 
normal are approximately equal). The performance of the 
diagnostic algorithm depended on the principal component 
Scores which were included. Four different diagnostic algo 
rithms were developed using principal component Scores 
derived from eigenvectors accounting for increasing 
amounts of total variance. From the available pool of 
principle component Scores, the Single principal component 
Score yielding the best initial performance was identified, 
and then the principal component Score that most improved 
this performance was Selected. This proceSS was repeated 
until performance is no longer improved by the addition of 
principal components Scores, or all available Scores were 
Selected. The pool of available eigenvectorS is specified by 
a variance criterion, eigenvector significance level (ESL), 
that represents the minimum variance fraction accounted for 
by the Sum of the n largest eigenvalues. In this work we 
examined 4 ESLS, corresponding to 65%, 75%, 85% and 
95% of the total variance. 
Comparing Performance of Various Excitation Wavelength 
Combinations 
At each ESL, the wavelength combinations were ranked 
in order of decreasing performance, based upon the Sum of 
Sensitivity and Specificity. The combinations were ranked 
and evaluated based upon training performance. However, 
as the ESL approaches 100%, over-training becomes more 
likely, Since the available pool of eigenvectors will account 
for nearly 100% of the variance, including variance due to 
noise. The magnitude of diagnostically important variances 
is unknown. 
The risk of over-training risk was assessed at the top 25 
wavelength combinations of two, three, and four excitation 
wavelengths, by comparing the training Set performance to 
the performance of an algorithm developed from the same 
data after the diagnoses corresponding to each measurement 
site had been randomized. This provides a dataset with the 
Same variance Structure as the original dataset, but where the 
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diagnostic performance is not expected to exceed that of 
chance. In order to make equivalent comparisons, the dis 
ease prevalence in the real Sample was maintained in the 
randomly assigned diagnoses. Diagnostic algorithms were 
then developed again which minimized the number of 
misclassified Samples at a specified eigenvector Significance 
level (ESL). Random diagnoses were assigned fifty times for 
each wavelength combination and the average and Standard 
deviation of the Sum of the Sensitivity and Specificity were 
calculated. Ideally, for completely normally distributed data, 
the sum of the sensitivity and specificity should be one for 
the randomized diagnosis at all levels of training Signifi 
cance. However, if over-training occurs, this Sum will be 
greater than one. The top 25 wavelength combinations were 
then ranked again based on the absolute difference between 
the training Set performance and random diagnosis assign 
ment. This method allows the top wavelength combinations 
to be ranked in order of their robustness, or lack of propen 
sity to over-train. For a given number of wavelengths per 
combination, the differences were ranked acroSS all four 
eigenvector Significance levels. The largest difference, usu 
ally seen at ESL values of 65%, was selected as the optimal 
wavelength combination. This criterion Selects the wave 
length combination that is least prone to over-training. 
Validation of Algorithm Performance 
Although the optimal wavelength combination has been 
identified based upon comparison of its performance to that 
which can be achieved when the tissue diagnoses have been 
randomized, our estimates of algorithm performance are still 
biased since they are based on the same training Set used to 
develop the algorithm. An unbiased performance estimate 
must be made to assess the true potential of this wavelength 
combination. The effects of over-training in performance 
estimation can be minimized by using Separate training and 
validations Sets, or by using the method of cross-validation. 
The data set here was not sufficiently large to divide into 
Separate training and validation Sets, therefore we used the 
croSS-Validation method. In this method, all data from one 
patient are temporarily removed from the data Set, the 
algorithm is developed using the remaining data Set, and 
then the new algorithm is applied to the left out sites. This 
is repeated until data from each patient has been left out 
once. CroSS validation was used to provide an unbiased 
estimate of the performance of the top three combinations of 
excitation wavelengths with each normalization. 
Reduction of Emission Wavelength Number 
We investigated whether effective diagnostic algorithms 
could be developed using reduced numbers of emission 
wavelengths at the top performing excitation wavelength 
combinations. We calculated the component loadings asso 
ciated with the eigenvectors corresponding to the principal 
component Scores Selected in these algorithms. A component 
loading represents the correlation between each principal 
component and the original pre-processed fluorescence 
emission spectra at each excitation wavelength. The com 
ponent loadings at each excitation wavelength were evalu 
ated to Select fluorescence intensities at a minimum number 
of excitation-emission wavelength pairs required for the 
algorithms to perform with a minimal decrease in classifi 
cation accuracy. Portions of the component loadings most 
highly correlated (correlation >0.5 or <-0.5) with corre 
sponding emission Spectra at each excitation wavelength 
were Selected and the reduced data matrix was then used to 
regenerate and evaluate the algorithms. 
Results 
Fluorescence EEMs from 62 sites from 20 subjects were 











were measured from the tongue, eight from the floor of 
mouth (FOM), seven from the buccal mucosa, four from the 
gingiva, one from the palate, and five from the lip. There 
were 52 normal, four dysplastic, and Six cancerous Sites. The 
data Set consisted of two types of normal Sites: adjacent 
normals and normals from a population without oral cancer. 
Adjacent normals are the Visually normal Sites taken from 
patients that have Suspected lesions elsewhere in the oral 
cavity. In this data Set there were 17 adjacent normal 
(histologically normal) Sites from eleven patients, and 35 
Visually normal Sites taken from nine patients. 
The Visual Screening accuracy of the head and neck 
physicians for this data set was 100% sensitivity and 83% 
Specificity. This performance was determined by comparing 
the Visual impressions of the clinicians to the histologic 
findings upon excision. Results of the analysis of the Spec 
troscopic data are presented according to the normalization 
method used. 
Normalization by Peak Emission Intensity of the Concat 
enated Vector 
The top 25 combinations of one to four excitation wave 
lengths were ranked in order of the largest difference in the 
Sum of the Sensitivity and the Specificity in the training Set 
and the average performance with randomly assigned diag 
noses. The top 3 combinations correspond to the following 
excitation wavelength combinations: (350 380 400 480), 
(350 380 400 490), and (350 380 400). All of these com 
binations demonstrate approximately the same training Set 
performance, with 100% sensitivity and 90% specificity. 
These combinations have three wavelengths in common. 
Since no performance benefit was observed when a fourth 
wavelength was added for the top performing combinations, 
combinations of four wavelengths were not pursued any 
further. The top 25 combinations of three excitation 
wavelengths, ranked in order of the largest difference in the 
Sum of the Sensitivity and the Specificity in the training Set 
and the average performance with randomly assigned diag 
noses are given in Table 2. The ranking of each combination 
based upon training Set performance is given as well. Table 
2 gives the diagnostic performance of each combination for 
both the training Set and the average performance for the 
data Set with randomized diagnosis. The random diagnosis 
performance demonstrated that the combinations showed 
varying propensities to over-train. 
A histogram depicting the frequency at which each wave 
length appeared in the top 25 combinations from Table 2 is 
shown in FIG. 34 for various ESLS. At low ESL values of 
65%, 75% and 85% the diagnostic importance of excitation 
at 350, 380, and 400 nm is evident. This is seen in the 
histograms for wavelength combinations of two and four as 
well (data not shown). 
To provide an unbiased estimate of performance of these 
algorithms, the diagnostic performance of the top wave 
length combinations was evaluated by using the method of 
croSS-Validation using the full data Set. The wavelength 
combination (350, 380, 400 nm) demonstrated a cross 
validation performance of 100% sensitivity and 88% speci 
ficity. The other two combinations (350, 380, 400, 480 nm) 
(350,380, 400,490 nm) demonstrated identical performance 
upon cross validation with a sensitivity of 100% and a 
specificity of 90%. 
The emission spectra corresponding to all 62 Sites at the 
three excitation wavelengths common to these combinations 
are shown in FIG. 36. Visual examination of FIG. 36 
confirms the diagnostic potential of this wavelength com 
bination. The identified combinations demonstrate the 
importance of the relative intensities as Seen following 
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normalization to the maximum intensity in the concatenated 
emission vector. With this normalization, the normal sites 
demonstrate greater fluorescence intensity at 380 nm 
excitation, 450 nm emission than the abnormal Sites. 
Additionally, the remaining emission peaks tend to be more 
intense in normal Sites than for abnormal sites in most 
instances. The normal Sites misclassified as abnormal are 
easily seen in FIG. 36. Histologically, these sites demon 
Strated increased vascularity, Suggesting that the increased 
hemoglobin absorption is one cause of the reduced relative 
fluorescence intensity from these sites. 
The algorithm based on the combination of 350, 380 and 
400 nm excitation wavelengths Selected only a Single prin 
cipal component Score, associated with the eigenvector that 
accounted for most of the total variance. FIG. 37 shows this 
eigenvector and the associated component loading. The 
eigenvector depicts the general lineshape of the normalized 
spectra shown in FIG. 37. The component loading shows 
that the principal component Score for this eigenvector is 
highly correlated to approximately four regions of the con 
catenated emission vector. Single emission intensities within 
these ranges were Selected arbitrarily and are denoted as 
solid green circles in FIG. 37. These points correspond to the 
emission intensities of 418 and 470 nm at 350 nm excitation, 
448 nm emission at 380 nm excitation, and 502 nm emission 
at 400 nm excitation. An algorithm was developed using the 
Same data reduction and classification methods as above 
based upon this reduced data Set. The training performance 
of the reduced algorithm is 100% sensitivity and 90% 
specificity, and the cross-validated performance is 90% 
sensitivity and 90% specificity compared to 100% sensitiv 
ity and 88% specificity of for the algorithm based on the 
entire emission spectra. This algorithm uses a higher ESL of 
95%. Since the reduced data Set contains leSS Variance 
introduced by noise. Motivated by the desire to construct a 
Simple device that could interrogate or image large areas of 
tissue, a reduced algorithm based upon a single emission 
wavelength was evaluated. The emission wavelength chosen 
was common to all three emission spectra, 472 nm. The 
training performance of this reduced algorithm was 100% 
Sensitivity, 88% specificity, and upon croSS Validation it was 
90% sensitivity and 88% specificity. 
Normalization of Each Emission Spectra by its Peak Emis 
Sion Prior to Concatenation 
The analysis was repeated using concatenated vectors in 
which each emission spectrum was normalized to its peak 
intensity. This method removes relative intensity informa 
tion and relies on differences in fluorescence lineshape. The 
maximum difference between traming performance and the 
performance after random diagnosis assignment was 0.58 
compared to 0.82 using the other normalization method. 
Consequently, the top wavelength combination identified 
(350, 380, 400, 430 nm) showed poor performance upon 
cross-validation with a sensitivity of 50% and a specificity 
of 88%. It is interesting to note that the previously identified 
wavelengths, (350, 380, 400 nm) are also a part of this 
combination, indicating that the line shape at these wave 
lengths contains diagnostic information. 
Discussion and Conclusions 
This Example identified the optimal excitation wave 
lengths for in Vivo detection of oral cancers with fluores 
cence spectroscopy. The optimal excitation wavelengths 
were found to be 350,380 and 400 nm. An unbiased estimate 
of an algorithm based on the entire emission Spectra at these 
excitation wavelengths yields a sensitivity of 100% and 
specificity of 88%. Increasing the number of excitation 











algorithm performance was obtained when data were nor 
malized to the peak emission intensity of the concatenated 
vector than when each emission Spectrum was normalized to 
its own peak emission wavelength. The discriminating abil 
ity of this wavelength combination is due to differences in 
both relative intensity and Spectral line shape. The number 
of emission wavelengths could be significantly reduced as 
well without compromising algorithm performance. An 
algorithm based on four emission intensities: 418 and 470 
nm at 350 nm excitation, 448 nm emission at 380 nm. 
excitation, and 502 nm emission at 400 nm excitation 
yielded 90% sensitivity and 90% specificity upon cross 
validation. When only a single emission wavelength of 472 
nm, common to all three excitation wavelengths, was used 
algorithm performance on croSS validation was 90%. Sensi 
tivity and 88% specificity. 
The unbiased performance estimate for the diagnostic 
algorithms based on fluorescence spectroscopy have a 
higher Sensitivity than current Visual Screening techniques 
done by experts. In their hands, Visual Screening has been 
reported to have a sensitivity of 74% and specificity of 99%. 
The performance of Visual Screening by experts in this Study 
was 100% sensitivity, 83% specificity. 
It is interesting to note that emission Spectra obtained at 
400 nm excitation are included in a majority of the top 
combinations. Hemoglobin has a strong absorption maxi 
mum near this location, Suggesting that differences in 
absorption due to perfusion may offer diagnostic informa 
tion. This Suggests that the combinations of reflectance and 
fluorescence spectroScopy may offer improved diagnostic 
performance. 
Head and Neck Analysis-Reflectance 
A FastEEM System was also used to measure tissue 
reflectance Spectra over the visible region of the Spectrum at 
three Source-detector fiber Separations. We have analyzed 
these data with at least two goals: (1) to determine the 
diagnostic potential of reflectance spectroscopy for detec 
tion of neoplasia of the oral cavity, and (2) to determine the 
combined diagnostic potential of fluorescence and reflec 
tance spectroScopy for detection of neoplasia of the oral 
cavity. 
Study Design 
9 normal volunteers and 11 patients with a known or 
Suspected premalignant or malignant oral cavity lesion were 
recruited to participate in the Study at the Head and Neck 
Surgery Clinical at The University of Texas M.D. Anderson 
Cancer Center. Written informed consent was obtained from 
each perSon in the Study. 
Instrument 
The Spectroscopic System used to measure reflectance 
Spectra has been described in detail previously and is briefly 
Summarized here. It includes of a Xenon arc lamp and a 295 
nm long-pass filter which provides broadband illumination, 
a fiber optic probe which directs light to the tissue and 
collects difflusely reflected light from three locations 
(position 1, position 2, position 3), and an imaging spec 
trograph and CCD which detects the reflected light intensity 
as a function of wavelength. Fibers for illumination and 
collection of diffuse reflectance are arranged in a ring at the 
edge of the probe. The collection fibers are located 1.1, 2.1 
and 3 mm from a single illumination fiber. All fibers have a 
core diameter of 200 microns. White light from the Xe lamp 
is coupled to the proximal end of the illumination fiber. The 
distal ends of the fibers are flush with the probe tip and 
placed in direct contact with the sample Surface. Using this 
system, oral cavity tissue reflectance spectra from 390-590 
nm with a spectral resolution of 4 nm were collected in 
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approximately 30 Seconds. The Signal to noise ratio 
exceeded 75:1 for 90% of the data. 
Procedure 
Reflectance spectra were wavelength calibrated with a 
mercury light Source. Dark current and background were 
recorded before each measurement with the same Settings 
but with illumination turned off. These background mea 
Surements were Subtracted from each reflectance measure 
ment offline. Reflectance data are reported relative to a 
2.68% by volume solution of 1.072 micron diameter poly 
styrene microSpheres (PolyScience Inc., Warrington, Pa.). 
The probe was placed on the outside wall of a 1 cm path 
length cuvette containing the microSphere Solution. The total 
integrated reflectance of this Standard was measured on a 
double beam spectrophotometer (U-3300 Hitachi, Tokyo, 
Japan) with an integrating sphere attachment (Labsphere 
Inc., North Sutton, N.H.). This was used to correct the 
reflectance measurements of the microSphere Solution made 
with the Spectroscopic System. TiSSue Spectra at each col 
lection fiber position were divided pointwise by the cor 
rected Standard reflectance Spectrum at the corresponding 
fiber position. 
Before the probe was used it was disinfected with Metri 
cide (Metrex Research Corp.) in accordance with Standard 
protocol. The probe was then guided into the oral cavity and 
its tip positioned flush with the mucosa. Then reflectance 
Spectra were measured. 
Reflectance spectra were measured from 9 Volunteers 
with no history of oral cavity neoplasia at 35 clinically 
normal sites in the oral cavity (see Table 3). No biopsies 
were obtained from Volunteers. Following visual Screening 
in 11 patients with a known or Suspected premalignant or 
malignant oral cavity lesion, reflectance spectra were mea 
Sured from 27 sites. The physician placed the fiber optic 
probe on a lesion or Suspected lesion and the reflectance of 
that site was measured. In addition to the three to five 
Visually abnormal Sites, reflectance spectra were measured 
from one to three contralateral normal Sites. Post 
Spectroscopy, abnormal Sites were tattooed with India Ink 
where the probe measured the Spectra. A clinical diagnosis 
of each lesion as normal, abnormal (not dysplastic), abnor 
mal (dysplastic) or cancerous was recorded by an experi 
enced head and neck Surgeon (AMG) or dental oncologist 
(RJ). During follow up Surgery, a 2–4 mm biopsy of the 
tissue was taken from the tattooed area. These specimens 
were evaluated by an experienced pathologist (BK) using 
light microScopy and classified as normal, mucosal reactive 
atypia (MRA), dysplasia or cancer using Standard diagnostic 
criterion. Biopsies with multiple diagnoses were classified 
according to the most Severe pathological diagnosis. The 
pathologist and clinicians were blinded to the results of the 
Spectroscopic analyses. 
Data Analysis 
Reflectance Spectra were further processed to reduce 
noise. A moving average with a width of 10 nm was applied 
to each spectrum; following this, intensities of all reflectance 
spectra were extracted in 5 nm steps from 400 to 585 nm and 
individually analyzed. In addition, the first (slope) and 
Second derivatives of the reflectance spectra were calculated 
between 400 and 580 nm in 5 nm steps. 
An exploratory data analysis was carried out to determine 
which Source-detector Separations and wavelength regions 
were useful to Separate three tissue categories: normal, 
dysplasia and cancer. The normal class contained Sites which 
were clinically and/or histologically normal as well as 
benign changes Such as inflammation. 
For each diagnostic category (normal, dysplasia, cancer) 











the intensity at each wavelength, and the first and Second 
derivative at each wavelength. These values were calculated 
Separately for each Source detector Separation. The Student's 
t-test was used to determine whether differences in these 
mean values were Statistically significant between groups of 
two categories. We examined normal tissues VS. abnormal 
tissues (dysplasia and cancer) as well as normal tissues vs. 
dysplasia. 
Parameters which were most Statistically significant, cor 
responding to the lowest p-values, were examined further for 
diagnostic ability. We constructed two-dimensional Scatter 
plots which showed the most Statistically significant param 
eter values for each Site measured to determine which 
parameters could most effectively discriminate between the 
two categories of normal and abnormal (dysplasia and 
cancer). All calculations and graphs were produced with the 
Matlab(R) (Mathworks Inc.) and the Statistical Toolbox for 
Matlab. 
Results 
FIGS. 38 through 40 show the reflectance spectra, first 
and Second derivative at each of the three Source detector 
separations for all sites measured. FIGS. 41 through 43 show 
the average value plus and minus one Standard deviation for 
normal, dysplastic and cancer Sites. Normal Sites are shown 
in green, dysplasia in blue and cancer in red. In general, the 
Spectra of cancer Sites show the highest reflectance intensity 
at all wavelengths measured, while spectra of normal and 
dysplastic Sites are lower in intensity and more Similar. 
Differences in intensity are greatest at position 1 and least at 
position 3. The slope and second derivative of the reflec 
tance spectra are greater (lower) for cancers at 440 and 480 
nm (520 nm). 
FIG. 44 shows the p values comparing the mean intensity, 
mean first and Second derivatives of normal tissue verSuS 
abnormal tissues, at each wavelength at the three different 
Source detector separations. FIG. 45 shows the p values 
comparing the mean intensity, mean first and Second deriva 
tives of normal tissue Versus dysplastic tissues, at each 
wavelength at the three different Source detector Separations. 
A low value indicates a Statistically Significant result, we are 
particularly interested in those with values less than 0.05. 
At each Source-detector fiber Separation, we ranked the 
intensity, first and Second derivatives at each wavelength in 
order of increasing p-value. Tables 4-6 Show the results 
when normal and abnormal tissues were compared, Tables 
7-9 show the results when normal and dysplastic tissues 
were compared. Results are shown for p-values less than or 
equal to 0.05. 
In order to explore the diagnostic contributions provided 
by these wavelength regions, we highlighted all regions 
where the p-value was less than or equal to 0.01 for first and 
Second derivatives and less than or equal to 0.02 for inten 
sity. These values are highlighted in gray in tables 4-9. This 
resulted in a total of 15 different parameters. The slope and 
second derivative near 440-460 nm at positions 1 and 2 were 
identified as diagnostically useful regions, as was the Slope 
and second derivative near 500-510 nm at position 3. The 
intensity from 450-51 nm and 570-585 nm at position 2 
were also identified as diagnostically useful. 
Two dimensional Scatterplots containing all possible pair 
wise combinations of these 15 groups of parameters were 
generated (105 total combinations). FIGS. 46–48 show three 
representative examples. FIG. 46 shows the second deriva 
tive at 430 nm for position 2 vs. the second derivative at 495 
nm for position one. The Straight line represents an algo 
rithm to Separate normal findings from dysplasias and 
cancers, and results in a Sensitivity of 80% and a specificity 
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of 85%. FIG. 47 shows the Second derivative at 450 nm for 
position 1 vs. the first derivative at 510 nm for position three. 
The Straight line represents an algorithm to Separate normal 
findings from dysplasias and cancers, and results in a 
sensitivity of 80% and a specificity of 82%. FIG. 48 shows 
the second derivative at 410 nm for position 1 vs. the first 
derivative at 510 nm for position three. The straight line 
represents an algorithm to Separate normal findings from 
dysplasias and cancers, and results in a Sensitivity of 70% 
and a specificity of 75%. In each case, the lines were drawn 
to minimize the total number of Samples misclassified. 
These Sensitivity and Specificity values are slightly lower 
than those achieved in the previous Section using fluores 
cence alone, and reflect the greater Overlap in the reflectance 
of tissues from the three groups than is seen in the fluores 
cence spectra. However, the fluorescence algorithms were 
based on multi-variate classifiers to enable the use of more 
than two parameters in the algorithm. These techniques were 
next pursued using reflectance spectra. 
Multi-Variate Discriminant Algorithms 
Reflectance spectra were analyzed to determine which 
wavelength ranges and Source-detector fiber Separations 
contained the most diagnostically useful information and to 
estimate the performance of multi-variate diagnostic algo 
rithms based on this information. We considered algorithms 
based on multi-variate discriminant analysis. First, we 
developed algorithms based on reflectance spectra, or their 
first or Second derivatives over various wavelength ranges at 
each Source-detector fiber Separation in order to determine 
which types of spectra, wavelength ranges and fiber Sepa 
rations contained the most diagnostic information. In 
addition, we developed algorithms using the concatenated 
spectra (or their first or second derivatives) at all fiber 
Separations over various wavelength ranges. In each case, 
the algorithm development process, described in detail 
below, consisted of the following major steps: (1) data 
reduction to reduce the dimensionality of the data Set, (2) 
feature Selection and classification to develop algorithms 
which maximized diagnostic performance and minimized 
the likelihood of over-training in a training Set, (3) unbiased 
evaluation of these algorithms using the technique of croSS 
validation. 
Diagnostic Categories 
Multi-variate discriminant algorithms were Sought to 
Separate two tissue categories: normal and abnormal. The 
abnormal class contained sites with dysplasia, carcinoma in 
Situ and Squamous cell carcinoma, the normal class con 
tained Sites which were clinically and/or histologically nor 
mal as well as benign changes Such as inflammation. 
Algorithm Development 
For each of the different types of Spectra and wavelength 
ranges, spectra from the entire data Set were used as a 
training Set to develop multi-variate algorithms to Separate 
normal and abnormal tissues based on their reflectance. 
Algorithm development included two steps: (1) data reduc 
tion and (2) development of a classification algorithm which 
maximized diagnostic performance. For each type of data, 
principal component analysis was performed using the entire 
dataset and eigenvectors accounting for 65, 75, 85, 95% and 
99% of the total variance were retained. Principal compo 
nent Scores associated with these eigenvectors were calcu 
lated for each Sample. Discriminant functions were then 











classification was based on the Mahalanobis distance, which 
is a multivariate measure of the Separation of a point from 
a dataSet in n-dimensional Space. Each Sample was held out 
one at a time and the Mahalanobis distances between to the 
held out Sample and the remaining normal and abnormal 
Samples were calculated; the Sample was classified accord 
ing to the category corresponding to the Smallest distance. 
The sensitivity and specificity of the algorithm were then 
evaluated relative to diagnoses based on histopathology (in 
patients Suspected to have oral cavity malignancy) or clini 
cal impression (in normal volunteers). Overall diagnostic 
performance was evaluated as the Sum of the Sensitivity and 
the Specificity, thus minimizing the number of misclassifi 
cations (when prevalence of disease and normal are approxi 
mately equal). The performance of the diagnostic algorithm 
depended on the principal component Scores which were 
included. Five different diagnostic algorithms were devel 
oped using principal component Scores derived from eigen 
vectors accounting for increasing amounts of total variance. 
From the available pool of principle component Scores, the 
Single principal component Score yielding the best initial 
performance was identified, and then the principal compo 
nent Score that most improved this performance was 
Selected. This proceSS was repeated until performance was 
no longer improved by the addition of principal components 
Scores, or all available Scores were Selected. The pool of 
available eigenvectorS is specified by a variance criterion, 
eigenvector Significance level (ESL), that represents the 
minimum variance fraction accounted for by the Sum of the 
in largest eigenvalues. In this work we examined 5 ESLS, 
corresponding to 65%, 75%, 85%, 95% and 99% of the total 
variance. 
Comparing Performance of Various Data Types and Wave 
length Ranges 
At each ESL, wavelength range and type of data we 
calculated the Sum of Sensitivity and Specificity. AS the ESL 
approaches 100%, over-training becomes more likely, Since 
the available pool of eigenvectors will account for nearly 
100% of the variance, including variance due to noise. The 
magnitude of diagnostically important variances is 
unknown. The risk of over-training risk was assessed for 
each of the types of input data, by comparing the training Set 
performance to the performance of an algorithm developed 
from the same data after the diagnoses corresponding to 
each measurement Site had been randomized. This provides 
a dataset with the Same variance Structure as the original 
dataset, but where the diagnostic performance is not 
expected to exceed that of chance. In order to make equiva 
lent comparisons, the disease prevalence in the real Sample 
was maintained in the randomly assigned diagnoses. Diag 
nostic algorithms were then developed again which mini 
mized the number of misclassified Samples at a Specified 
eigenvector Significance level (ESL). Random diagnoses 
were assigned fifty times for each wavelength combination 
and the average and Standard deviation of the Sum of the 
Sensitivity and Specificity were calculated. Ideally, for com 
pletely normally distributed data, the sum of the sensitivity 
and Specificity should be one for the randomized diagnosis 
at all levels of training Significance. However, if over 
training occurs, this Sum will be greater than one. At each 
ESL, wavelength range and type of data we calculated the 
absolute difference between the training Set performance and 
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random diagnosis assignment. This method allows the best 
types of data and wavelength ranges to be identified based 
on their robustness, or lack of propensity to over-train. 
Unlike our analysis of the fluorescence from oral cavity, in 
this case, all Sensitivity and Specificity values were calcu 
lated for the case of cross-validation. This proved to be 
necessary Since the eigenvectors which contained diagnos 
tically useful information contributed a relatively smaller 
amount of the total variance for reflectance than for fluor 
Scence. The largest differences, were Selected as the optimal 
data type and wavelength range. This criterion Selects the 
data type and wavelength range that is least prone to 
over-training. 
Results-Multi-Variate Discriminant Algorithms 
Tables 10-12 show the absolute difference between the 
training Set performance and random diagnosis assignment 
for the different data types, wavelength ranges and ESLS. We 
Selected an improvement of 0.5 as Significant for first and 
Second derivative data and an improvement of greater than 
0.4 as significant for intensity data (since this is easier to 
measure in a multi-spectral imaging System). Wavelength 
ranges, data types and ESLS with at least this improvement 
are highlighted in Tables 10-12. Eight types of data met 
these criteria; however, the wavelength range associated 
with Several of them overlapped significantly. In this case, 
the combination with the best performance increase was 
Selected, resulting in the following four combinations: (1) 
Intensity at position 2 from 395-475 nm at 95% ESL, (2) 
Intensity at positions 1–3 from 425-500 nm at 99% ESL, (3) 
Slope at position 1 from 450-525 nm at 65% ESL and (4) 
Slope at position 3 from 395-550 nm at 95% ESL. Table 13 
gives the croSS-Validated Sensitivity and Specificity for algo 
rithms based on these data types, wavelength ranges and 
ESLS. The best performance was achieved using the slope at 
position 3 from 395-550 nm at 95% ESL, with a cross 
validated sensitivity of 70% and a specificity of 100%. This 
compares favorably to the scatter plot shown in FIG. 47, 
which shows the second derivative at 450 nm for position 1 
VS. the slope at 510 nm for position three, where a simple 
linear discriminant algorithm resulted in a sensitivity of 80% 
and a specificity of 82%. 
Head and Neck Analysis-Combination of 
Fluorescence and Reflectance 
In general, the performance of multi-variate algorithms 
based on reflectance spectroScopy alone was Somewhat 
lower than that based on fluorescence spectroScopy alone. 
However, from an instrumentation point of View, it may be 
easier to measure reflectance images and spectra Since Signal 
to noise ratio is higher. Therefore, we explored the combi 
nation of reflectance and fluorescence SpectroScopy and 
wheter it may provide better discrimination. Further, we 
examined whether the good performance of the fluorescence 
algorithm may be maintained if the number of fluorescence 
excitation wavelengths were reduced, but reflectance Spectra 
were measured. 
In Our previous analyses, we identified a combination of 
emission spectra at three excitation wavelength as optimal 
for diagnosis based on fluorescence SpectroScopy and four 
types of reflectance data which were optimal for diagnosis. 











tions of data at ESLs of 65%, 75%, 85%, 95% and 99%: (a) 
Fluorescence at three excitation wavelengths +each type of 
reflectance data, (b) Fluorescence at all combinations of two 
excitation wavelengths +each type of reflectance data, and 
(c) Fluorescence at each single excitation wavelength +each 
type of reflectance data. 
The performance of these combinations was compared to 
that which could be achieved with fluorescence alone. Since 
the number of samples where both fluorescence and reflec 
tance data were available was Smaller than that for either 
type of data alone, we re-evaluated the performance of 
algorithms based on reflectance or fluorescence data alone 
using this reduced dataset. We also evaluated the perfor 
mance of fluorescence alone at one or two excitation wave 
lengths using this reduced dataset. Table 14 shows the 
number of patients and Sites where both reflectance and 
fluorescence data were available. Results, reported as Sen 
Sitivity and Specificity giving best performance under croSS 
validation, are shown in Tables 15-18 for each type of 
reflectance data. 
The performance of the fluorescence algorithm based on 
three excitation wavelengths does not improve when any of 
the four types of reflectance data are also incorporated. The 
performance of fluorescence algorithms based on two exci 
tation wavelengths was lower than that for three excitation 
wavelengths, incorporation of any of the four types of 
reflectance spectra did not improve performance. The per 
formance of fluorescence algorithms based on a Single 
excitation wavelength was lower than that for two and three 
excitation wavelengths. Best results were obtained using 
spectra at 400 nm excitation. Incorporation of any of the four 
types of reflectance spectra did not improve performance. 
TABLE 2 
Ranking of wavelength combinations of three based upon the difference 
between training and random diagnosis assignment performance, A. 
ESL = 65% 
Performance (Se + Sp 
Rank Wavelength Train 
Random Training Combination ing Random A 
1. 1. 35O 38O 400 .90 13 O.17 O.77 
2 7 35O 38O 390 .78 13 - 0.14 O.66 
3 2 35O 38O 460 87 .25 + 0.12 0.62 
4 3 35O 38O 450 85 25 O.12 O.59 
5 15 36O 37O 400 77 2O. O.13 O.S7 
6 12 38O 400 430 .78 .23 - 0.12 0.56 
7 11 38O 400 410 .78 .23 - 0.12 0.55 
8 9 35O 4OO SOO .78 .24 + 0.12 0.54 
9 23 33O 41O 430 77 .23 - 0.13 0.54 
1O 4 360 400 440 8O 26 - 0.14 0.54 
11 24 330 410 440 77 23 O. O.54 
12 1O 37O 38O 400 .78 .25 + 0.14 0.53 
13 2O 33O 400 410 77 .23 - 0.14 0.53 
14 17 33O 350 38O 77 .24 + 0.13 0.53 
15 8 35O 38O 430 .78 26 - 0.13 0.52 
16 14 42O 490 SOO .78 26 - 0.12 0.52 
17 18 33O 350 400 77 .25 + 0.14 0.52 
18 22 33O 400 440 77 26 - 0.14 0.50 
19 21 33O 400 430 77 27 O.13 OSO 
2O 13 390 4OO 42O .78 30 - 0.13 O-49 
21 5 35O 37O 430 .79 31 - 0.12 O.48 
22 25 35O 360 400 77 3O O. O.47 
23 6 35O 36O 370 .78 .34 + 0.14 0.44 
24 16 33O 340 400 77 32 - 0.14 O.44 
25 19 33O 360 400 77 33 - 0.14 O.44 
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Summary of sites measured and corresponding clinical or histopathologic diagnosis. 
Intensity p value Slope 
Intensity p value Slope 
Floor 
# of # of of Buccal 
sites patients Tongue Mouth Mucosa Gingiva Palate Lip 
Total Sites 62 2O 37 8 7 4 1. 5 
Normals 52 2O 32 5 7 3 O 5 
Normal 35 9 25 1. 4 5 
Adjacent 17 11 7 4 3 3 
Abnormals 1O 9 5 3 O 1. 1. O 
Dysplasia 
Mild 1. 1. 1. 
Moderate 1. 1. 1. 
Severe 2 2 1. 1. 
Cancer 
Invasive 4 3 2 1. 1. 
Submucosal 1. 1. 1. 
Verrucus 1. 1. 1. 
TABLE 3 
25 
Normal Dysplasia Cancer 
Position 1 -# Sites 31 4 6 
Position 1 - # Patients 16 4 5 
Position 2 - # Sites 32 4 6 
Position 2 - # Patients 15 4 5 
Position 3 - # Sites 31 4 6 s70 
Position 3 - # Patients 15 4 5 575 
Position 1-3 - # Sites 27 4 6 




TABLE 4 52O 
525 
Normal-Abnormal 
Position One 530 
535 
2nd 40 540 
Intensity p value Slope p value Derivative p value 565 
450 O.05 450 O.O1 450 O 440 
455 O.05 400 O.O2 410 O.O1 545 
460 O.05 455 O.O3 465 O.04 550 
465 O.05 435 O.04 425 O.05 45 555 
470 O.05 440 O.04 430 O.05 
475 O.05 430 O.05 455 O.05 560 





Intensity p value Slope p value 2nd Derivative p value 55 
490 
450 O.O2 465 O.O1 430 O.O1 495 
455 O.O2 470 O.O1 435 O.O1 
460 O.O2 560 O.O1 550 O.O1 
465 O.O2 445 O.O2 440 O.O2 
470 O.O2 450 O.O2 445 O.O3 
475 O.O2 455 O.O2 42O 0.04 60 
48O O.O2 460 O.O2 465 O.04 
485 O.O2 475 O.O2 470 O.04 
490 O.O2 48O O.04 475 O.04 
495 O.O2 540 O.05 
500 O.O2 
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TABLE 7 TABLE 11 
Absolute difference between the sum of the sensitivity and specificity for 
cross-validated training set performance and cross-validated random 
diagnosis assignment for the first derivative data at different source 
detector fiber separations, wavelength ranges and ESLs. 
Normal-Dysplasia 
Position One 
Intensity p value Slope p value 2nd Derivative p value S. 
Slope Range 65% 75% 85% 95% 99% 
10 
515 O 495 O Position 1 395-475 +0.4.11 +0.370 +0.351 +0.201 +0.089 
500 O.O3 Position 1 425-500 +0.401 +0.421 +0.311 +0.327 +0.186 
Position 1 450-525 +0.506 +0.464 +0.273 +0.313 +0.064 
Position 1 475-550 +0.244 +0.277 +0.270 +0.158 -0.048 
Position 1 500-585 +0.154 +0.093 +0.004 -0.029 +0.132 
15 Position 1 395-550 +0.492 +0.251 +0.322 +0.162 -0.168 
TABLE 8 Position 1 395-585 +0.323 +0.285 +0.252 +0.190 +0.282 
Position 2 395-475 +0.277 +0.264 +0.265 +0.202 +0.357 
Normal-Dysplasia Position 2 425-500 +0.295 +0.268 +0.272 +0.187 -0.110 
Position Two Position 2 450-525 +0.239 +0.2O3 +0.215 -0.012 +0.109 
Position 2 475-550 +0.161 +0.144 +0.205 +0.160 +0.366 
Intensity p value Slope p value 2nd Derivative p value 20 Position 2 500-585 +0.110 +0.471 +0.434 +0.391 +0.214 
Position 2 395-550 +0.224 +0.168 +0.224 +0.123 -0.044 
505 O Position 2 395-585 +0.157 +0.201 +0.354 +0.307 -0.134 
Position 3 395-475 +0.134 +0.141 -0.017 +0.108 +0.454 
Position 3 425-500 -0.116 -0.146 -0.152 +0.296 +0.288 
Position 3 450-525 +0.247 +0.198 +0.429 +0.578 +0.339 
25 Position 3 475-550 +0.281 +0.374 +0.222 +0.500 +0.356 
TABLE 9 Position 3 500-585 +0.156 +0.492 +0.498 +0.426 +0.326 
Position 3 395-550 -0.028 +0.059 +0.686 +0.649 +0.137 
Normal-Dysplasia Position 3 395-585 +0.129 +0.163 +0.209 +0.028 +0.147 
- Position Three- Position 123 395-475 +0.329 +0.326 +0.383 -0.053 +0.222 
Intensity p value Slope p value 2nd Derivative p value 30 Position 123 425-500 +0.332 +0.304 +0.291 +0.297 -0.088 
Position 123 450-525 +0.379 +0.381 +0.432 -0.026 +0.301 
455 O.05 Position 123 475-550 +0.036 +0.207 +0.264 +0.2O3 +0.249 
Position 123 500-585 +0.198 +0.397 +0.318 +0.077 +0.206 
Position 123 395-550 +0.373 +0.429 +0.414 -0.029 -0.026 
Position 123 395-585 +0.211 +0.383 +0.145 -0.125 -0.039 
TABLE 10 35 
Absolute difference between the sum of the sensitivity and specificity for 
cross-validated training set performance and cross-validated random TABLE 12 
diagnosis assignment for the intensity data at different source-detector 
fiber separations, wavelength ranges and ESLS. Absolute difference between the sum of the sensitivity and specificity for 
40 cross-validated training set performance and cross-validated random 
Wave- diagnosis assignment for the second derivative data at different source 
length detector fiber separations, wavelength ranges and ESLs. 
Intensity Range 65% 75% 85% 95% 99% 
Wave 
Position 1 395-475 +0.182 +0.141 +0.213 +0.219 +0.101 2nd length 
Position 1 425-500 +0.236 +0.216 +0.262 +0.314 +0.272 Derivative Range 65 75 85 95 99 
Position 1 450–525 +0.316 +0.281 +0.345 +0.367 +0.225 S -H
Position 1 475-550 +0.262 +0.231 +0.311 +0.305 +0.286 Position 1 395-475 +0.400 +0.341 +0.277 +0.287 +0.440 
Position 1 500-585 +0.239 +0.215 +0.242 +0.253 +0.173 Position 1 425-500 +0.399 +0.358 +0.406 +0.440 +0.182 
Position 1 395-550 +0.268 +0.242 +0.343 +0.373 +0.186 Position 1 450-525 +0.420 +0.272 +0.195 +0.082 +0.053 
Position 1 395-585 +0.283 +0.273 +0.305 +0.346 +0.083 Position 1 475-550 -0.020 +0.008 -0.018 +0.190 +0.021 
Position 2 395-475 +0.340 +0.384 +0.373 +0.395 +0.317 Position 1 500-585 -0.268 -0.281 -0.245 +0.111 -0.102 
Position 2 425-500 +0.293 +0.324 +0.307 +0.275 +0.209 50 Position 1 395-550 +0.369 +0.294 +0.112 +0.065 +0.282 
Position 2 450-525 +0.256 +0.257 +0.265 +0.242 +0.229 Position 1 395-585 +0.201 +0.158 -0.002 -0.022 +0.164 
Position 2 475-550 +0.175 +0.178 +0.201 +0.189 +0.164 Position 2 395-475 +0.321 +0.343 +0.315 +0.264 +0.402 
Position 2 500-585 +0.185 +0.169 +0.224 +0.205 +0.116 Position 2 425-500 +0.300 +0.363 +0.248 +0.068 +0.010 
Position 2 395-550 +0.271 +0.296 +0.326 +0.288 +0.120 Position 2 450-525 +0.015 +0.056 +0.178 -0.118 +0.043 
Position 2 395-585 +0.262 +0.265 +0.286 +0.293 +0.013 Position 2 475-550 -0.130 +0.014 +0.019 -0.031 -0.014 
Position 3 395-475 +0.125 +0.079 -0.034 +0.048 +0.047 55 Position 2 500-585 -0.153 +0.181 +0.028 +0.037 +0.117 
Position 3 425-500 +0.116 +0.076 +0.145 +0.348 +0.174 Position 2 395-550 +0.269 +0.265 +0.279 +0.256 +0.116 
Position 3 450-525 +0.141 +0.104 +0.163 +0.148 +0.317 Position 2 395-585 +0.248 +0.323 +0.073 +0.254 +0.154 
Position 3 475-550 -0.351 -0.404 -0.341 -0.348 +0.145 Position 3 395-475 +0.081 +0.129 +0.259 +0.402 +0.372 
Position 3 500-585 -0.260 -0.313 -0.281 -0.299 +0.155 Position 3 425-500 +0.242 +0.257 +0.278 +0.377 +0.296 
Position 3 395-550 -0.127 -0.155 -0.102 -0.188 +0.121 Position 3 450-525 +0.186 +0.183 +0.377 +0.468 +0.242 
Position 3 395-585 +0.000 +0.000 +0.000 +0.000 +0.000 60 Position 3 475-550 +0.032 +0.124 -0.031 +0.314 +0.265 
Position 123 395-475 +0.386 +0.417 +0.402 +0.269 +0.243 Position 3 500-585 -0.120 +0.208 +0.269 +0.129 +0.015 
Position 123 425-500 +0.355 +0.392 +0.369 +0.307 +0.426 Position 3 395-550 -0.118 -0.057 -0.078 +0.318 -0.022 
Position 123 450-525 +0.318 +0.343 +0.333 +0.275 +0.194 Position 3 395-585 +0.141 +0.168 +0.338 +0.290 +0.406 
Position 123 475-550 +0.267 +0.265 +0.273 +0.193 +0.341 Position 123 395-475 +0.351 +0.337 +0.270 -0.01 
Position 123 500-585 +0.302 +0.296 +0.317 +0.117 +0.132 Position 123 425-500 +0.349 +0.247 +0.198 +0.222 
Position 123 395-550 +0.323 +0.351 +0.348 +0.308 -0.044 Position 123 450-525 +0.212 +0.271 +0.043 +0.087 
Position 123 395–585 +0.300 +0.308 +0.310 +0.130 +0.030 65 Position 123 475-550 +0.153 +0.161 +0.252 +0.114 
Position 123 500-585 +0.214 +0.237 +0.216 -0.165 
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TABLE 12-continued 
Absolute difference between the sum of the sensitivity and specificity for 
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cross-validated training set performance and cross-validated random 
diagnosis assignment for the second derivative data at different source 
detector fiber separations, wavelength ranges and ESLs. 
Wave 
2nd length 
Derivative Range 65 75 85 95 99 
Position 123 395-550 +0.231 +0.220 +0.159 -0.025 
Position 123 395-585 +0.222 +0.243 +0.231 -0.115 
TABLE 13 
Cross validated performance of algorithms based on selected data types, 
wavelength ranges and ESLs. Combinations are ranked in order of 
decreasing Sum of Sensitivity plus Specificity. 
Wavelength 
Position Data Type Range ESL 
3 Slope 395-550 85% 
123 Intensity 425-5OO 99% 
1. Slope 450-525 65% 
2 Intensity 395-475 95% 
TABLE 1.4 




Position 1 + Fluorescence EEM 
# Sites 
# Patients 
Position 2 + Fluorescence EEM 
# Sites 
# Patients 
Position 3 + Fluorescence EEM 
# Sites 
# Patients 
































Cross-validated performance of algorithms based on combinations of 
fluorescence and reflectance data based on the slope at position 3 from 
395-550 nm. Strategies based on fluorescence alone are shown with an 
asterisk; strategies based on fluorescence + reflectance 
Type of Data 
* Fluorescence at 350, 380 400 mm 
excitation alone 
Fluorescence at 350, 380 
excitation + Reflectance 
* Fluorescence at 350, 38 
excitation alone 
Fluorescence at 350, 380 
excitation + Reflectance 































Cross-validated performance of algorithms based on combinations of 
fluorescence and reflectance data based on the slope at position 3 from 
395-550 nm. Strategies based on fluorescence alone are shown with an 
asterisk; strategies based on fluorescence + reflectance 
have no asterisk. 
Type of Data ESL Sensitivity Specificity 
Fluorescence at 350, 400 mm 65% 50% 83% 
excitation alone 
Fluorescence at 350, 400 nm. 65% 50% 83% 
excitation + Reflectance Data 
Fluorescence at 380, 400 mm 65% 63% 87% 
excitation alone 
Fluorescence at 380, 400 nm. 65% 63% 87% 
excitation + Reflectance Data 
Fluorescence at 350 mm 65% 50% 67% 
excitation alone 
Fluorescence at 350 mm 65% 50% 67% 
excitation + Reflectance Data 
Fluorescence at 380 mm 65% 50% 47% 
excitation alone 
Fluorescence at 380 mm 95% 50% 83% 
excitation + Reflectance Data 
Fluorescence at 400 mm 65% 75% 70% 
excitation alone 
Fluorescence at 400 mm 85% 75% 73% 
excitation + Reflectance Data 
TABLE 16 
Cross-validated performance of algorithms based on combinations of 
fluorescence and reflectance data based on the intensity at position 1-3 
from 425-500 nm. Strategies based on fluorescence alone are shown with 
an asterisk; strategies based on fluorescence + reflectance have no 
asterisk. 
Type of Data ESL Sensitivity Specificity 
*Fluorescence at 350, 380 400 mm 65% 63% 89% 
excitation alone 
Fluorescence at 350, 380 400 mm 65% 63% 85% 
excitation + Reflectance Data 
*Fluorescence at 350, 380 nm. 65% 63% 85% 
excitation alone 
Fluorescence at 350, 380 nm. 65% 63% 85% 
excitation + Reflectance Data 
Fluorescence at 350, 400 mm 65% 50% 81% 
excitation alone 
Fluorescence at 350, 400 nm. 65% 50% 81% 
excitation + Reflectance Data 
Fluorescence at 380, 400 mm 65% 50% 85% 
excitation alone 
Fluorescence at 380, 400 nm. 95% 50% 89% 
excitation + Reflectance Data 
Fluorescence at 350 mm 65% 50% 62% 
excitation alone 
Fluorescence at 350 mm 65% 38% 73% 
excitation + Reflectance Data 
Fluorescence at 380 nm. 65% 50% 46% 
excitation alone 
Fluorescence at 380 mm 65% 38% 58% 
excitation + Reflectance Data 
Fluorescence at 400 nm. 65% 75% 73% 
excitation alone 
Fluorescence at 400 mm 65% 88% 69% 
excitation + Reflectance Data 
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TABLE 1.7 
Cross-validated performance of algorithms based on combinations of 
fluorescence and reflectance data based on the slope at position 1 from 
450-525 nm. Strategies based on fluorescence alone are shown with an 
asterisk strategies based on fluorescence + reflectance have no asterisk. 
Type of Data ESL Sensitivity Specificity 
* Fluorescence at 350, 380 400 mm 65% 75% 86% 
excitation alone 
Fluorescence at 350, 380 400 mm 65% 75% 86% 
excitation + Reflectance Data 
* Fluorescence at 350, 380 mm 65% 63% 86% 
excitation alone 
Fluorescence at 350, 380 nm. 65% 63% 86% 
excitation + Reflectance Data 
* Fluorescence at 350, 400 mm 65% 50% 83% 
excitation alone 
Fluorescence at 350, 400 nm. 75% 63% 83% 
excitation + Reflectance Data 
* Fluorescence at 380, 400 mm 65% 50% 86% 
excitation alone 
Fluorescence at 380, 400 nm. 95% 63% 90% 
excitation + Reflectance Data 
Fluorescence at 350 mm 65% 50% 66% 
excitation alone 
Fluorescence at 350 mm 65% 50% 66% 
excitation + Reflectance Data 
Fluorescence at 380 nm. 65% 25% 48% 
excitation alone 
Fluorescence at 380 mm 85% 38% 66% 
excitation + Reflectance Data 
Fluorescence at 400 nm. 65% 75% 76% 
excitation alone 
Fluorescence at 400 mm 65% 75% 76% 
excitation + Reflectance Data 
TABLE 1.8 
Cross-validated performance of algorithms based on combinations 
of fluorescence and reflectance data based on the intensity at 
position 2 from 395-475 nm Strategies based on fluorescence 
alone are shown with an asterisk; strategies based on 
fluorescence + reflectance have no asterisk. 
Type of Data ESL Sensitivity Specificity 
* Fluorescence at 350, 380 400 mm 65% 75% 90% 
excitation alone 
Fluorescence at 350, 380 400 mm 65% 75% 90% 
excitation + Reflectance Data 
* Fluorescence at 350, 380 mm 65% 63% 87% 
excitation alone 
Fluorescence at 350, 380 nm. 65% 63% 87% 
excitation + Reflectance Data 
* Fluorescence at 350, 400 mm 65% 50% 83% 
excitation alone 
Fluorescence at 350, 400 nm. 65% 50% 83% 
excitation + Reflectance Data 
* Fluorescence at 380, 400 mm 65% 63% 87% 
excitation alone 
Fluorescence at 380, 400 nm. 95% 63% 87% 
excitation + Reflectance Data 
Fluorescence at 350 mm 65% 25% 63% 
excitation alone 
Fluorescence at 350 mm 99% 50% 67% 
excitation + Reflectance Data 
Fluorescence at 380 nm. 65% 50% 53% 
excitation alone 
Fluorescence at 380 mm 95% 50% 83% 
excitation + Reflectance Data 
Fluorescence at 400 nm. 65% 75% 70% 
excitation alone 
Fluorescence at 400 mm 65% 63% 83% 
excitation + Reflectance Data 
All of the methods and apparatus disclosed and claimed 











tation in light of the present disclosure. While the apparatus 
and methods of this invention have been described in terms 
of certain embodiments, it will be apparent to those of skill 
in the art that variations may be applied to the methods 
and/or apparatus described herein without departing from 
the concept, Spirit and Scope of the invention. 
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What is claimed is: 
1. An apparatus for performing fluorescence and Spatially 
resolved reflectance spectroscopy on a Sample, comprising: 
a light Source; 
a monochromator in optical communication with Said 
light Source; 
a reflectance illumination fiber in optical communication 
with Said light Source; 
a fluorescence excitation fiber in optical communication 
with Said monochromator; 
an imaging Spectrograph; 
a fluorescence collection fiber in optical communication 
With Said imaging Spectrograph; 
a reflectance collection fiber in optical communication 
with Said imaging spectrograph and in Spaced relation 
with said reflectance illumination fiber; and 
a detector in optical communication with Said imaging 
Spectrograph; 
wherein Said reflectance illumination fiber, Said fluores 
cence excitation fiber, Said fluorescence collection 
fiber, and said reflectance collection fiber define a fiber 
optic probe, Said probe comprising a center Section and 
an outer Section, Said fluorescence excitation fiber and 
Said fluorescence collection fiber being positioned in 
Said center Section, and Said reflectance illumination 
fiber and Said reflectance collection fiber being posi 
tioned in Said outer Section. 
2. The apparatus of claim 1, wherein Said light Source 
comprises a Xe arc lamp. 
3. The apparatus of claim 1, wherein Said monochromator 
comprises a double monochromator. 
4. The apparatus of claim 1, wherein Said detector com 
prises a thermo-electrically cooled CCD camera. 
5. The apparatus of claim 1, wherein Said fluorescence 
excitation fiber and Said fluorescence collection fiber are 
integral. 
6. The apparatus of claim 1, wherein one or more of Said 
fibers are positioned flush with Said Sample. 
7. The apparatus of claim 1, further comprising a Spacer 













8. The apparatus of claim 1, wherein Said reflectance 
illumination fiber, Said fluorescence excitation fiber, Said 
fluorescence collection fiber, and Said reflectance collection 
fiber define a fiber optic probe. 
9. The apparatus of claim 8, wherein said probe is 
configured to be positioned within a trocar. 
10. The apparatus of claim 8, wherein said probe com 
prises a center Section and an outer Section, Said fluorescence 
excitation fiber and Said fluorescence collection fiber being 
positioned in Said center Section, and Said reflectance illu 
mination fiber and Said reflectance collection fiber being 
positioned in Said outer Section. 
11. The apparatus of claim 1, comprising a plurality of 
fluorescence excitation and collection fibers arranged in a 
circular bundle. 
12. The apparatus of claim 1, comprising a plurality of 
reflectance collection fibers defming a plurality of collection 
positions. 
13. The apparatus of claim 12, wherein said plurality of 
collection positions are spaced between about 0 and about 
10 millimeters from said reflectance illumination fiber. 
14. The apparatus of claim 1, wherein Said reflectance 
collection fiber defines a collection position at about 180 
degrees relative to Said reflectance illumination fiber. 
15. The apparatus of claim 1, wherein said reflectance 
collection fiber defines a collection position at about 90 
degrees relative to Said reflectance illumination fiber. 
16. The apparatus of claim 1, wherein Said reflectance 
collection fiber defines a collection position at about 45 
degrees relative to Said reflectance illumination fiber. 
17. The apparatus of claim 1, further comprising a one or 
more fibers in optical communication with Said light Source 
and configured to illuminate Said Sample during operation of 
Said apparatus. 
18. The apparatus of claim 1, comprising a plurality of 
fluorescence excitation fibers arranged in one or more rows 
adjacent Said monochromator. 
19. The apparatus of claim 1, comprising a plurality of 
fluorescence excitation fibers and a plurality of reflectance 
collection fibers arranged in a Single row adjacent Said 
imaging spectrograph. 
20. The apparatus of claim 19, further comprising one or 
more unconnected fibers interspersed with Said plurality of 
fluorescence excitation fibers and Said plurality of reflec 
tance collection fibers. 
21. The apparatus of claim 1, further comprising a fiber 
connected from Said light Source to Said imaging Spec 
trograph to monitor Spectral output of Said light Source. 
22. The apparatus of claim 1, further comprising a con 
troller coupled to Said detector. 
23. The apparatus of claim 1, wherein Said center and 
outer Sections are circular. 
24. An apparatus for measuring fluorescence and Spatially 
resolved reflectance spectra of a Sample, comprising: 
a light Source, 
a monochromator in optical communication with Said 
light Source; 
a fiber optic probe in optical communication with Said 
light Source and with Said monochromator, Said probe 
comprising a plurality of fluorescence excitation and 
collection fibers in Spaced relation and Surrounded at 
least partially by a plurality of reflectance collection 
fibers in Spaced relation with a reflectance illumination 
fiber; 
an imaging Spectrograph in optical communication with 
said plurality of fluorescence collection fibers and with 
Said plurality of reflectance collection fibers, and 
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a detector in optical communication with Said imaging 
Spectrograph. 
25. The apparatus of claim 24, wherein said plurality of 
reflectance collection fibers and Said reflectance illumination 
fiber are positioned concentrically about Said plurality of 
fluorescence excitation and collection fibers. 
26. The apparatus of claim 24, wherein at least one of Said 
plurality of reflectance collection fibers defines a collection 
position at about 180 degrees relative to Said reflectance 
illumination fiber. 
27. The apparatus of claim 24, wherein at least one of Said 
plurality of reflectance collection fibers defines a collection 
position at about 90 degrees relative to Said reflectance 
illumination fiber. 
28. The apparatus of claim 24, wherein at least one of said 
plurality of reflectance collection fibers defines a collection 
position at about 45 degrees relative to Said reflectance 
illumination fiber. 
29. The apparatus of claim 24, wherein said plurality of 
collection positions are spaced between about 0 and about 
10 millimeters from said reflectance illumination fiber. 
30. The apparatus of claim 24, wherein said probe com 
prises between twenty-one and forty-six optical fibers. 
31. A method for combined fluorescence and spatially 
resolved reflectance spectroscopy of a Sample, comprising: 
providing a reflectance illumination fiber, a fluorescence 
excitation fiber, a fluorescence collection fiber, and a 
reflectance collection fiber that define a fiber optic 
probe comprising a center Section and an Outer Section, 
Said fluorescence excitation fiber and Said fluorescence 
collection fiber being positioned in Said center Section, 
and Said reflectance illumination fiber and Said reflec 
tance collection fiber being positioned in said outer 
Section; 
directing radiation to Said Sample with Said fluorescence 
excitation fiber; 
collecting radiation from Said Sample with Said fluores 
cence collection fiber; 
directing Said radiation from Said Sample to an imaging 
Spectrograph and a detector; 
illuminating Said Sample with Said reflectance illumina 
tion fiber; 
collecting reflected light from Said Sample with Said 
reflectance collection fiber; and 
directing Said reflected light from Said Sample to an 
imaging spectrograph and a detector. 
32. The method of claim 31, wherein said collecting 
reflected light comprises collecting reflected light from a 
plurality of collection positions with a plurality of reflec 
tance collection fibers. 
33. The method of claim 31, wherein said collecting 
reflected light comprises collecting reflected light from Said 
Sample with a reflectance collection fiber defming a collec 
tion position at about 180 degrees relative to Said reflectance 
illumination fiber. 
34. The method of claim 31, wherein said collecting 
reflected light comprises collecting reflected light from Said 
Sample with a reflectance collection fiber defining a collec 
tion position at about 90 degrees relative to Said reflectance 
illumination fiber. 
35. The method of claim 31, wherein said collecting 











Sample with a reflectance collection fiber defining a collec 
tion position at about 45 degrees relative to Said reflectance 
illumination fiber. 
36. The method of claim 31, wherein said sample com 
prises ovarian, head and neck, or cervical tissue. 
37. The method of claim 31, further comprising analyzing 
Spectral data from Said detector to characterize Said Sample. 
38. The method of claim 37, wherein said analyzing 
comprises pre-processing Said data and reducing a dimen 
Sion of Said data using principal component analysis. 
39. The method of claim 38, wherein said analyzing 
further comprises Selecting one or more diagnostic principal 
components of Said data and forming one or more algo 
rithms. 
40. The method of claim 40, wherein said analyzing 
further comprises forming one or more composite algo 
rithms. 
41. The method of claim 39, wherein said analyzing 
further comprises evaluating at least one of Said algorithms 
using a croSS-Validation technique. 
42. The method of claim 31, further comprising correcting 
Said radiation collected with Said fluorescence collection 
fiber using a measured background fluorescence. 
43. The method of claim 31, wherein said center and outer 
Sections are circular. 
44. A method for combined fluorescence and spatially 
resolved reflectance spectroscopy of a Sample, comprising: 
providing a probe comprising a plurality of fluorescence 
excitation and collection fibers in Spaced relation Sur 
rounded at least partially by a plurality of reflectance 
collection fibers in Spaced relation with a reflectance 
illumination fiber; 
directing radiation to Said Sample with a fluorescence 
excitation fiber; 
collecting radiation from Said Sample with a fluorescence 
collection fiber; 
directing Said radiation from Said Sample to an imaging 
Spectrograph and a detector; 
illuminating Said Sample with a reflectance illumination 
fiber; 
collecting reflected light at a plurality of collection posi 
tions from Said Sample with Said plurality of reflectance 
collection fibers arranged in Spaced relation; 
directing Said reflected light from Said Sample to an 
imaging spectrograph and a detector to produce Spec 
tral data; 
pre-processing Said data, and 
reducing a dimension of Said data using principal com 
ponent analysis. 
45. The method of claim 44, further comprising selecting 
one or more diagnostic principal components of Said data 
and forming one or more algorithms. 
46. The method of claim 45, further comprising forming 
one or more composite algorithms. 
47. The method of claim 46, further comprising evaluat 
ing at least one of Said algorithms using a croSS-Validation 
technique. 
48. The method of claim 44, further comprising correcting 
Said radiation collected with Said fluorescence collection 
fiber using a measured background fluorescence. 
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